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ABSTRACT 
Jacob I. Stuckey: Design and characterization of chemical probes targeting the chromodomains of 
Polycomb Repressive Complex I 
(Under the direction of Stephen V. Frye) 
 
 Eukaryotic DNA is wound around histone proteins to form repeating units of nucleosomes that are 
packaged into higher order structures to form chromosomes. Nucleosomal packaging is dynamically 
regulated to control the expression of the genome through regulating access of transcription factors to 
specific genes in response to stimuli. Critical for these processes are modifications to the N-terminal tails 
of histones. In particular, methylation of specific histone lysine residues has a profound impact on 
transcription. This “mark” recruits protein complexes that contain methyl-lysine “reader” modules that bind 
to the mark and facilitate transcriptional silencing or activation of the underlying gene. Mutation and 
misregulation of proteins that “write,” “read” and “erase” these marks play a foundational role in the 
development and progression of nearly all cancers.  
 Chemical tools that antagonize these writers, readers and erasers have been developed in recent 
years. These tools have been valuable in explicating the biology of these proteins, and in some cases, as 
therapeutic agents. Development of antagonists of methyl-lysine readers has lagged compared to both 
methyl-lysine writers and erasers. Herein we describe the design, development and characterization of 
antagonists of the chromodomain reader modules contained in Polycomb Repressive Complex I (PRC1). 
PRC1 contains one of five chromodomains; CBX2, -4, -6, -7 or -8. PRC1 complexes containing any one 
of these proteins play critical roles in normal, growth and development. Accordingly, misregulation of 
PRC1 chromodomains contributes to the initiation and development of numerous cancers. We developed 
a series of potent, peptidic antagonists of PRC1 chromodomains and an expanded set of chemical tools 
around one of these molecules, UNC3866, which has the highest affinity for the chromodomains of CBX4 
and -7. We demonstrated the ability of UNC3866 to inhibit proliferation in a metastatic prostate cancer 
cells through the induction of a senescent-like state. Further optimization of UNC3866 led to a second-
generation antagonist of PRC1 chromodomains with a dramatically improved residence time for CBX7 
iv 
 
and increased cellular potency. This work has produced a valuable tool set for studying CBX biology and 
laid the ground work for continued efforts to evaluate and improve CBX antagonists as potential 
therapeutic agents. 
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CHAPTER I: INTRODUCTION 
CHROMATIN REGULATION 
 Remarkably, the entire genome of a eukaryotic organism is contained within each one its cells. 
This chemical information is organized and packaged into dense structures known as chromosomes. For 
humans, the genome is packaged into 23 pairs chromosomes that originate in a single cell following 
conception and eventually give rise to a person composed of more than 200 different cell types made 
from trillions of individual cells1. While each of these cells, with the exception of red blood cells and 
platelets, contains the same 23 pairs of chromosomes, each cell utilizes a mere fraction of this genetic 
information to accomplish its biological function. The mechanisms of genomic regulation that account for 
this are complex, highly evolved processes that are only beginning to be unraveled.  
 Initial insight into these mechanisms was gained through the study of the simpler genomes of 
prokaryotic organisms that lack many of the features found in eukaryotic chromosomes. These studies 
led to what is known as the “operon model” of genomic regulation. In this model, activator and repressor 
proteins, known as transcription factors, bind to specific DNA sequences in ways that are sensitive to the 
concentrations of metabolites and environmental nutrients. Transcription factors, metabolic sensing and 
positive and negative feedback loops then act together as sophisticated control networks regulating 
families of genes2. However, while this model partially accounts for genomic regulation in higher 
organisms, by itself, the operon model is insufficient for explaining the regulation of the more complicated 
genomes of eukaryotic organisms. This is because non-coding and coding DNA sequences have 
accumulated throughout evolution in higher organisms to the degree that, in humans, each individual cell 
contains approximately two meters of DNA that is packed within a nucleus that can range from 2-10 μm in 
diameter. The spatial compaction of such a large amount of chemical matter was enabled by the 
simultaneous evolution of mechanisms to package and organize this vast library of chemical information. 
Specifically, eukaryotic DNA is stored as chromatin, which is the overall complex, of DNA, RNA and their 
associated proteins. Within chromatin, the nucleosome is the basic functional unit for regulating genomic 
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expression. A nucleosome contains 147 base pairs of DNA wound around an octamer of histone proteins, 
two copies each of histones H2A, H2B, H3 and H4 (Fig. 1.1).  Nucleosomal repeats are then organized 
into higher order structures that makeup the overall chromatin architecture. The organization of 
nucleosomes into these higher-order structures controls access of transcription factors to DNA, in turn 
controlling the transcription of the entire genome2-4. The evolution of mechanisms to “open” and “close” 
chromatin enabled eukaryotic cells to dynamically regulate the exposure of specific genes to transcription 
factors, providing a mechanism for both differentiation into different cell types and for more precise 
genomic regulation in response to environmental stimuli2-4. 
 
Figure 1.1. Model of a nucleosome. DNA (gray) is wrapped around an octamer of histone proteins. The 
histone tails of H2A (salmon), H2B (yellow), H3 (cyan), and H4 (green) are intrinsically disordered and 
protrude out from the nucleosome. Figure adapted from PDB 5B0Z. 
 
 Histones were once thought to contribute to genomic regulation by serving primarily as static 
structural elements that only passively participate in controlling the transcription of the underlying DNA 
sequence5. This assumption was challenged as numerous studies demonstrated that nucleosomes, 
especially histones, are a unique canvas for posttranslational modifications (PTMs). These PTMs occur 
primarily on the highly disordered N-terminal portion, or “tail”, of histones that protrude out from the 
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nucleosomal core and are enriched in basic amino acids2, 3, 5, 6 (Fig. 1.1). Some of the known PTMs to 
histones include arginine and lysine methylation7; lysine acetylation5, 7, 8, crotonylation9, 
hydroxyisoburtyrylation10, sumoylation11, ubiquitination12-14; and serine/threonine phosphorylation5 (Fig. 
1.2). 
 
Figure 1.2. Overview of the histone code hypothesis. Posttranslational modifications installed by writers 
form a putative code that is recognized by readers and can be removed by erasers to regulate gene 
expression. There are many readers for the various histone PTMs. In the interest of simplicity, only a 
methyl-lysine reader is depicted. Nucleosome models were adapted from PDB 5B0Z. 
  
 Correlations established between patterns of these PTMs and transcription of the underlying 
gene(s) led to the proposal of the “histone code” hypothesis5, wherein individual histone PTMs are 
thought of as “marks” and discrete patterns of these marks are installed and then recognized within cells 
to bring about distinct phenotypes5. Enzymes and enzymatic complexes that install histone PTMs have 
come to be known as “writers” of the histone code, while enzymes that remove these PTMs have come to 
be known as “erasers” of the histone code. Proteins and protein complexes that recognize and bind to 
these PTMs are known as “readers” of the histone code and are largely responsible for affecting the 
downstream biology associated with a particular mark or pattern of marks6, 7 (Fig. 1.2). 
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THERAPEUTIC INTEREST IN CHROMATIN REGULATORY PROTEINS 
 Misregulation and mutation of the readers, writers and erasers of the histone code initiates and 
contributes to a variety of human disease states, including, but not limited to; neuropsychiatric diseases, 
inflammation, metabolic disorders, and especially cancer7, 15-26. Of the various histone marks, lysine 
acetylation (Kac) and methylation (Kme) are the most abundant and widely studied7. Readers, writers and 
erasers of these two marks consist of a large number of potentially “druggable” proteins7, 27. The term 
“druggability” here refers to the likelihood of modulating a specific protein with a small-molecule27. 
Important factors governing the “druggability” of a given protein include the hydrophobicity of the binding 
pocket(s) as well as the pocket’s volume and degree of enclosure28. It is important to note that, because 
the ability to potently target a macromolecule with a small-molecule does not guarantee the ability to 
generate drug-like molecule that can accomplish a desired therapeutic outcome, “druggability” is a 
misnomer and discussion of protein targets is best thought of in terms of “tractability for ligand discovery” 
and not “druggability”.  
 The existence of multiple chemically tractable writers, readers and erasers of lysine acetylation 
and methylation has given rise to intense interest in pharmacological modulation of these proteins21, 23-25, 
29-34. This interest has thus far yielded five US FDA approved antagonists of lysine deacetylases with 
numerous more currently being investigated in clinical trials35. Additionally, at least five antagonists of 
histone lysine methylation and eleven antagonists of readers of lysine acetylation are currently being 
investigated in clinical trials36. Interest in antagonism of the erasers of lysine methylation is increasing 
with preliminary data suggesting that some of these molecules will soon be under investigation in clinical 
trials as well34, 37. However, ligand discovery efforts focused on targeting Kme reader proteins have 
lagged. One explanation for the hesitancy to target these proteins is over concerns of their tractability. 
Only a limited number of reports focused on antagonists of Kme reader proteins have surfaced in recent 
years, primarily from academic settings31, 38-40.  Despite this initial reluctance toward discovery of ligands 
for Kme reader proteins, the potential utility of such molecules is vast. The therapeutic potential of many 
of these proteins is an area of great interest as genetic manipulation of numerous Kme readers has 
provided strong evidence for their therapeutic relevance7, 17-20, 22, 26, 41-57 (Table 1.1). Chemical probes58-61 
that target these proteins are therefore valuable and essential tools for both addressing the tractability of 
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targeting different Kme readers with small molecule antagonists and for validating the therapeutic 
potential of this target class.  
 
Table 1.1. Examples of Kme readers of potential therapeutic relevance  
 
Reader Family 
 
Protein 
Potential therapeutic 
relevance  
PHD Finger 
 
JARID1A 
PHF23 
 
leukemia26 
Tandem Tudor 53BP1 
 
breast50, 51 
skin52 
colorectal53 
lung51 
 
MBT 
 
SFMBT1 
 
breast54 
WD40 EED 
 
colorectal55 
breast56 
prostate57 
leukemia22 
 
Chromodomain 
 
CBX4 
 
Hepatocellular carcinoma47 
CBX7 
 
prostate15, 16, 18 
ovarian48 
leukemia19 
lymphoma62 
gastric17 
 
CBX8 
 
MLL-AF9 leukemia44 
osteosarcoma41 
colorectal49 
 
 
 While there is currently no agreed upon, universal definition of a chemical probe, one can loosely 
define a chemical probe as a molecule with sufficient potency and selectively for a given target both in 
vitro and in vivo (minimally cellular) to associate the molecule’s phenotypic effects with modulation of the 
target of interest. Ideally, chemical probes are monospecific for a single protein. Pragmatically, this will 
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rarely be the case and as such, molecules require extensive characterization against numerous proteins 
targets from multiple protein families before they can be used as validated chemical probes58-61.  
 One of the key roles of chemical probes is to bridge the gap between target discovery and target 
validation. Development of potent and selective chemical probes addresses the key issue of target 
tractability in drug discovery and agreement between the phenotypic effects of a chemical probe and 
genetic manipulation of the probe’s protein target provides strong validation for the target’s therapeutic 
relevance. Thus, high quality chemical probes are essential for selecting which projects in a drug 
discovery portfolio should be pursued further in medicinal chemistry campaigns that seek to produce 
therapeutically useful molecules. Ultimately, regardless of whether they lead to novel, therapeutically 
relevant molecules, the development of chemical probes is a pressing area of research as probes provide 
the research community with an important tool that can be used to more fully interrogate and understand 
biological systems. 
       
THE TRACTABILITY OF CHEMICAL PROBE DISCOVERY FOR READERS OF HISTONE LYSINE 
METHYLATION 
 Questions concerning the general tractability of Kme reader domains originate, in part, from the 
structural diversity present in this class of proteins28, 63, 64. Reader domains of methyl-lysine binding 
proteins belong to one of at least 8 different families28, 63-65 (Fig. 1.3). The central structural similarity 
shared amongst nearly all Kme readers is recognition of methylated-lysine through an aromatic cage. The 
only known exceptions at this time are the ADD domain65 and certain PHD fingers that recognize 
unmethylated-lysine. Methyl-lysine reader aromatic cages are large enough to accommodate the 
hydrophobic side chain of methyl-lysine and engage the methylated amine through cation-, electrostatic 
and van der Waals interactions. Selectivity between different methylation states (mono-, di- and 
trimethylation) is conferred primarily by cage geometry and amino acid composition with readers of lower 
methylation states utilizing acidic residues that participate in a key hydrogen bond with the secondary or 
tertiary ammonium63, 64 (Fig. 1.3 and Fig. 1.4) 
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Figure 1.3. Kme reader domain families. Representative members from each of the 8 Kme reader 
domains are shown. Reader domains (light blue) are shown as cartoon representations with their 
aromatic cage and cognate histone (pale yellow) shown in the stick representation. Surface 
representations are depicted for residues within 4Å of histones to illustrate the approximate surface areas 
used for binding from each of the various reader domains. 
 
 Analysis of the structural elements of the different Kme reader domains immediately surrounding 
the aromatic cage further illuminates the complexity of these proteins as a target class. Recognition of 
methylated histones is accomplished primarily through two-different binding mechanisms: i) surface-
groove interactions or ii) cavity-insertion (Figures 1.3 and 1.4). Surface-groove readers are sensitive to 
both the degree of lysine methylation and the residues surrounding the modified lysine while cavity-
insertion readers primarily sense the presence of specific methylation states with little preference for the 
surrounding sequence63, 64.  
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Figure 1.4. Comparison of surface-groove and cavity-insertion binders. (a) Surface-groove recognition of 
H3K4me3 by JARID1A. Note the large surface area of interaction, shallow surface area used and the 
multiple hydrogen bonds formed between JARID1A and H3 (PDB 2KGI). (b) Cavity –insertion recognition 
of H4K20me2 by L3MBTL1 (PDB 2RJE). Note the deeper cavity formed by the aromatic cage, smaller 
surface area of interaction, and fewer hydrogen bonds compared to the JARID1A-H3 interaction.  
  
 Each of these binding mechanisms presents unique hurdles for the development of potent ligands 
for these proteins. While cavity-insertion readers are attractive for the design of small-molecules because 
of their enclosed binding pockets, these pockets are relatively small with few moieties available for 
forming stable interactions66. In contrast, while surface-groove Kme readers tend to bind more tightly to 
their histone substrates compared to cavity-insertion binders, they are unfavorable for ligand discovery 
efforts because they utilize large, open areas of their surface for binding histones26, 67, 68. The challenges 
in targeting each of these classes of Kme readers were quantified in a study utilizing a computational 
analysis comparing the histone binding sites of multiple families of Kme readers and bromodomains (Kac 
readers). These studies quantitatively scored the “druggability” of these proteins and concluded that 
methyl-lysine binding proteins are, on average, considerably less tractable for ligand discovery efforts 
than bromodomains, which have been effectively targeted in multiple small-molecule ligand discovery 
campaigns28. 
 
 
 
a) b) 
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SCREENING FOR ANTAGONISTS OF METHYL-LYSINE READERS 
 While Kme readers appear to be less tractable as a target class compared to Kac readers, 
individual families within the Kme reader class of proteins do appear to be promising for the development 
of potent small molecules28. Additionally the therapeutic potential of many of these proteins warrants 
further investigation into the tractability of Kme readers. In order to explore the tractability of any target 
class, robust, cost-effective high-throughput screening methods are required. This was one of the most 
significant initial challenges in targeting Kme reader domains. As opposed to enzymatic protein targets, 
which offer the advantage of catalyzing a chemical reaction that can be monitored for the disappearance 
of substrate(s) or the appearance of product(s), Kme reader domains perform their biological function 
through simple binding, a considerably more difficult event to monitor than chemical reactions.  
 Monitoring for blockade of binding interactions is typically accomplished through assays which 
utilize tagged versions of one binding partner that undergoes a measurable change when it has been 
displaced from its binding partner. Traditional high-throughput displacement assays such as fluorescence 
polarization have been applied to screen for methyl-lysine antagonists38, 40, but the weak nature of the 
reader-histone interactions requires the use of relatively large amounts of protein. This is problematic 
primarily for two reasons. First, the large amount of protein required places practical limits on the number 
of compounds that can be screened against the desired target, thereby decreasing the likelihood of 
discovering a useful hit molecule. Second, it precludes simultaneous screening against other Kme 
readers. Screening against multiple targets with similar biological functions is known as target class 
screening and is advantageous because it both provides knowledge of the selectivity profile of 
compounds for closely related proteins and enables the serendipitous discovery of antagonists for Kme 
readers that were not the subject of the original screen. 
 The challenges in developing a high-throughput platform targeting Kme readers were largely 
overcome through the use of AlphaScreen® technology. AlphaScreen® is a bead-based, proximity assay 
that measures the transfer of singlet oxygen between a donor and acceptor bead. The assay functions 
through the use of tagged Kme readers domains (usually a His-tag). This tag is recognized by Ni2+, which 
coats the singlet oxygen acceptor bead. The streptavidin coating on the singlet oxygen donor bead 
causes these beads bind to selectively bind to the biotinylated histone substrate of the reader domain. 
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When the histone is engaged with the reader domain, the donor and acceptor beads are brought into 
close proximity with each other. Donor beads are then excited with 680 nm λ light, generating singlet 
oxygen that is in close enough proximity to diffuse to the acceptor bead and stimulate the acceptor to 
bead to generate an emission event in the 520-620 nm λ range. The presence of multiple streptavidin and 
Ni2+ molecules on the surface of the donor and acceptor beads creates an avidity effect that overcomes 
the weak nature of histone-reader interactions, allowing for a dramatic increase in assay sensitivity and a 
decrease in both required protein and cost69. Antagonists of the interaction displace the peptide from the 
reader domain, preventing transfer of singlet oxygen, which can only diffuse distances less than 200 nm, 
between the donor and acceptor beads.  Monitoring for a dose-dependent loss of the emission event in 
the 520-620 nm λ range then enables the identification of Kme reader antagonists. 
 The advantages of AlphaScreen® technology in screening make it a valuable tool for identifying 
antagonists of Kme reader domains, but this assay format is not without its drawbacks. Compounds that 
can chelate the acceptor beads or absorb light in the wavelengths important for the assay will show 
inhibition in AlphaScreen® even if they do not physically interact with the protein of interest. Additionally, 
as with most other high-throughput assays, AlphaScreen® technology is limited in its ability to distinguish 
between true, selective binders and non-specific aggregators. Therefore, this platform must always be 
used in conjunction with orthogonal biophysical techniques to distinguish between tractable hit molecules 
and assay artifacts. 
 The issues associated with AlphaScreen® can largely be addressed through the use of 
orthogonal biophysical techniques as secondary assays. The gold standard of biophysical techniques for 
characterizing protein-ligand interactions is isothermal titration calorimetry70 (ITC). A typical ITC 
experiment measures the energy released when titrating a ligand into a solution of the protein target of 
interest. The results of this experiment provide the stoichiometry, affinity, enthalpy and entropy of the 
interaction, thus providing a complete thermodynamic picture of the binding equilibrium71. ITC is 
indispensable for distinguishing between the assay artifacts, aggregators and true binders that emerge 
from AlphaScreen®. However, because of the large amounts of both compound and protein required, 
there is a practical limit on the number of compounds that ITC can be used to evaluate. While both 
AlphaScreen® and ITC have their own unique limitations, pairing the high-throughput and cost-effective 
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AlphaScreen® platform with ITC as a secondary assay produces a powerful combination for identifying 
and characterizing antagonists of Kme reader domains.   
 In addition to ITC, surface plasmon resonance (SPR) is another validated biophysical technique 
that can provide valuable information concerning protein-ligand interactions. SPR is medium-throughput 
assay format where the protein target of interest is immobilized to a gold surface. Compounds are then be 
flowed across the protein-coated surface and binding of the compound is quantified by measuring the 
changes in the refractive index of the solvent layer near the surface72. Like ITC, this assay can be used to 
measure binding affinity, but it also can be used to characterize the kinetics of the interaction. Combining 
AlphaScreen®, ITC and SPR allows for the identification of histone competitive antagonists with complete 
characterization of both the thermodynamic and kinetic parameters of the protein-antagonist interaction; 
information that is invaluable for the design of improved compounds.         
 
EXAMPLES OF PREVIOUS CHALLENGES AND SUCCESSES OF SMALL-MOLECULE CHEMICAL 
PROBE DISCOVERY EFFORTS TARGETING METHYL-LYSINE READERS 
 Initial reports of Kme reader antagonists focused on small-molecules that targeted the cavity-
insertion binder, L3MBTL1. This protein recognizes H4K20me1 and H4K20me2 through a 3-domain 
repeat of MBT domains66, 73, 74. These efforts ultimately led to the development UNC669 (Fig. 1.5a), which 
possesses a 4-(pyrrolidin-1-yl)piperidin-1-yl moiety as a conformationally-constrained methyl-lysine mimic 
that specifically engages the second MBT domain of L3MBTL1 with modest affinity (ITC Kd = 5 µM)74. 
Disappointingly, the lack of significant functionalities surrounding the aromatic cage has thus far 
prevented the development of submicrolar antagonists of L3MBTL1.  
 In addition to L3MBTL1, UNC669 also interacts, with similar affinities, with the 3-MBT domain 
repeat of L3MBTL3 and the tandem Tudor domains of 53BP1. Like L3MBTL1, both L3MBTL3 and 53BP1 
are H4K20me2 readers. SAR efforts around UNC669 targeting 53BP1, led to UNC1021 (Fig. 1.5a), which 
possesses a second 4-(pyrrolidin-1-yl)piperidin-1-yl moiety around a slightly different aromatic core than 
UNC669. While UNC1021 does not possess increased affinity for 53BP1 as intended, it was 
serendipitously discovered through target class screening that UNC1021 potently antagonizes the MBT 
repeats of L3MBTL3 (AlphaScreen® IC50 = 0.04 µM). Continued SAR studies led to the identification of 
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UNC1215 (Fig. 5a, AlphaScreen® IC50 = 0.04 µM, ITC Kd = 0.12 µM), a cellularly active chemical probe 
of L3MBTL3 and the first chemical probe for any Kme binding protein. The mechanism for the increased 
potency of these dibasic compounds for L3MBTL3 was uncovered through the use of X-ray 
crystallography. These studies revealed that L3MBTL3 forms a 2:2 dimeric complex with UNC1215. Here 
the lack of significant interactions with residues outside of the aromatic cage is overcome by additional 
contacts formed between each L3MBTL3 monomer as well as the interaction between a second reader 
pocket from each L3MBTL3 monomer and the additional constrained methyl-lysine mimic of a second 
molecule of UNC1215 (Fig. 5b)75. 
 
Figure 1.5. Antagonists of Kme readers. (a) Structures of L3MBTL1 and L3MBTL3 antagonists UNC669, 
UNC1021 and UNC1215. (b) Crystal structure of 2 molecules of UNC1215 (pale yellow) bound to a 
homodimer of the 3-MBT repeats of L3MBTL3 (one monomer is shown in light blue and the other in 
salmon). (c) Crystal structure of UNC2170 (pale yellow) bound to a homodimer of tandem Tudor domains 
of 53BP1 (one monomer is shown in light blue and one in salmon). UNC2170 can exist in two different 
conformations within the 53BP1 homodimer, both of which are shown in the image. 
a) 
c) b) 
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 While UNC1021 and its derivatives failed to improve 53BP1 potency as intended, continued 
target class screening efforts eventually identified a fragment-like ligand, UNC2170 (Fig. 1.5a), with low 
micromolar potency for 53BP1. This molecule utilizes a t-butyl amine to interact with the aromatic cage of 
53BP1. The identification of a second, distinct small molecule antagonist of 53BP1 in addition to UNC669 
and its subsequent derivatives was encouraging; especially considering that 53BP1 recognizes 
H4K20me2 with an open and shallow surface-groove. While the regions surrounding the aromatic cage of 
53BP1 present more attractive functionalities for targeting with small-molecule ligands than L3MBTL1 or 
L3MBTL3, SAR studies revealed minimal tolerance for modification to UNC2170. X-ray crystallography 
and ITC studies revealed that the tandem Tudor domain of 53BP1, similar to L3MBTL3 and UNC1215, 
dimerizes around UNC2170 (Fig. 5c). However, the complex formed between 53BP1 and UNC2170 is 
instead a 1:2 complex (1 molecule of UNC2170 to 2 molecules of 53BP1). The dimeric complex of 53BP1 
formed around UNC2170 leaves little steric tolerance for any modifications to the compound, explaining 
the lack of tractable SAR around this compound76. 
 Difficulties targeting the MBT repeats of L3MBTL1 exemplify the difficulties in targeting cavity-
insertion binders63, 66, 73, 74 and despite multiple seemingly tractable hit molecules starting points for 
targeting 53BP1; this protein has so far proven intractable for the development of potent small 
molecules76. In contrast, L3MBTL3 has proven highly tractable for the design and discovery of potent 
antagonists. In fact, there are now multiple series of compounds capable of targeting the MBT domains of 
L3MBTL375, 77, 78. However, the origin of these compounds was primarily serendipitous in nature75. Taken 
together, these examples highlight the challenge of rationally identifying and designing potent antagonists 
of Kme reader proteins. 
 While the discovery of UNC1215 proved that some Kme readers can, in fact, be tractable 
macromolecular targets, UNC1215 has been of limited utility in answering any significant biological 
questions. The biological role of L3MBLT3 is relatively unknown, making it challenging to test specific 
hypotheses with UNC1215. Additionally, UNC1215 does not appear to have any observable phenotypic 
or morphological effects on cells that suggest a cellular role for L3MBTL3. In time, UNC1215 may prove 
to be a useful tool, but the current lack of utility of UNC1215 has led to an increased focus on ligand-
discovery efforts for Kme readers that are more readily correlated with specific phenotypes in biological 
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systems. Focusing on these readers is more likely to produce molecules that will address pressing 
biological questions. 
 
THE CBX FAMILY OF CHROMODOMAINS 
 One Kme reader family that has been linked to multiple specific phenotypes of interest is the 
chromodomain family of reader proteins. The chromodomain is a trimethyl-lysine binding structural motif 
that consists of three beta strands packed against a C-terminal alpha helix that mediates protein-protein 
interactions. Chromodomains are believed to target their associated protein and protein complexes to 
specific sites on chromatin. They are essential for proper genomic regulation in numerous organisms 
spanning fungi, plants and animals79. In mammals, perhaps the best studied chromodomain-containing 
proteins are the Chromobox Homolog (CBX) proteins15-20, 41-49, 62, 68, 80-93.  
 There are eight mammalian CBX proteins that are divided into two different families, the 
Heterochromatin 1 (HP1; CBX1, -3 and -5) and Polycomb (Pc; CBX2, -4, -6, -7 and -8) families68, 79. 
Members of both of these protein families possess an N-terminal chromodomain that selectively bind to 
ARKme3S motifs. The structures of CBX chromodomains have been thoroughly characterized and have 
been shown to recognize ARKme3S motifs through a surface-groove recognition mechanism68 (Fig. 1.6). 
However, despite their high degree of structural similarity and binding preferences, there are differences 
in the binding preferences between these two families of chromodomains. HP1 chromodomains 
selectively bind to the ARKme3S motif of H3K9me3 while Pc chromodomains are generally capable of 
binding to the ARKme3 motifs of both H3K9me3 and H3K27me368, 94. The differences in the binding 
preferences between these two families of chromodomains despite their high degree of structural 
similarity is believed to be mediated by the more polar surface of HP1 chromodomains relative to the 
lipophilic surface of Pc chromodomains. The polar surface of HP1 chromodomains more favorably 
interacts with the polar side chains surrounding the ARKS motif of H3K9me3 while the lipophilicity of Pc 
chromodomains increases their promiscuity between these marks68 (Fig. 1.6c, d and Table 1.2) 
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Figure 1.6. Comparison of Pc and HP1 CBX chromodomains. (a) Overlay of the chromodomains of 
CBX2, -6, 7 and -8 when bound to H3K9me3 or H3K27me3 (there is currently no published structure of 
CBX4 bound to H3). (b) Overlay of the chromodomains of CBX1, -3 and -5 chromodomains bound to 
H3K9me3. (c) Surface representation of CBX7 bound to H3K27me3. (d) Surface representation of CBX5 
bound to H3K9me3. Note the similar folds for both Pc and HP1 chromodomains. For (c) and (d), regions 
of gray represent lipophilic surfaces while blue and red indicate polar areas that are electron deficient 
(blue) and electron rich (red). Note the greater polarity of CBX5 (d), resulting in a more open binding 
groove compared to CBX7 (c).   
 
Table 1.2. Comparison between Pc and CBX chromodomains 
 
Chromodomain Family 
Polycomb (Pc) Heterochromatin Protein1 (HP1) 
Members CBX2, -4, -6, -7 and -8 CBX1, -3 and -5 
Histone substrate H3K9me3 and H3K27me3 H3K9me3 selective 
Binding affinity Approximate Kd’s between 50-100 μM Approximate Kd’s between 5-40 μM 
Nature of binding surface Lipophilic Polar 
a) b) 
c) d) 
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 The more hydrophobic and enclosed nature of Pc chromodomains suggests that these proteins 
are more tractable for ligand discovery efforts, a fact that is reiterated by their “druggability” scores 
wherein three out of four Pc CBX chromodomains analyzed were scored as “druggable” (CBX2, -6  and-
7) while only one out of three HP1 chromodomains (CBX1) was scored as “druggable”.  The only 
chromodomain not analyzed in this study was the chromodomain of CBX4, for which there is no structure 
available of the chromodomain bound to H328. 
 
THE CANONICAL POLYCOMB SIGNALING PATHWAY
 
Figure 1.7. Domain maps of Pc CBX proteins. Each Pc CBX protein contains an N-terminal 
chromodomain for binding to H3 and a C-terminal Pc Box for interaction with PRC1. Only domains 
annotated at www.uniprot.org are shown.  
 
 In addition to their chromodomains, each Pc CBX protein also possesses a C-terminal domain 
known as a Pc box (Fig. 1.7) that mediates their incorporation into Polycomb Repressive Complex 1 
(PRC1). This complex is essential for regulating cellular growth, proliferation and stem cell pluripotency19, 
45, 46, 81, 94. Canonical PRC1 is built around 4 main subunits, a RING finger protein, a PCGF family 
member, one CBX component and an HPH protein family member. The existence of multiple redundant 
family members for each of these subunits creates the potential for at least 180 permutations of canonical 
PRC192 (Fig. 1.8). 
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Figure 1.8. Composition of canonical PRC1. Boxes list each of the different orthologues for each core 
component. 
  
 Under the canonical polycomb signaling model, PRC1 is hypothesized to function downstream of 
PRC2, a methyltransferase a complex that is minimally composed of one of two methyltransferases, 
EZH1 or EZH2, and the scaffolding proteins SUZ12 and EED, a known H3K27me3 reader. PRC2 is 
responsible for deposition of H3K27me3 on nucleosomes which is then thought to recruit PRC1 to 
specific genomic loci through methyl-lysine binding by the CBX component of PRC1. The RING finger 
component of PRC1 then monoubiquitinates H2AK119. The presence of H2AK119ub on nucleosomes is 
associated with compacted chromatin and DNA methylation, resulting in stable repression of the 
underlying gene91, 92, 95 (Fig. 1.9). 
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Figure 1.9. Canonical Polycomb Signaling pathway. H3K27me3 is deposited by PRC2 (PDB 5HYN), 
minimally composed of EZH2 (red), EED (blue) and SUZ12 (gray). H3K27me3 then recruits PRC1 
through the Pc CBX component of the complex, allowing H2AK119 ubiquitination by the RING finger 
component. Recruitment of PRC1 to nucleosomes is associated with chromatin compaction, DNA 
methylation and stable genomic repression. The nucleosome image was adapted from PDB 5B0Z. 
  
 This simplistic model was derived from studies in Drosophila and provided a useful initial 
framework in which to begin exploring the biology of PRC1 in mammals. However, there is a growing 
body of literature that challenges the relevance of the canonical polycomb signaling pathway in mammals. 
For example, the composition of PRC1 is highly variable. In fact, there are now known to be a subset of 
PRC1 complexes in cells that differ from canonical PRC1 in that they lack a CBX component entirely. The 
lack of a known H3K27me3 reader in these non-canonical complexes creates an entire new branch of 
PRC1 biology that is PRC2-independent14, 89. 
 Additional studies have continued to raise considerable doubt as to the validity of the canonical 
polycomb signaling model in mammals. One study found that mutations and deletions of the CBX 
chromodomains that abolish H3K27me3 binding do not significantly alter the association of PRC1 with 
chromatin or with sites of H3K27me396. One possible explanation for this result could be explained by a 
recent study that found that EED is a component of both PRC1 and PRC2. The authors of this study 
postulated that EED orchestrates polycomb signaling by first localizing PRC2 to nucleosomes after which, 
PRC1 is localized to nucleosomes by binding to EED and competing away the other components of 
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PRC257. This however is refuted by the observation that even in EED null cells; the association of PRC1 
components is unchanged compared to WT96.  
 The canonical role of both the CBX component and deposition of H2AK119ub in PRC1-mediated 
genomic silencing have also been challenged by studies showing that the ubiquitination module of PRC1 
does not require a CBX protein nor H3K27me3 to interact with nucleosomes. Further, the presence of 
RING1B on chromatin, and not its catalytic activity, is responsible for PRC1-mediated transcriptional 
silencing and chromatin compaction12. Despite these challenges, there is still considerable evidence 
supporting the canonical signaling model18, 19, 93, indicating that signaling through PRC1 and PRC2 is 
extraordinarily complicated and that these two complexes are likely to be involved in multiple signaling 
pathways and feedback loops, making general statements about their physiological roles challenging. 
 
THE BIOLOGICAL FUNCTION OF PC CBX PROTEINS  
 While an in depth understanding of the polycomb signaling pathway(s) remains elusive, it is clear 
that Pc CBX proteins are critical for normal cellular function. For example, CBX7 is critical for repression 
of the inactive X chromosome94. Additionally, CBX2, -4 and -7 function within a tightly regulated feedback 
loop that controls cellular differentiation19, 45, 46, 81, 88, 89, 96. In embryonic stem cells, the predominant Pc 
CBX protein is CBX7, where it functions to help the cells maintain a pluripotent state. Interestingly, it does 
so at least partially through repression of CBX2 and -4. During differentiation, CBX7 is downregulated 
through expression of certain microRNAs, allowing CBX2 and -4 levels to increase. These two CBXs in 
turn repress expression of CBX7 in order to help maintain a differentiated state46, 88. A similar mechanism 
was observed for the regulation of hematopoietic stem cell differentiation where CBX7 expression is 
associated with pluripotency and is down regulated during differentiation when CBX2, -4 and -8 levels 
begin to increase19. The association of CBX7 with pluripotency is also correlated with stem cell self-
renewal and proliferation, while expression of the remaining Pc CBXs during differentiation correlates with 
reduced proliferation and eventually senescence19, 46, 88.  
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POLYCOMB CHROMODOMAINS IN CANCER 
 Given their role in regulating differentiation and proliferation, it is not surprising that Pc CBX 
proteins have been implicated in the development and progression of multiple cancers15-20, 41-44, 47-49, 62, 80, 
82-85, 87, 90.  Despite its shortcoming as general model for signaling through PRC1, there is evidence that 
the canonical polycomb signaling pathway plays a part in the development and progression of some 
cancers18, 19, 93. Therefore, it is encouraging that EZH2 antagonists have shown promise as therapeutic 
agents in laboratory models of multiple cancer types and are currently being evaluated in multiple clinical 
trials21, 23-25, 32, 36. While EZH2 antagonists are still many years from being validated as safe and effective 
therapeutic agents, their initial success is highly suggestive that antagonists targeting other components 
of polycomb signaling pathways are a viable therapeutic strategy. 
 Regardless of their biological role with respect to EZH2, Pc CBX proteins present a unique and 
interesting target class for potential oncology therapeutics. To date, CBX7 has been the most extensively 
characterized Pc CBX protein and regulation of its expression has been found to contribute to a variety of 
cancer types15-20, 42, 43, 48, 62, 80, 82-85, 87. Interest in the role of CBX7 in cancer began when it was identified in 
a genetic screen for cDNAs capable of bypassing replicative senescence in normal human prostate 
epithelial cells. CBX7 was found to dramatically increase cellular lifespan in a manner similar to c-Myc 
and the ability of CBX7 to confer a proliferative advantage was shown to be dependent on both its 
chromodomain and Pc box. Therefore, this activity requires both its ability to bind to methyl-lysine and to 
be incorporated into PRC1. These studies concluded that increased proliferative capacity bestowed by 
CBX7 overexpression is a conserved mechanism across different cell-types and is driven by repression of 
the INK4a/ARF locus by CBX715. These conclusions were further supported by a follow-up study focusing 
on the role of CBX7 in multiple prostate cancer cell lines. This study also suggested that CBX7 is 
important in the transition of prostate tumors to androgen independence16. 
 The notion that increased CBX7 overexpression is a general mechanism for increasing 
proliferative capacity was soon challenged by additional studies80, 82-85, 87. Studies in patient-derived 
thyroid cancer cell lines indicated that CBX7 functions as a tumor suppressor in thyroid tissues and found 
that loss of CBX7 expression correlates with increasing malignancy in these tumors. Further complicating 
matters, this study concluded that CBX7 functions to repress the INK4a/ARF locus in thyroid tissue as 
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well, indicating that the role of CBX7 in regulating cell proliferation is more complicated than simple 
regulation of the INK4a/ARF locus80. Continued studies have demonstrated the ability of CBX7 to function 
as a tumor suppressor in multiple cell lines, including lung, colon, breast and pancreatic cancers82-85, 87.  
One study even suggested that the more generalizable function of CBX7 is to serve as a tumor 
suppressor based on a CBX7-knockout mouse model which found that CBX7-KO mice were especially 
susceptible to developing adenomas and carcinomas of both the liver and lungs in adulthood. Studies 
with these mice also suggested that CBX7 positive regulates expression of the INK4a/ARF locus87, in 
direct contrast to previous studies15, 16, 80. However, despite the evidence for CBX7 serving as a tumor 
suppressor80, 82-85, 87, additional studies in prostate18, 43, leukemia19, lymphoma62, gastric17, and ovarian48 
cancers have supported the notion that CBX7 overexpression is generally oncogenic. Interestingly, these 
studies disagree on the general role of CBX7 in regulating the INK4a/ARF locus and how this relates to 
cell proliferation. 
 Although less explored than CBX7, a similar conflict exists concerning the roles of CBX2, -4 and -
8. In the context of stem cells, CBX2, -4 and -8 expression is associated with reduced proliferative 
capacity19, 46, 88. However, each of these proteins has also been shown to enhance proliferative capacity 
in at least one cancer type41, 44, 47, 49, 90, 93. CBX2 for instance has been found to be upregulated in tumors 
of the pancreas, central nervous system, colon, endometrium, ovaries, breast and lung. Additionally, 
analysis of the Oncomine database found that CBX2 mRNA levels are frequently increased in metastatic 
tumors in comparison to primary tumors. This same study did not uncover a single instance of 
underexpression of CBX2 in the Oncomine database90. Another study uncovered upregulation of CBX2 in 
neuroendocrine prostate cancer, a highly aggressive subtype of prostate cancer with a median survival of 
less than a year. This study revealed that, in addition to CBX2, EZH2 is also upregulated in this cancer 
subtype, suggesting that CBX2 contributes to the disease through the canonical polycomb signaling 
pathway93.  
 Similar to CBX7, CBX4 and -8 are each capable of bypassing cellular senescence41, 45, 49. In 
human epidermal stem cells, the chromodomain of CBX4 is responsible for repressing senescence, 
independent of its incorporation into PRC145. Additionally, CBX4 has been found to be upregulated in 
multiple hepatocellular carcinoma cell lines and clinical samples. Encouragingly, RNAi-mediated 
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knockdown of CBX4 was found to inhibit cell proliferation and to delay cell cycle progression in these cell 
lines47. Similar to CBX4, CBX8 is capable of bypassing senescence in a PRC1-independent fashion41, 44, 
49. CBX8 is known to be critical for the development of MLL-AF9 leukemias, again in a PRC1-independent 
manner, and its removal in mice does not affect normal hematopoietic development nor is it associated 
with any aberrant phenotype44.  
 In comparison to the other Pc CBX proteins, CBX6 has been severely understudied to date. Little 
is known about the biological role of CBX6 except that it appears to exist only in a limited subset of PRC1 
complexes and preferentially associates with other proteins outside of the context of PRC186. Additionally, 
only one study to date has evaluated the role of CBX6 in any cancer type, the findings of which suggest 
that CBX6 functions as a tumor suppressor in glioblastoma multiforme cell lines20. Little more can be said 
of the disease relevance of CBX6 at this time. 
 
SUMMARY 
 Readers, writers and erasers of the histone code play a critical role in regulating genomic 
expression in mammalian organisms. Overexpression and mutation of these proteins contributes to a 
variety of diseases, especially cancer. Encouragingly, many of these proteins have been shown to be 
pharmacologically tractable and antagonists of some of these proteins are showing promise in preclinical 
studies and clinical trials. However, many of these proteins are still unexplored in terms of small-molecule 
discovery efforts, particularly readers of lysine methylation.  
 The Pc CBX family of Kme3 readers is an important family of proteins that regulates cellular 
proliferation and differentiation. Further, these proteins have been linked to numerous cancer types. 
These proteins are highly similar in their chromodomains and bind to both H3K9me3 and H3K27me3 in 
vitro through a surface-groove recognition mechanism. The binding surface of these chromodomains is 
more lipophilic and enclosed than the structurally similar HP1 chromodomains, suggesting that they may 
be more tractable for targeting with small molecules.  
 Genetic manipulation of individual Pc CBX chromodomains has indicated that the contribution of 
these proteins in oncogenic signaling pathways is context dependent. The uncertainty surrounding the 
functions of these proteins in cancer, especially CBX7, is a clear indication that improved tools, especially 
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chemical probes, are needed to more clearly elucidate the function and therapeutic relevance of these 
proteins. Further, the roles of Pc CBX proteins in regulating cellular differentiation suggests that chemical 
probes for these proteins will also be valuable tools for exploring and understanding stem cell biology.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
24 
 
CHAPTER II: DEVELOPMENT OF HIGH AFFINITY LIGANDS FOR THE CBX7 CHROMODOMAIN 
INTRODUCTION 
 The pressing biological questions and lack of chemical probes available for Pc CBX proteins 
prompted us to undertake a discovery effort targeting this family of proteins. We opted to target the 
chromodomain of CBX7 initially due to its extensive biological characterization15-19, 42, 43, 46, 48, 62, 80, 82-89, 94, 
existing structural information68 and availability of an established AlphaScreen® competition assay 
developed in our lab66, 69, 74, 75. We set out to produce a validated, selective chemical probe for the 
chromodomain CBX7 with the understanding that monospecific chemical probes are often not readily 
feasible within highly homologous protein families, such the Pc CBX chromodomains. Therefore, we 
understood that any antagonists of the CBX7 chromodomain were likely to exhibit limited selectivity within 
the Pc CBX family of chromodomains. This is common among first-in-class chemical probes. 
Nonetheless, the utility of these molecules can still be profound. For example, the first in class 
bromodomain antagonist, JQ1, was not selective within the BET family of bromodomains but has greatly 
improved our knowledge of the role of BET bromodomains in numerous disease states8, 29. Further, the 
success of JQ1 in modulating many of these disease states sparked intense interest across multiple 
pharmaceutical and academic labs across the world, eventually leading to the identification of more 
potent and selective antagonists of BET bromodomains29. It is likely that efforts targeting Pc CBX 
chromodomains will ultimately follow a similar course. The homology of these proteins not only in terms of 
their chromodomain as a whole, but especially in the regions within their chromodomains that directly 
interact with H3 suggests a low probability of discovering molecules that are highly specific to individual 
chromodomains31. Nonetheless, potent, well-characterized molecules targeting these chromodomains are 
still likely to serve as valuable tools for elucidating the biology of these proteins and, similar to JQ1, may 
eventually lead to more selective and potent antagonists.   
 Our decision to focus on CBX7 was due in large part to the previous structural characterization of 
CBX7, which included NMR structures of the chromodomain in the apo form (PDB 2K1B), bound to 
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H3K9me3 (PDB 2L12) and bound to H3K27me3 (PDB 2L1B). These studies revealed that the CBX7 
aromatic cage (consisting of Phe11, Trp32 and Trp35) is disorganized in the apo form of the 
chromodomain. Recognition of H3K9me3 and H3K27me3 involves rearrangement of the chromodomain 
around the histone to form and functional aromatic cage and recognition of both histones occurs via an 
anti-paralle β-strand interaction (Fig. 2.1). In conjunction with these structural studies, mutagenesis 
studies were also done with both H3K9me3 and H3K27me3 peptides to better understand the binding 
preferences of CBX7. Encouragingly, these studies revealed that, while CBX7 is selective for ARKme3S 
motifs, it is not specific for this motif. In fact, these studies uncovered that the arginine of this consensus 
sequence is amenable to mutation to various hydrophobic residues to produce more potent peptidic 
ligands for CBX7. These extensive studies revealed that the overall consensus binding motif for CBX7 is 
actually A(R/I/L/F/Y/V)Kme3(S/T). The discovery of this binding motif led to the identification of a series of 
peptide sequences from the methyltransferase, SETDB1, which contain one of these consensus binding 
sequences. Each of these sequences binds to the chromodomain of CBX7 even more tightly than either 
H3K9me3 or H3K27me368. The success of these studies in finding more potent peptides that interact with 
CBX7 than either H3 substrate, in addition to the “druggability score of CBX728, suggested that CBX7 is a 
tractable target for discovery efforts.
 
Figure 2.1. Comparison of the apo, H3K9me3-bound and H3K27me3 bound structure of CBX7. 
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 Herein, we describe our approach toward the development of potent antagonists of the 
chromodomain of CBX7. Our initial efforts sought to identify a small molecule based lysine mimetic 
targeting the CBX7 aromatic cage that proved unsuccessful. This led us to pursue optimization of peptidic 
antagonists derived from one of the SETDB1 peptide sequences found to bind CBX7 more potently than 
both H3K9me3 and H3K27me3. Our first focus was to identify the shortest sequence capable of binding 
to CBX7. Next, we sought to replace the trimethyl ammonium moiety of this sequence. In order to 
increase the potency of our peptidic ligands, we utilized molecular dynamics simulations to guide our 
discovery efforts, culminating in the development of UNC3866, the most potent CBX7 antagonist 
published to date31, 38-40, 97. Finally, UNC3866 was derivatized to produce two additional tool compounds. 
The first compound, UNC4219, is a negative control compound that differs only by a single methyl group 
and displays no interaction with CBX7 at concentrations up to 100 µM. The second tool compound, 
UNC4195, is a biotinylated analog of UNC3866 that retains high affinity for CBX7 that was synthesized to 
serve as an affinity reagent for use in biochemical and cell-based experiments.  
 At the onset of the research described in this chapter, there were no reports of antagonists 
targeting the chromodomain of CBX7. During the course of the work described in this chapter, two studies 
were published from different laboratories detailing their efforts toward the development of CBX7 
antagonists38, 40. The first study described a peptide SAR approach, similar to the one described in this 
chapter, focused around the ALKme3S consensus sequence that was identified from SETDB138, 68. This 
study identified a peptide with a Kd of ~200 nM for the chromodomain of CBX7. No studies were reported 
that extensively detailed the selectivity of this peptide, nor its effects in cell-based assays38. A second 
study was published claiming to identify a weak, small molecule antagonist of the chromodomain of 
CBX7. SAR studies around this molecule proved ineffective for improving its potency and while cell-based 
experiments are described, these results are of questionable statistical significance40. Our own ITC 
studies with this molecule and a subsequent small molecule from the same group also reported to interact 
with CBX797 failed to confirm the ability of either molecule to bind to the chromodomain CBX7 in vitro. 
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RESULTS AND DISCUSSION 
Screening for small molecule antagonists of CBX7 
 Previously, we screened a library of ~2000 unique small molecules that were synthesized in-
house against the chromodomain of CBX7. These compounds had been designed to target multiple 
protein families and several hundred of these compounds were antagonists of the methyl-lysine reader 
domains of L3MBTL1, L3MBTL3 and/or 53BP1. Somewhat surprisingly, none of these molecules were 
inhibitory of the CBX7-H3 interaction when tested at concentrations up to 30 µM. We decided to pursue 
identification of small molecule CBX7 antagonists instead of exploring peptidic inhibitors initially because 
of the known challenges of developing peptides that antagonize intracellular targets. All peptides that had 
been shown to interact with CBX7 were minimally 9 amino acids long, putting their molecular weight at 
~1000 Da or more68, 94. In general, there is a negative correlation between molecular weight and passive 
membrane permeability. Further, each amide bond within a peptide endows the molecule with two 
heteroatoms, a carbonyl as a hydrogen bond acceptor and an amide nitrogen, which acts as a hydrogen 
bond donor. This greatly increases the polar character of the molecules, further reducing their 
permeability98. Additionally, to achieve single-digit micromolar affinity for CBX7, initial peptides identified 
in the literature required the presence of a trimethylated-lysine residue68, 94. The presence of a trimethyl-
ammonium is likely to be problematic in biological systems because the permanent cationic nature of the 
molecule makes it susceptible to trapping in both lysosomes and endosomes while also presenting a 
metabolic liability in that it can be inactivated by lysine demethylases99-101. Therefore, we elected to first 
pursue approaches focused on identifying small-molecules capable of antagonizing CBX7.  
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Figure 2.2. Structures of commercially available antagonists for quaternary ammonium binding proteins 
tested against CBX7. The IC50 for all of these compounds was determined to be >30 µM. 
 We reasoned that, because CBX7 is a reader of trimethylation with limited-to-no affinity for mono- 
and di-methylation, our in-house library of Kme antagonists were not active because their reader domain 
targets were all readers of mono- and dimethylation. To address this, we selected a set of compounds 
known to antagonize either muscarinic or nicotinic receptors, both of which recognize quaternary amines, 
with the hope that they may have off-target activity for the Kme3 binding region of CBX7. Disappointingly, 
none of these compounds displayed antagonism of the CBX7-H3 interaction in AlphaScreen® (Fig. 2.2). 
We simultaneously performed computational docking studies of the 100,000 compound UNC CICBDD 
diversity library with CBX7 in an effort to find a useful small molecule starting point. The top scorers were 
narrowed to a list of 32 compounds for screening against CBX7. Despite the fact that many of these 
compounds contained known methyl-lysine mimetics, none of these showed evidence of CBX7 
antagonism at concentrations up to 30 µM (Fig. 2.3). 
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Figure 2.3. Structures of top compounds from docking studies with CBX7 and the CICBDD diversity 
library. IC50 values for all compounds were >30 µM.  
 
 Our lack of success in identifying any small molecules capable of interacting with CBX7 prompted 
us to revisit a peptide-based approach. As discussed previously, there are many drawbacks to pursuing 
peptidic antagonists; however, peptides are the only class of molecules known to interact potently (Kd ~5 
M) with the chromodomain of CBX7. Therefore, in spite of their drawbacks, we performed a series of 
SAR studies targeting CBX7 using peptidic ligands. We elected to perform these studies around the 
RGFALKme3STHG peptide sequence identified from SETDB1. We chose this peptide because its 
published potency (Kd = 5 µM) was considerably better than both H3K9me3 (Kd = 55 µM) and H3K27me3 
(Kd = 110 µM) peptides68. Additionally, its lack of an arginine at the (-1) position from the Kme3 and the 
presence of a UV chromophore from the phenylalanine made it synthetically more attractive than other 
peptide sequences. Based on the aforementioned problems with peptidic antagonists, we focused first on 
determining the shortest possible peptide capable of antagonizing the CBX7-H3 interaction in an effort to 
increase the passive permeability of any derivative molecules by decreasing the size of the peptide and 
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reducing the number of hydrogen bond donors and acceptors98. Our second goal for this first SAR study 
was to determine whether any of the backbone amides of these peptides were dispensable for interaction 
with CBX7. Our final goal for this first study was to replace the Kme3 of our peptides with a non-
quaternary amine functionality. 
 
Identification of the minimal binding sequence required for CBX7 antagonism 
 In order to determine the minimal sequence necessary for binding to the chromodomain of CBX7. 
We focused on whether, in the context of shorter peptides, the entire consensus motif 
(A(R/I/L/F/Y/V)Kme3(S/T)) is needed for binding. All molecules synthesized were capped at the N-
terminus with a UV chromophore to aid in purification (Table 2.1, compounds 1-18; for compounds 3 and 
10, the FMOC protecting group was used as the chromophore to determine if it could pick up any 
additional interactions to aid in binding).  As Table 2.1 shows, antagonism of the CBX7-H3 interaction 
requires the entire ALKmeS motif plus an additional residue at the N-terminus; in this context, Phe. 
Compounds 1-14 were designed to simultaneously interrogate the requirement of the C-terminal serine 
and the lysine C-terminus. The lack of activity for any of these compounds suggests that additional 
interactions C-terminal to the Kme3 side chain are required for CBX7 interaction. Compounds 15-18 were 
synthesized to capture the full ALKme3S motif as well as up to 2 additional residues at the N-terminus as 
previous work suggested that these residues may be important for binding68. Only in the case of 5-residue 
peptide or longer was antagonism of the CBX7-H3 interaction observed (compounds 17-18). 
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Table 2.1 Exploration of sequence and length requirements for interaction with the CBX7 chromodomain 
 
Compound UNC ID R1 R2 R3 
CBX7 
IC50 
(µM) 
1 UNC2404 
 
 
 
>30 
2 UNC2403 
 
 
 
>30 
3 UNC2339 
 
 
 
>30 
4 UNC2401 
 
 
 
>30 
5 UNC2720 
 
 
 
>30 
6 UNC2588 
 
 
 
>30 
7 UNC2934 
 
 
 
>30 
8 UNC2994 
 
 
 
>30 
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Compound UNC ID R1 R2 R3 
CBX7 
IC50 
(µM) 
9 UNC2746 
 
 
 
>30 
10 UNC2338 
 
 
 
>30 
11 UNC2402 
 
 
 
>30 
12 UNC2745 
 
 
 
>30 
13 UNC2747 
 
 
 
>30 
14 UNC2597 
 
 
 
>30 
15 UNC2596 
  
 
>30 
16 UNC2864 
  
 
>30 
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Compound UNC ID R1 R2 R3 
CBX7 
IC50 
(µM) 
17 UNC2867 
  
 
1.1 ± 
0.63 
18 UNC2868 
 
 
 
7.4 ± 
4.7 
Data are reported as the average ± the standard deviation of the mean (n ≥ 2). 
 
 Compounds 17 and 18 were evaluated by ITC for biophysical confirmation of their binding and 
characterization of the thermodynamic parameters of the interaction (Fig. 2.4). While binding was 
observed for both compounds, only UNC2868 (compound 18) displayed saturable binding to CBX7 that 
could be reliably quantified, Kd = 10.3 ± 0.9 µM.  While it is unknown why UNC2868 displays better 
binding by ITC than UNC2867 despite appearing weaker in AlphaScreen®, it was nonetheless 
encouraging that we could validate these molecules as CBX7 antagonists in ITC. We elected to utilize 
UNC2868 as a scaffold for future SAR studies because of its robust ITC results.   
 
Figure 2.4. ITC studies with CBX7 and (left) UNC2867 and (right) UNC2868.  
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 We next explored the importance of the backbone of UNC2868 for interaction with CBX7. To do 
this, we chose to N-methylate select amides of UNC2868 based on the CBX7-H3K9me3 NMR structure 
(Fig. 2.5, PDB 2L12). Based on this structure, we reasoned that the N-H’s of the Ser, Kme3 and Leu 
residues were essential for binding. Therefore, we explored the effect of N-methylating the Ala, Phe and 
Gly or UNC2868 (Table 2.2). As can be seen in Table 2.2, methylation of both the Ala and Phe residues 
causes a loss of detectable binding at concentrations up to 30 µM. On the other hand, N-methylation of 
the glycine residue had no significant effect on binding when compared to the unmethylated analog, 
suggesting that this amide was dispensable for binding. 
 
Figure. 2.5. Hydrogen bonding between CBX7 and H3K9me3.  Hydrogen bonds are shown as black 
dashes. The arrows indicate which corresponding amides selected for methylation on UNC2868. PDB 
2L12 
 
Table 2.2 Effect of select backbone methylations of UNC2868 on binding to CBX7 
 
Compound UNC ID R1 R2 R3 
CBX7 ITC Kd 
(µM) 
19 UNC3261 
   
>30 
20 UNC3375 
   
>30 
21 UNC3403 
   
11 ± 3.0 
Data are reported as the average ± the standard deviation of the mean (n ≥ 2). 
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 In parallel with the studies in Table 2.2, we performed an SAR study around UNC2868 to find a 
suitable replacement for the Kme3 residue. Quaternary amines are problematic because they are 
susceptible to endosomal and lysosomal trapping99, 100, and can serve as substrates for demethylase 
enzymes101. We therefore explored the tolerance of the aromatic cage of CBX7 for various non-Kme3 
containing peptides in the context of UNC2868. We explored secondary, tertiary, non-basic and di-basic 
compounds to help identify non-quaternary ammonium species that can antagonize the chromodomain of 
CBX7 (Table 2.3). 
 We first synthesized compounds 22-25 as controls for our AlphaScreen® assay. These 
compounds behaved as expected with unmethylated (22), acetylated (23) and benzoylated (24) analogs 
displaying no evidence of interaction in the conditions of the assay and reduction of the methylation state 
to dimethyl (25) resulting in loss of potency. We next explored a series of bulkier secondary amines (26-
31), including one di-basic compound (31). In general, none of these modifications were well tolerated by 
CBX7. Simple isopropylation (26) showed weak antagonism, but increasing the size of the alkyl 
substituent proved detrimental for binding (27 and 28). Interestingly, fusion of the cyclopentyl and 
cyclohexyl groups of these two compounds into a norbornyl compound (29) restored activity of the 
compound to levels similar to the isopropyl derivative (26). Further increasing the lipophilicity of the ring 
system to an adamantyl derivative (30) abolished activity in our assay.  
 The highly lipophilic nature of the norbornyl moiety of 29 led us to question the importance of the 
cation- interaction between this compound and the aromatic cage of CBX7. If the norbornyl moiety is 
responsible for the interaction with the aromatic cage residues, then there would be little to no cation- 
interactions contributing to binding. To investigate this, we synthesized the di-basic 31 in an attempt to 
recover any lost cation- interactions. While this compound contains an additional bridge carbon, we 
hypothesized that the addition of a second basic amine could compensate for the increased steric bulk of 
the compound. Surprisingly, 31 displayed no activity in our assay at concentrations up to 100 µM. The 
lack of activity for this compound prompted us to remove the basicity of the amine through simple 
acetylation (32). Surprisingly, this compound displayed slightly improved affinity for CBX7 compared to 
29. Unfortunately, 32 has limited aqueous solubility, precluding validation of its binding to CBX7 by ITC. 
Nonetheless, taken together with compounds 24-25, this data suggests that the presence of basic 
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nitrogen is dispensable for interaction with the aromatic cage of CBX7 if sufficient lipophilic interactions 
are present on the molecule to compensate for the loss of the cation- interaction. However, compound 
33 suggests that the presence of a basic nitrogen is preferred as methylation of 29, rather than 
acetylation (32) resulted in a compound approximately equipotent to the trimethyl-lysine of UNC2868. 
Encouraged by 33, we explored other tertiary amines at this position (34-38). Interestingly, while 
considerably less lipophilic than the methyl, norbornyl-lysine of 33, the diethyl-lysine of 35 was found to 
be equipotent for CBX7. Restriction of the terminal methyls of this compound in the form of the 
pyrrolidinyl-lysine of 36 reduced binding approximately 3-fold. Affinity was only recovered when the ring 
size was increased to 7-atoms (38). Finally, we synthesized the more strongly basic 39 and di-basic 
compound 40 to test whether these could form improved and/or additional cation- interactions with the 
aromatic cage of CBX7. While the activity of these compounds was detectable in our assay, it was 
considerably weaker than the Kme3 of UNC2868. Taken together, this data indicate that presence of a 
Kme3 is not required for interaction with CBX7 and that the loss of the quaternary ammonium of this 
residue can be compensated for by tertiary amines with certain lipophilic functionalities, but not through 
additional or improved cation- interactions.    
 
Table 2.3 Exploration of Kme3 replacements for UNC2868 
 
Compound UNC ID R CBX7 IC50 (µM) 
18 UNC2868 
 
7.4 ± 4.7 
22 UNC3189 
 
>100 
23 UNC3267 
 
>100 
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Compound UNC ID R CBX7 IC50 (µM) 
24 UNC3546 
 
>100 
25 UNC3188 
 
24 ± 0.53 
26 UNC3563 
 
34 ± 1.2 
27 UNC3315 
 
51 ± 3.8 
28 UNC3314 
 
>100 
29 UNC3265 
 
37 ± 2.5 
30 UNC3264 
 
>100 
31 UNC3266 
 
>100 
32 UNC3649 
 
17 ± 8 
33 UNC3313 
 
3.9 ± 0.3 
34 UNC3260 
 
>100 
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Compound UNC ID R CBX7 IC50 (µM) 
35 UNC3567 
 
4.0 ± 0.6 
36 UNC3580 
 
13 ± 2 
37 UNC3581 
 
14 ± 2 
38 UNC3648 
 
4.0 ± 0.4 
39 UNC3564 
 
41 ± 8 
40 UNC3566 
 
52 ± 4.2 
Data are reported as the average ± the standard deviation of the mean (n ≥ 2). 
  
 Our studies in Table 2.3 presented us with 3 suitable replacements for the Kme3 of UNC2868; 
methyl, norbornyl (33, UNC3313), diethyl (35, UNC3567), and azepane (38, UNC3648). The synthesis of 
UNC3648 was considerably less efficient than both UNC3313 and UNC3567. Therefore, we elected to 
forgo this modification in favor of the other two for follow up SAR studies. Binding of 33 (UNC3313); the 
unmethylated analog of 33, 29 (UNC3265); and 35 (UNC3567) was confirmed by ITC (Fig. 2.6). 
Interestingly, despite the different activities of UNC3313 and UNC3265 in AlphaScreen®, these 
compounds were approximately equipotent by ITC (12 µM vs 15 µM, respectively). UNC3567 showed the 
most potent binding by ITC, though only by approximately 2-fold over UNC3265 and UNC3313. The 
diethyl-lysine of UNC3567 and the norbornyl of UNC3265 were chosen as methyl-lysine replacements for 
subsequent analogs because of their validated, similar binding affinities and synthetic ease. 
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Figure. 2.6. ITC studies between CBX7 and peptides with various Kme3 replacements. Numbers in 
parentheses indicate the number of replicates for each experiment. Data are reported and the average ± 
the standard deviation of the mean. 
 
 While we were encouraged by our ability to replace the Kme3 of UNC2868, these efforts did not 
afford any significant improvements in binding affinity for CBX7. We therefore pursued a series of SAR 
studies focused on improving the potency of our target compounds. Initially, we were intrigued by the 
ability of the norbornyl functionality of UNC3265 to bind in the absence of any cation- interactions, 
therefore, we elected to use this moiety as our initial Kme3 replacement. We first started by attempting to 
reduce the peptidic nature and size of our compounds. Our backbone methylation studies in Table 2.2 
indicated that the N-terminal amide of our antagonists was dispensable for binding. Compound 41 (Table 
2.4), which does not contain this amide, was therefore synthesized and found to show stronger activity 
than its parent compound (UNC3265, 29). While this was an improvement, we were still unable to 
accomplish submicromolar potencies for our compounds. The extensive amino acid SAR that had been 
done previously68 suggested that the core amino acid sequence (FALKme3S) was largely optimized, 
prompting us to seek out an alternative approach for accessing higher potency compounds. 
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 We were intrigued by the conformational rearrangement that CBX7 has to undergo to organize its 
aromatic cage in order to allow for Kme3 recognition (Figures 2.1 and 2.7). CBX7 has to rearrange in 
such a way that the N-terminus of the chromodomain is displaced approximately 18.6 Å (Fig. 2.6c) in 
order to position Phe11 in close enough proximity to Trp32 and Trp35 to form a functional aromatic cage. 
We reasoned that a physical understanding of this process would aid in the design of more potent 
compounds.   
 
Figure 2.7. Comparison of CBX7 in the bound and apo conformations. (a) Comparison of the backbone 
conformations and aromatic cage of CBX7 in the apo (salmon) and H3-bound (light blue) conformations, 
histone not shown. (b) Comparison of the CBX7 aromatic cage in the apo (salmon) and bound (light blue) 
conformations. H3K9me3 is shown in pale yellow. (c) Measurement of the displacement of the N-terminus 
of CBX7 during binding to H3K9me3. (PDB 2L12) 
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 We therefore turned to adaptively biased molecular dynamics simulations using the previously 
published NMR structure of CBX7 bound to H3K9me3 (PDB 2L12). We computed possible histone exit 
paths from this structure and the pathway shown in Fig. 2.8 was favored when we considered a truncated 
form of H3K9me3 (residues 4-10), which was most analogous to our pepitidic antagonists. Starting from 
the bound state as shown in Fig. 2.8, Frame I, the N-terminus of CBX7 opens by losing partial contact 
with H3 (transition from Frame I to II). Subsequently, the Kme3 loses contact with the aromatic cage 
(transition from Frame II to III), leaving H3 engaged with CBX7 primarily through hydrophobic contacts 
made with V13, D50 and L53 (Frame III). Complete dissociation of H3 and CBX7 occurs following the 
loss of these contacts. 
 
Figure 2.8. Molecular dynamics simulation of the CBX7-H3K9me3 interaction.  Free energy plot depicting 
the calculated binding pathway of CBX7-H3K9me3. Arrows are drawn from potential energy wells to 
representative structures associated with that well. Frames I-III represent one possible dissociative path 
of H3 from CBX7, and the reverse of these frames represents the corresponding associative path of 
CBX7 and H3. The N-terminus label is referring to the N-terminus of CBX7. 
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 Association of CBX7 and H3 is simply the microscopic reversal of this exit path and is analogous 
to β-hairpin folding between two anti-parallel β-strands. In this case, one β-strand is formed by the 
histone; the other by residues 8-13 of CBX7.  Therefore, establishing the appropriate contacts between 
the N-terminal portion of the H3 peptide (residue Q5, Fig. 2.8, Frame III and Fig. 2.9) and CBX7 (namely 
residues V13, D50 and L53) during association is analogous to forming the critical β-turn during hairpin 
folding. Once the turn is formed, backbone hydrogen bonds ‘zip’ the β-hairpin into the fully folded state. In 
the case of CBX7, in addition to the formation of an extensive hydrogen bond network, this also orients 
Phe11 of CBX7 to contact the Kme3 and facilitates formation of the aromatic cage. We utilized this 
pathway for H3 binding as a model for the association of CBX7 with our antagonists and hypothesized 
that optimizing the N-terminal interactions of these compounds with CBX7 would facilitate the necessary 
hydrogen bonding for closure of CBX7 around the molecules, thereby increasing ligand affinity. 
 
Figure 2.9 Hydrophobic contacts made by H3Q5 during association of CBX7 and H3K9me3 peptides 
  
 Compounds 42-44 were synthesized to begin interrogating our binding hypothesis from the MD 
simulations. Compounds 42 and 43 were synthesized to mimic the hydrogen bond donation functionality 
of Gln5 of H3. Neither of these compounds showed significantly stronger interaction with the 
chromodomain of CBX7 than 41. However, replacement of the phenyl ring of 41 with a naphthyl moiety 
(44) led to a sub-micromolar antagonist in AlphaScreen®. Unfortunately, 44 exhibits minimal solubility in 
aqueous buffers, precluding characterization of its interaction with CBX7 in ITC. Nonetheless, these 
results supported our binding hypothesis derived from the MD simulations wherein hydrophobic 
interactions at this position are important for nucleating clasp closure and entrance into the bound state. 
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Further, this data indicates that the hydrophobic contacts are amenable to optimization in order to 
approve the affinity of our antagonists for CBX7.  
 
Table 2.4. Initial N-terminal modifications of a norbornyl-lysine containing CBX7 antagonist 
 
Compound UNC ID R CBX7 IC50 (µM) 
41 UNC3486 
 
10 ± 3 
42 UNC3562 
 
5.4 ± 2 
43 UNC3565 
 
9.8 ± 0.6 
44 UNC3556 
 
0.75 ± 0.01 
Data are reported as the average ± the standard deviation of the mean (n ≥ 2). 
 
 The insoluble nature of 44 prompted us to reconsider the use of norbornyl-lysine as our Kme3 
replacement. The need for N-terminal hydrophobic functionalities as suggested by our data in Table 2.4 
indicated that use of a more soluble modified lysine derivative would be important for allowing 
characterization of our compounds with CBX7 by ITC. Therefore, we chose to use diethyl-lysine as our 
Kme3 mimetic for future analogs. Compound 45, which is the diethyl analog of 44 was synthesized and 
found to be approximately equipotent to 44 and still insoluble, again preventing its characterization by 
ITC. Compounds 46 and 47, which each contain an additional heteroatom, were synthesized with the 
intention of increasing the solubility of this series of compounds. While the indole of 46 was equipotent to 
napthyl (45), insertion of the additional methylene group in 47 reduced binding approximately 2-3 fold. 
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While we do not expect the presence of the primary amine to have any effect on binding based on our 
studies in Table 2.2, we cannot completely rule out this possibility.  
 
Table 2.5. N-terminal modifications of a diethyl-lysine containing CBX7 antagonist 
 
Compound UNC ID R CBX7 IC50 (µM) CBX7 Kd (ITC, µM) 
45 UNC3772 
 
0.56 ± 0.3 N/D 
46 UNC3771 
 
0.56 ± 0.2 N/D 
47 UNC3773 
 
1.4 ± 0.4 3.4 (1) 
48 UNC4973 
 
N/D 5.2 ± 1 
49 UNC4974 
 
N/D 0.33 ± 0.005 
50 UNC3867 
 
0.62 ± 0.6 0.22 ± 0.03 
51 UNC3769 
 
0.086 ± 0.02 0.14 ± 0.02 
52 UNC3865 
 
0.13 ± 0.07 0.16 ± 0.008 
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53 UNC3866 
 
0.064 ± 0.01 0.097 ± 0.002 
54 UNC4975 
 
N/D 0.24 ± 0.01 
55 UNC3768 
 
0.11 ± 0.09 N/D 
56 UNC3770 
 
0.22 ± 0.1 N/D 
Data are reported as the average ± the standard deviation of the mean (n ≥ 2 except where noted in 
parentheses). 
 
 The apparently detrimental effect of increasing the spacing between the N-terminal amide of 
these molecules and the aromatic ring system prompted us to pursue a series of compounds which 
eliminated any methylene spacers. Further, the insolubility of the bicyclic ring systems prompted us to 
pursue alternative hydrophobic functionalities. Our studies in Table 2.1 indicated that a simple benzoyl 
cap (17) is insufficient for sub-micromolar antagonism of CBX7. Therefore, we performed a short SAR 
study in which we added a single methyl group at the ortho-, meta- or para- positions to test the effect on 
binding to CBX7. These compounds proved soluble enough for characterization by ITC. Therefore, we 
assessed their binding to CBX7 directly using this technique. Placing the methyl group at the ortho-
position of the benzoyl cap (48) showed low micromolar affinity for CBX7. Shifting this methyl group to the 
meta-position (49) bestowed sub-micromolar activity to this compound. Shifting to the para-position 
proved to be the optimal position for this alkyl substituent. Consistent with our MD hypothesis, increasing 
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the lipophilicity of the alkylation at this position (50-53) further improved the potency with tert-butyl 
substitution at the para-position (53, UNC3866) providing our most potent antagonist with a Kd of 97 nM. 
Encouragingly, we saw consistent trends in both AlphaScreen® and ITC for compounds 50-53. While the 
data for compounds 48-53 was consistent with our hypothesis that binding at this portion of the molecule 
is driven primarily by van der Waals’ interactions, we sought to further investigate this by tuning the 
electronics of the benzoyl cap (compounds 54-56). The tert-butyl of UNC3866 is weakly electron-
donating, therefore, we replaced this functionality with a more strongly electron-donating methoxy- 
functional group. This resulted in an approximately 2.5-fold reduction in binding affinity as determined by 
ITC. The electron-withdrawing functionalities of 55 and 56 were also detrimental to binding. Particularly 
interesting is that the trifluoro-methyl group of 56 reduced binding when compared to the isopropyl of 52. 
This was surprising because trifluoro-methyl and isopropyl groups are approximately the same size and 
hydrophobicity. Taken together, this data suggests that the tert-butyl of UNC3866 is optimal for interaction 
with CBX7 in terms of the degree and positioning of alkylation as well as stereoelectronics of the aromatic 
ring. 
 In collaboration with Jinrong Min at the Structural Genomics Consortium in Toronto, we solved 
the X-ray co-crystal structure of UNC3866 bound to CBX7 (PDB 5EPJ) at a resolution of 1.6 Å to improve 
our understanding for the potency of UNC3866 for CBX7 (Fig 2.10). Consistent with our data in Table 2.1 
and Table 2.2, each backbone amide of UNC3866 participates in at least one hydrogen bond with the 
backbone of CBX7. The induced fit binding mechanism coupled with the extensive network of hydrogen 
bonds likely accounts for the length requirements of our peptidic antagonists as well as our lack of 
success in discovering small molecule antagonists of the CBX7 chromodomain. The N-terminal 
rearrangement of CBX7 to form the aromatic cage is likely paid for energetically by the formation of these 
hydrogen bonds. Without these, the aromatic cage is too disorganized to form significant interactions with 
shorter peptides and small molecules. 
 The N-terminal tert-butyl benzoyl cap of UNC3866 primarily contacts the side chains of D50, R52, 
and L53 (Fig. 3c). The guanidinium moiety of R52 forms a salt bridge with D50 and this rigidified R52 
side-chain forms a hydrophobic groove with L53 within which the tert-butyl phenyl group of UNC3866 is 
embedded. Based on our MDS studies, we suspect that the 70-fold affinity increase observed upon 
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substitution of our initial benzoyl-glycyl cap, present on UNC3567, for the tert-butyl benzoyl cap of 
UNC3866 is the result of an improvement in the ability of this moiety to nucleate closure of CBX7 around 
the molecule through interactions with D50, R52 and L53.  
 
Figure. 2.10. X-ray co-crystal structure of UNC3866 (pale yellow) bound to CBX7 (light blue). PDB code 
5EPJ. 
 
 We utilized this crystal structure to design additional analogs of UNC3866 to serve as tool 
compounds for studying CBX Pc proteins and characterizing UNC3866 (Fig. 2.11). We first synthesized a 
negative control analog, UNC4219, which differs from UNC3866 only by Nα-methylation of the Ala residue 
of UNC3866 and is inactive at concentrations up to 100 µM as assessed by ITC (Fig. 2.11b). This 
modification was chosen based on both the UNC3866-CBX7 co-crystal structure (Fig. 2.10) and our SAR 
studies in Table 2.2. Additionally, the crystal structure indicated that the methyl ester of UNC3866 is 
solvent exposed and not making any significant interactions with the chromodomain. We therefore 
generated a biotinylated analog of UNC3866, UNC4195, by hydrolyzing the methyl ester and attaching 
biotin through an amine terminated PEG-linker. This reagent maintains high affinity for CBX7 as 
determined by ITC (Kd = 220 ± 22 nM). 
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Figure 2.11. CBX7 chemical tool kit. (a) Structures of UNC3866 and its corresponding negative control, 
UNC4219. (b) Representative ITC curves for CBX7 with UNC3866 (black) and UNC4219 (blue). (c) 
Structure of biotinylated affinity reagent analog of UNC3866, UNC4195. 
 
CONCLUSIONS 
 These studies have provided valuable insight into the tractability of targeting CBX7. Our studies 
suggest that small molecules are unlikely to be capable of potently engaging the chromodomain of CBX7. 
However, it is possible that our studies aimed at identifying traditional small molecule antagonists of 
CBX7 were simply outside of the appropriate chemical space. However, the induced-fit mechanism of 
binding to CBX7 described here suggests that peptidic antagonists are required for formation of and 
interaction with the aromatic cage of CBX7. An alternative approach could be to search for small 
molecules capable of binding to the apo conformation of CBX7, although currently, there are no known 
endogenous ligands capable of binding to this conformation, giving little guidance as to which areas of 
chemical space would be worth exploring to identify such molecules. 
 While peptides suffer from a number of drawbacks as discussed, our studies have proven that 
this class of molecules can be modified to produce potent CBX7 antagonists. These studies have shed 
considerable light on the binding preferences of CBX7 and have identified the key region of CBX7 to 
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target for improving affinity of for this chromodomain. While UNC3866 is not a drug-like molecule, the 
purpose of chemical probe discovery efforts is to produce biologically useful molecules. The utility of 
chemical probes is based primarily on their selectivity and demonstrated ability to modulate their given 
target within a biological system. Just as first-in-class chemical probes may exhibit limited selectivity, they 
also can suffer from poor drug-like properties. Nevertheless, these molecules still have the potential for 
answering important biological question and their development provides the initial chemical scaffold and 
SAR necessary for ultimately further improving both their selectivity and drug-like properties. Our studies 
involving further biophysical and selectivity characterization of UNC3866 are discussed in chapter III and 
our efforts to characterize UNC3866 in cellular and in vivo settings are discussed in chapter IV. 
 
METHODS 
Adaptively Biased Molecular Dynamics Simulations 
Adaptive biasing potential102 was implemented in GROMACS 4.5.5103. The bias parameters were b=0.8, 
c=0.0005/δt, where δt=2 fs is the molecular dynamics time step. The Gaussian width was 1/4 Angstrom. 
This choice of bias parameters floods stable states extremely slowly, to minimize adaptation of the bias 
near transition states. Thus, one may argue for approximate state-to-state dynamics as has recently been 
done for metadynamics104 following the principles of hyperdynamics105. Using the first frame of the 
CBX7+H3K9me3 NMR structure, two collective variables were defined: RMSD of clasp, and RMSD of 
peptide. We used the Kabsch algorithm to align the reference and trajectory during the simulation. All 
simulations were performed in a cubic box with a minimum of 12 Angstroms between the protein or 
peptide and the nearest cube face, resulting in 23710 atoms after adding water and salt. System 
construction included 5 nsec of isothermal–isobaric equilibration at 1 bar. Production simulations were 
carried out in the canonical ensemble with stochastic velocity rescaling106. Van der Waals and direct 
electrostatic interactions used a 10 Å cutoff. Long-range electrostatics were treated with the particle mesh 
Ewald approach with a grid spacing of 1.6 Å. The neighbor list was updated every five steps. We ran five 
128 ns simulations to get some intuition that could inform ligand design. All images from the simulations 
were rendered using the PyMOL Molecular Graphics System, Version 1.7.4 Schrödinger, LLC. 
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ITC Experiments 
All ITC measurements were recorded at 25 °C with an AutoITC200 microcalorimeter (MicroCal Inc., MA).  
All protein and compound stock samples were in the target buffer (25 mM Tris-HCl, pH 8, 150 mM NaCl, 
and 2 mM β-mercaptoethanol), and then diluted in the same buffer to achieve the desired concentrations: 
50 µM protein and 0.5 mM compound.  The concentration of the protein stock solution was established 
using the Edelhoch method, whereas compound stock solutions were prepared based on mass. A typical 
experiment included a single 0.2 µl compound injection into a 200 µl cell filled with protein, followed by 25 
subsequent 1.5 µl injections of compound.  Injections were performed with a spacing of 180 seconds and 
a reference power of 8 µcal/sec.  Control experiments were performed titrating each compound into buffer 
under identical conditions to determine the heat signals, if any, that arise from diluting the compound.  If 
applicable, the heats of dilution generated were then subtracted from the protein-compound binding 
curves. The initial data point was routinely deleted.  The titration data was analyzed using Origin Software 
(MicroCal Inc., USA) by non-linear least squares, fitting the heats of binding as a function of the 
compound:protein ratio to a one site binding model.   
 
Kme Reader AlphaScreen® Assays 
The AlphaScreen® assay (Perkin Elmer) was generally performed as previously described.69 In brief, 
compound plates (1 µL at 10 mM highest concentration; 3-fold, 10-point dilutions in DMSO) were diluted 
in 1X assay buffer (20 mM TRIS pH 8.0, 25 mM NaCl, 2 mM DTT and 0.05% Tween-20) to 1 mM using a 
Multimek robotic pipettor (Nanoscreen) and 1 µL was spotted into the wells of 384-well low-volume 
Proxiplates (Perkin Elmer). To these plates 9 µL of protein-peptide mix in 1X assay buffer was added by 
Multidrop (Thermo) to bring the final compound concentration to 100 µM and incubated for 30 min at 
room temperature. Next, 2 µL of a 1:1 mixture of streptavidin-conjugate donor and nickel-chelate or α-
GST acceptor beads (45 µg/mL in 1X assay buffer) were added and the plates were allowed to incubate 
for an additional 30 min in the dark at room temperature. After incubation, the plates were read on an 
EnVision multi-label reader equipped with an HTS AlphaScreen laser (Perkin Elmer). The expression and 
purification of the constructs used in this assay was described previously76. 
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Table 2.6 CBX7 peptide substrate used in AlphaScreen® 
Protein Peptide Peptide sequence 
CBX7 H3K9Me3 ARTKQTARK(Me3)STGGKAPRKQL-K(Biotin)-NH2   
 
Protein Expression and Purification 
All expression constructs were transformed into Rosetta BL21(DE3)pLysS competent cells (Novagen, 
EMD Chemicals, San Diego, CA).  Protein expression was induced by growing cells at 37°C with shaking 
until the OD600  reached ~0.6-0.8 at which time the temperature was lowered to 18°C and expression 
was induced by adding 0.5mM IPTG and continuing shaking overnight.  Cells were harvested by 
centrifugation and pellets were stored at -80°C.   
His-tagged proteins were purified by re-suspending thawed cell pellets in 30ml of lysis buffer (50mM 
sodium phosphate pH 7.2, 50mM NaCl, 30mM imidazole, 1X EDTA free protease inhibitor cocktail 
(Roche Diagnostics, Indianapolis, IN)) per liter of culture.  Cells were lysed on ice by sonication with a 
Branson Digital 450 Sonifier (Branson Ultrasonics, Danbury, CT) at 40% amplitude for 12 cycles with 
each cycle consisting of a 20 second pulse followed by a 40 second rest.  The cell lysate was clarified by 
centrifugation and loaded onto a HisTrap FF column (GE Healthcare, Piscataway, NJ) that had been 
preequilibrated with 10 column volumes of binding buffer (50mM sodium phosphate pH 7.2, 500mM NaCl, 
30mM imidazole) using an AKTA FPLC (GE Healthcare, Piscataway, NJ).  The column was washed with 
15 column volumes of binding buffer and protein was eluted in a linear gradient to 100% elution buffer 
(50mM sodium phosphate pH 7.2, 500mM NaCl, 500mM imidazole) over 20 column volumes.  Peak 
fractions containing the desired protein were pooled and concentrated to 2ml in Amicon Ultra-15 
concentrators 3,000 molecular weight cut-off (Merck Millipore, Carrigtwohill Co. Cork IRL).  Concentrated 
protein was loaded onto a HiLoad 26/60 Superdex 75 prep grade column (GE Healthcare, Piscataway, 
NJ) that had been preequilibrated with 1.2 column volumes of sizing buffer (25mM Tris pH 7.5, 250mM 
NaCl, 2mM DTT, 5% glycerol) using an ATKA Purifier (GE Healthcare, Piscataway, NJ).  Protein was 
eluted isocratically in sizing buffer over 1.3 column volumes at a flow rate of 2ml/min collecting 3ml 
fractions.  Peak fractions were analyzed for purity by SDS-PAGE and those containing pure protein were 
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pooled and concentrated using Amicon Ultra-15 concentrators 3,000 molecular weight cut-off (Merck 
Millipore, Carrigtwohill Co. Cork IRL). 
GST-tagged proteins were purified by re-suspending thawed cell pellets in 30ml of lysis buffer (1xPBS, 
5mM DTT, 1X EDTA free protease inhibitor cocktail (Roche Diagnostics, Indianapolis, IN)) per liter of 
culture.  Cells were lysed on ice by sonication as described for His-tagged proteins.  Clarified cell lysate 
was loaded onto a GSTrap FF column (GE Healthcare, Piscataway, NJ) that had been pre-equilibrated 
with 10 column volumes of binding buffer (1xPBS, 5mM DTT) using a AKTA FPLC (GE Healthcare, 
Piscataway, NJ).  The column was washed with 10 column volumes of binding buffer and protein was 
eluted in 100% elution buffer (50mM Tris pH 7.5, 150mM NaCl, 10mM reduced glutathione) over 10 
column volumes.  Peak fractions containing the desired protein were pooled and concentrated to 2ml in 
Amicon Ultra-15 concentrators, 10,000 molecular weight cut-off (Merck Millipore, Carrigtwohill Co. Cork 
IRL).  Concentrated protein was loaded onto a HiLoad 26/60 Superdex 200 prep grade column (GE 
Healthcare, Piscataway, NJ) that had been preequilibrated with 1.2 column volumes of sizing buffer 
(25mM Tris pH 7.5, 250mM NaCl, 2mM DTT, 5% glycerol) using an ATKA FPLC (GE Healthcare, 
Piscataway, NJ).  Protein was eluted isocratically in sizing buffer over 1.3 column volumes at a flow rate 
of 2ml/min collecting 3ml fractions.  Peak fractions were analyzed for purity by SDS-PAGE and those 
containing pure protein were pooled and concentrated using Amicon Ultra-15 concentrators 10,000 
molecular weight cut-off (Merck Millipore, Carrigtwohill Co. Cork IRL). 
 
General chemistry procedures 
Analytical LCMS data for all compounds were acquired using an Agilent 6110 Series system with the UV 
detector set to 220 nm.  Samples were injected (<10 µL) onto an Agilent Eclipse Plus 4.6 × 50 mm, 
1.8 µm, C18 column at room temperature.  Mobile phases A (H2O + 0.1% acetic acid) and B (MeOH + 
0.1% acetic acid) were used with a linear gradient from 10% to 100% B in 5.0 min, followed by a flush at 
100% B for another 2 minutes with a flow rate of 1.0 mL/min.  Mass spectra (MS) data were acquired in 
positive ion mode using an Agilent 6110 single quadrupole mass spectrometer with an electrospray 
ionization (ESI) source.  Reverse phase column chromatography was performed with a Teledyne Isco 
CombiFlash®Rf 200 using C18 RediSep®Rf Gold columns with the UV detector set to 220 nm and 254 
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nm. Mobile phases of A (H2O + 0.1% TFA) and B (MeOH or MeCN) were used with default column 
gradients. Preparative HPLC was performed using an Agilent Prep 1200 series with the UV detector set 
to 220 nm and 254 nm.  Samples were injected onto a Phenomenex Luna 250  30 mm, 5 µm, C18 
column at room temperature. Mobile phases of A (H2O + 0.1% TFA) and B (MeOH or MeCN) were used 
with a flow rate of 40 mL/min.  A general gradient of 0-15 minutes increasing from 10 to 100% B, followed 
by a 100% B flush for another 5 minutes.  Small variations in this purification method were made as 
needed to achieve ideal separation for each compound.  Analytical LCMS (at 220 nm) was used to 
establish the purity of targeted compounds.  All compounds that were evaluated in biochemical and 
biophysical assays had >95% purity as determined by LCMS. 
 
Synthesis of UNC2404 (1) 
 
Benzoic acid (200 mg, 1.6 mmol, 1.0 eq) and TBTU (680 mg, 2.1 mmol, 1.3 eq.) were dissolved in 6 mL 
of DMF. N-boc-cadaverine (1.2, 2.0 mmol, 410 µL) was added to the solution followed by TEA (690 µL, 
4.9 mmol, 3.0 eq.). The solution was stirred overnight at room temperature. The mixture was diluted with 
brine (100 mL) and extracted 3X with DCM (50 mL).  The organic extracts were combined and dried over 
Na2SO4, filtered and concentrated by rotary evaporation. The residue was taken up in 1.5 mL DCM. TFA 
(1 mL, excess) was added to the solution and the mixture was stirred at room temperature until complete. 
The reaction was concentrated by rotary evaporation and by vacuum-dried overnight to yield 303 mg 
(90%) of crude product. The crude product was carried forward without further purification as a TFA salt. 
MSI (ESI): 207 [M+H]+ 
 
N-(5-aminopentyl)benzamide 2,2,2-trifluoroacetate (30 mg, 1.5 mmol, 1.0 eq.) and K2CO3 (1.2 g, 8.8 
mmol, 6.0 eq.) were dissolved in 1.5 mL of EtOH. Iodomethane was added (920 µL, 15 mmol, 10 eq.) and 
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the reaction was stirred  at room temperature overnight. Iodomethane  was added (400 µL, 6.4 mmol, 5.0 
eq.) and the mixture was stirred until complete. The reaction was concentrated by rotary evaporation, 
taken up in 1600 mL of methanol and purified by HPLC ((H2O + 0.1% TFA)/MeOH) to yield 212 mg (58%) 
of the title compound as a trifluoroacetate salt. MSI (ESI): 249.25 [M]+ 
 
Synthesis of UNC2403 (2) 
 
Fmoc-Leu-OH (500 mg, 1.4 mmol, 1.0 eq) and TBTU (590 mg, 3.1 mmol, 1.3 eq.) were dissolved in 5 mL 
of DMF. N-boc-cadaverine (1.2, 1.7 mmol, 350 µL) was added to the solution followed by DIPEA (540 µL, 
1.8 mmol, 2.2 eq.). The solution was stirred for 2 hours at room temperature. The mixture was diluted with 
brine (100 mL) and extracted 3X with DCM (50 mL).  The organic extracts were combined and dried over 
Na2SO4, filtered and concentrated by rotary evaporation. The residue was purified by normal phase 
column chromatography (hexanes/EtOAc) to yield 747 mg (98%) of the desired product. MSI (ESI): 538 
[M+H]+ 
 
tert-butyl (S)-(5-(2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-4-methylpentanamido)pentyl) carbamate 
(100 mg, 0.19 mmol, 1.0 eq) was dissolved in 1.8 mL of THF. Diethylamine (190 µL, 1.9 mmol, 10 eq.) 
was added and the mixture was stirred at room temperature overnight. The mixture was concentrated by 
rotary evaporation and dried under high vacuum at room temperature overnight. The crude product was 
dissolved in 1 mL of DMF. Benzoic acid (27 mg, 0.22 mmol, 1.2 eq.), TBTU (78 mg, 0.24 mmol, 1.3 eq.) 
and TEA (78 µL, 0.56 mmol, 3.0 eq.) were added and the mixture was stirred at room temperature 
overnight. The solution was diluted in EtOAc (50 mL) and washed 3X with brine (50 mL). The organic 
extract was dried over Na2SO4, filtered, concentrated by rotary evaporation and purified by normal phase 
column chromatography (hexanes/EtOAc) to yield 64.8 mg (83%) of  tert-butyl (S)-(5-(2-benzamido-4-
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methylpentanamido)pentyl)carbamate. MSI (ESI): 420 [M+H]+. tert-butyl (S)-(5-(2-benzamido-4-
methylpentanamido)pentyl)carbamate was dissolved in 1.5 mL DCM. TFA (1 mL) was added and the 
reaction was stirred until completion. The crude product was concentrated by rotary evaporation and 
carried through without further purification. MSI (ESI): 320 [M+H]+ 
 
(S)-N-(1-((5-aminopentyl)amino)-4-methyl-1-oxopentan-2-yl)benzamide TFA salt (49 mg, 0.15 mmol, 1.0 
eq.) was dissolved in EtOH (1.5 mL). Sodium cyanoborohydride (29 mg, 0.46 mmol, 3.0 eq.) and 37% 
aqueous formaldehyde (50 µL, 0.68 mmol, 4.4 eq.) mmol, were added and the mixture was stirred until 
completion. The mixture was concentrated by rotary evaporation, taken up in 1600 mL of MeOH and 
purified by HPLC ((H2O + 0.1% TFA)/MeOH) to yield 21.5 mg (30%) of UNC2403 as a TFA salt. MSI 
(ESI): 348.3 [M+H]+ 
 
Synthesis of UNC2339 (3) 
 
 
tert-butyl (S)-(5-(2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-4-methylpentanamido)pentyl) carbamate 
(250 mg, 0.46 mmol, 1.0 eq.) was dissolved in 4 mL of DCM. TFA (3 mL, excess) was added and the 
mixture was stirred at room temperature for 1 hour. The solution was concentrated by rotary evaporation. 
The crude residue was taken up in 1 mL EtOH. Iodomethane (290 µL, 4.6 mmol, 10 eq) and K2CO3 (190 
mg, 1.4 mmol, 3.0 eq.) were added and the mixture was stirred overnight at room temperature. 
Iodomethane (290 µL, 4.6 mmol, 10 eq) and K2CO3 (190 mg, 1.4 mmol, 3.0 eq.) were added and the 
mixture was stirred overnight. The solution was concentrated by rotary evaporation and purified by HPLC 
((H2O + 0.1% TFA)/MeOH) to yield 226 mg (83%) of the title compound as a trifluoroacetate salt. MSI 
(ESI): 480.4 [M]+ 
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Synthesis of UNC2401 (4)
 
(S)-5-(2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-4-methylpentanamido)-N,N,N-trimethylpentan-1-
aminium 2,2,2-trifluoroacetate (170 mg, 0.29 mmol, 1.0 eq.) was dissolved in THF (3 mL). Octanethiol 
(500 µL, 2.9 mmol, 10 eq.) was added followed by dropwise addition of DBU (1.3 µL, .009 mmol, 0.3 eq.). 
The solution was stirred at room temperature. After one hour, 0.5 eq. of DBU was added. Upon 
completion, the solution was concentrated by rotary evaporation. The resulting residue was triturated with 
2 mL of ice cold ether. The ether was decanted followed by three additional ether triturations. The residue 
was placed on under high vacuum overnight to yield 92 mg (86%) of (S)-5-(2-amino-4-
methylpentanamido)-N,N,N-trimethylpentan-1-aminium. (S)-5-(2-amino-4-methylpentanamido)-N,N,N-
trimethylpentan-1-aminium was dissolved in 1 mL of DMF. Benzoic acid (36 mg, 0.30 mmol, 1.2 eq.), 
TBTU (100 mg, 0.32 mmol, 1.3 eq.) and DIPEA (95 µL, 0.54 mmol, 2.2 eq.) were added and the mixture 
was stirred at room temperature for 2 hours. The solution was diluted w/ DCM (50 mL) and brine (100 
mL). The aqueous layer was extracted 3X with 50 mL of DCM. Product was retained in the aqueous 
layer, which was concentrated and resuspended in 1600 µL MeOH. The suspension was then filtered and 
purified by HPLC ((H2O + 0.1% TFA)/MeOH) to yield 41 mg (35%) of UNC2401 as a trifluoroacetate salt. 
MSI (ESI): 362.3 [M]+ 
 
Synthesis of UNC2720 (5) 
 
Boc-cadaverine (100 µL, 0.49 mmol, 1.0 eq.) was dissolved in 5 mL of EtOH. Formaldehyde (37% aq., 
160 µL, 2.2 mmol, 4.4 eq.) and sodium cyanoborohydride (190 mg, 3.0 mmol, 6.0 eq.) were added and 
the mixture was stirred at room temperature for 15 minutes. Acetic acid (140 µL, 2.5 mmol, 5eq.) was 
added and the mixture was stirred at room temperature until complete. The solution was concentrated by 
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rotary evaporation and taken up in 5 mL of a 6N solution of HCl in isopropyl alcohol. Upon completion, the 
mixture was concentrated under rotary evaporation and carried forward without further purification. MSI 
(ESI): 131 [M+H]+ 
 
Boc-Leu-OH monohydrate (100 mg, 0.41 mmol, 1.0 eq.), N1,N1-dimethylpentane-1,5-diamine·2TFA salt 
(64 mg, 0.49 mmol, 1.2 eq.) and TBTU (170 mg, 0.54 mmol, 1.3 eq.) were dissolved in DMF (5 mL). TEA 
(340 µL, 3.0 mmol, 6.0 eq.) was added and the reaction was stirred at room temperature overnight. The 
mixture was diluted with EtOAc (50 mL) and washed 3X with saturated bicarbonate (50 mL). The 
aqueous washes were combined and extracted 3X with 50 mL EtOAc. The organic extracts were 
combined, dried over Na2SO4, concentrated by rotary evaporation and dried overnight under high 
vacuum. The residue was taken up 5 mL of a 6N solution of HCl in isopropyl alcohol. The solution was 
stirred at room temperature until the reaction was complete. The solution was concentrated by rotary 
evaporation and dried overnight under reduced pressure to afford the product as a dihydrochloride salt in 
quantitative yield. MSI (ESI): 122 [M+2H]2+, 244 [M+H]+. The product was carried forward without further 
purification. 
 
Boc-Ala-OH (91 mg, 0.48 mmol, 1.0 eq.), (S)-2-amino-N-(5-(dimethylamino)pentyl)-4-
methylpentanamide·2HCl (140 mg, 0.58 mmol, 1.2 eq.), and TBTU (200 mg, 0.63 mmol, 1.3 eq.) were 
dissolved in DMF (5 mL). TEA (400 µL, 2.9 mmol, 6 eq.) was added and the reaction was stirred at room 
temperature for 2 hours. The solution was diluted with 50 mL of EtOAc and washed 3X with saturated 
bicarbonate (50 mL). The aqueous washes were combined and extracted 3X with EtOAc (50 mL). The 
organic extracts were combined and dried over Na2SO4 and concentrated by rotary evaporation. The 
residue was taken up in 5 mL of DCM and stirred at room temperature until complete. The solution was 
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concentrated by rotary evaporation and dried under reduced pressure overnight to yield the product in 
nearly quantitative yield as a TFA salt. MSI (ESI): 157 [M+2H]2+, 314 [M+H]+  
 
Benzoic acid (49 mg, 0.40 mmol, 1.0 eq.), (S)-2-((S)-2-aminopropanamido)-N-(5-(dimethylamino)pentyl)-
4-methylpentanamide (150 mg, 0.48 mmol, 1.2 eq.) and TBTU (170 mg, 0.52 mmol, 1.3 eq.) were 
dissolved in EtOAc (4 mL). TEA (340 µL, 2.4 mmol, 6 eq.) was added and the mixture was stirred at room 
temperature until complete. The solution was concentrated and taken up in 1600 µL of MeOH, filtered and 
purified by HPLC ((H2O + 0.1% TFA)/MeOH) to yield 51 mg (30% of UNC2720 as a TFA salt. MSI (ESI): 
419.3 [M+H]+ 
 
Synthesis of UNC2588 (6) 
 
tert-butyl (S)-(5-(2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-4-methylpentanamido)pentyl) carbamate 
(300 mg, 0.56 mmol, 1.0 eq.) was dissolved in THF (5.5 mL). DEA (580 µL, 5.6 mmol, 10 eq.) was added 
and the solution was stirred overnight at room temperature. The mixture was concentrated by rotary 
evaporation and dried under reduced pressure overnight. The residue was taken up in DMF (2 mL) and 
stirred at room temperature. Fmoc-Ala-OH (210 mg, 0.67 mmol, 1.2 eq.), TBTU (230 mg, 0.73 mmol, 1.3 
eq.) and DIPEA (210 µL, 1.2 mmol, 2.2 eq.) were added and the reaction was stirred at room temperature 
until complete. The solution was diluted with EtOAc (50 mL), washed 2X with brine (50 mL). The organic 
layer was dried over Na2SO4.and concentrated by rotary evaporation to give 122 mg (36%) of the desired 
product. MSI (ESI): 609 [M+H]+. The crude product was carried forward without further purification.  
59 
 
 
tert-butyl ((5S,8S)-1-(9H-fluoren-9-yl)-8-isobutyl-5-methyl-3,6,9-trioxo-2-oxa-4,7,10-triazapentadecan-15-
yl)carbamate was dissolved in THF (2 mL) and stirred at room temperature. Diethylamine (200 µL, 
excess) was added and the reaction was stirred at room temperature until complete. The solution was 
concentrated by rotary evaporation and dried under reduced pressure overnight. The crude product was 
taken up in DMF (1 mL) and stirred at room temperature. Benzoic acid (17 mg, 0.14  mmol, 1.0 eq.), 
TBTU (57 mg, 0.18 mmol, 1.3 eq.) and TEA (57 µL, 0.41 mmol, 3.0 eq.) were added and the solution was 
stirred overnight. The mixture was diluted with EtOAc (50 mL) and washed 3X with brine (50 mL). The 
organic layer was dried over Na2SO4 and concentrated by rotary evaporation. The residue was taken up 
in 1.4 mL of DCM and stirred at room temperature. TFA (1 mL) was added and the reaction was stirred at 
room temperature until completion. The solution was concentrated by rotary evaporation and carried 
forward without further purification. MSI (ESI): 391 [M+H]+  
 
N-((S)-1-(((S)-1-((5-aminopentyl)amino)-4-methyl-1-oxopentan-2-yl)amino)-1-oxopropan-2-yl)benzamide 
(54 mg, 0.14 mmol, 1.0 eq.), K2CO3 (110 mg, 0.82 mmol, 6 eq.), iodomethane (86 µL, 1.4 mmol, 10 eq.) 
were taken up in EtOH (1.4 mL). The solution was stirred at room temperature. The mixture was 
concentrated by rotary evaporation and taken up in 1600 µL MeOH and filtered. The filtrate was purified 
by HPLC ((H2O + 0.1% TFA)/MeOH) to yield 18 mg (24%) of UNC2588 as a trifluoroacetate salt. MSI 
(ESI): 433.4 [M]+   
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Synthesis of UNC2934 (7) 
tert-butyl ((5S,8S)-1-(9H-fluoren-9-yl)-8-isobutyl-5-methyl-3,6,9-trioxo-2-oxa-4,7,10-triazapentadecan-15-
yl)carbamate (300 mg, 0.50 mmol, 1.0 eq.) was taken up in 2.5 mL THF and stirred at room temperature. 
Diethylamine (2.5 mL, excess) was added and the reaction was stirred at room temperature until 
complete. Once complete, the solution was concentrated by rotary evaporation and carried forward 
without further purification. MSI (ESI): 387 [M+H]+. The crude residue was taken up in DMF (5 mL) and 
stirred at room temperature. Fmoc-Phe-OH (230 mg, 0.60 mmol, 1.2 eq.), TBTU (210 mg, 0.65 mmol, 1.3 
eq.), and DIPEA (110 µL, 0.65 mmol, 1.3 eq.) were added and the reaction was stirred at room 
temperature until complete. The solution was diluted with EtOAc (50 mL), and washed 3X with brine (75 
mL). Precipitate was observed in the organic  layer. The organic layer suspension was collected and 
concentrated by rotary evaporation. The residue was purified by normal phase column chromatography 
(DCM/20% MeOH in DCM). Product-containing fraction were combined, concentrated by rotary 
evaporation and purified by normal phase column chromatography to yield 260 mg (68%) of the desired 
product. MSI (ESI): 756 [M+H]+ 
    
 tert-butyl ((5S,8S,11S)-5-benzyl-1-(9H-fluoren-9-yl)-11-isobutyl-8-methyl-3,6,9,12-tetraoxo-2-oxa-
4,7,10,13-tetraazaoctadecan-18-yl)carbamate (100 mg, 0.13 mmol, 1.0 eq.) was dissolved in DMF (1 mL) 
and stirred at room temperature. Diethylamine (1 mL, excess) was added and the reaction was stirred at 
room temperature until complete. The solution was concentrated by rotary evaporation and dried under 
reduced pressure overnight. The crude product was taken up in DMF (1 mL) and stirred at room 
temperature. Benzoic acid (19 mg, 0.13  mmol, 1.2 eq.), TBTU (55 mg, 0.17 mmol, 1.3 eq.) and TEA (55 
µL, 0.40 mmol, 3.0 eq.) were added and the solution was stirred until complete. The mixture was diluted 
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with EtOAc (50 mL) and washed 3X with brine (50 mL). The organic layer was dried over Na2SO4 and 
concentrated by rotary evaporation. The residue was purified by normal phase column chromatography 
(Hexanes/EtOAc). Product-containing fractions were combined, concentrated by rotary evaporation and 
taken up in 0.5 mL of DCM and stirred at room temperature. TFA (0.5 mL) was added and the reaction 
was stirred at room temperature until completion. The solution was concentrated by rotary evaporation 
and carried forward without further purification. MSI (ESI): 538 [M+H]+  
N-((S)-1-(((S)-1-(((S)-1-((5-aminopentyl)amino)-4-methyl-1-oxopentan-2-yl)amino)-1-oxopropan-2-
yl)amino)-1-oxo-3-phenylpropan-2-yl)benzamide (24 mg, 0.045 mmol, 1.0 eq.), K2CO3 (37 mg, 0.27 
mmol, 6 eq.), iodomethane (28 µL, 0.45 mmol, 10 eq.) were taken up in MeOH (0.5 mL). The was heated 
to 110°C by microwave irradiation and stirred vigorously for 10 minutes. The solution was diluted with 1 
mL of MeOH and filtered. The filtrate was purified by HPLC ((H2O + 0.1% TFA)/MeOH) to yield 18 mg 
(56%) of UNC2934 as a trifluoroacetate salt. MSI (ESI): 580.4 [M]+ 
Synthesis of UNC2994 (8) 
 
tert-butyl ((5S,8S,11S)-5-benzyl-1-(9H-fluoren-9-yl)-11-isobutyl-8-methyl-3,6,9,12-tetraoxo-2-oxa-
4,7,10,13-tetraazaoctadecan-18-yl)carbamate (160 mg, 0.21 mmol, 1.0 eq.) was dissolved in DMF (1 mL) 
and stirred at room temperature. Diethylamine (1 mL, excess) was added and the reaction was stirred at 
room temperature until complete. The solution was concentrated by rotary evaporation and dried under 
reduced pressure overnight. The crude product was taken up in DMF (1 mL) and stirred at room 
temperature. Fmoc-Gly-OH (74 mg, 0.25  mmol, 1.2 eq.), TBTU (87 mg, 0.27 mmol, 1.3 eq.) and DIPEA 
(47 µL, 0.27 mmol, 1.3 eq.) were added and the solution was stirred until complete. The mixture was 
diluted with EtOAc (50 mL) and washed 3X with brine (50 mL). The organic layer was dried over Na2SO4 
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and concentrated by rotary evaporation. The residue was purified by normal phase column 
chromatography (Hexanes/EtOAc) to yield 130 mg (76%) of the desired product. MSI (ESI): 813 [M+H]+ 
 
(9H-fluoren-9-yl)methyl tert-butyl ((4S,7S,10S)-4-benzyl-10-isobutyl-7-methyl-2,5,8,11-tetraoxo-3,6,9,12-
tetraazaheptadecane-1,17-diyl)dicarbamate carbamate (130 mg, 0.16 mmol, 1.0 eq.) was dissolved in 
DMF (0.75 mL) and stirred at room temperature. Diethylamine (0.75 mL, excess) was added and the 
reaction was stirred at room temperature until complete. The solution was concentrated by rotary 
evaporation and dried under reduced pressure overnight. The crude product was taken up in DMF (1.5 
mL) and stirred at room temperature. Benzoic acid (23 mg, 0.19  mmol, 1.2 eq.), TBTU (66 mg, 0.20 
mmol, 1.3 eq.) and DIPEA (55 µL, 0.31 mmol, 2.0 eq.) were added and the solution was stirred until 
complete. The mixture was diluted with EtOAc (50 mL) and washed 3X with brine (50 mL). The organic 
layer was dried over Na2SO4 and concentrated by rotary evaporation. The residue was purified by normal 
phase column chromatography (Hexanes/EtOAc) to yield 91 mg (83%) of the desired product. MSI (ESI): 
695 [M+H]+ 
 
tert-butyl ((6S,9S,12S)-6-benzyl-12-isobutyl-9-methyl-1,4,7,10,13-pentaoxo-1-phenyl-2,5,8,11,14-
pentaazanonadecan-19-yl)carbamate (91 mg, 0.13 mmol, 1.0 eq.) was taken up in 1.3 mL of DCM and 
the solution was stirred at room temperature. TFA (0.5 mL) was added and the reaction was stirred until 
completion. The solution was concentrated by rotary evaporation. The residue was taken up in MeOH (2 
mL) transferred to a microwave reaction vessel. Iodomethane (82 µL, 1.3 mmol, 10 eq.) and K2CO3 (110 
mg, 0.79 mmol, 6.0 eq.) was added, the vessel was sealed and placed into a microwave reactor. The 
solution was heated to 110°C for 10 min with vigorous stirring. The solution was filtered and purified by 
HPLC ((H2O + 0.1% TFA)/MeOH) to yield 29.1 mg (30%) of UNC2994 as a trifluoroacetate salt. MSI 
(ESI): 637 [M]+ 
63 
 
Synthesis of UNC2746 (9) 
 
Fmoc-Lys-OH (150 mg, 0.32 mmol, 1.0 eq.), Methylamine hydrochloride (26 mg, 0.38 mmol, 1.2 eq.), 
TBTU (130 mg, 0.42 mmol, 1.3 eq.) and DIPEA (120 µL, 0.70 mmol, 2.2 eq.) were dissolved in DMF (3 
mL) and stirred at room temperature until the reaction was complete. The solution was diluted with EtOAc 
(50 mL), washed 3X with brine (50 mL), dried over Na2SO4 and concentrated by rotary evaporation. The 
crude product was taken up in DMF (2.5 mL) and stirred at room temperature. Benzoic acid (33 mg, 0.27 
mmol, 1.0 eq.), TBTU ( 110 mg, 0.35 mmol, 1.3 eq.) and TEA (110 µL, 0.80 mmol, 3.0 eq.) were added 
and the solution was stirred overnight at room temperature. The solution was diluted with EtOAc (50 mL), 
washed 3X with brine (50 mL), dried over Na2SO4 and concentrated by rotary evaporation. The crude 
product was purified by normal phase column chromatography (hexanes/ EtOAc) to yield 65 mg (67%) of 
the desired product.  MSI (ESI): 264 [M+H]+  
 
Bz-Lys(Boc)-NMe (65 mg, 0.18 mmol, 1.0 eq.) was dissolved in DCM (2 mL). Two mL of TFA was added 
and the reaction was stirred at room temperature overnight. The solution was concentrated by rotary 
evaporation and taken up in MeOH (2 mL). Sodium cyanoborohydride (67 mg, 1.1 mmol, 6.0 eq.), 37% 
Aq. formaldehyde (59 µL, 0.79 mmol, 4.4 eq.) was added and the solution was stirred until the reaction 
was complete. The solution was filtered and purified by HPLC ((H2O + 0.1% TFA)/MeOH) to yield 14 mg 
(19%) of UNC2746 as a TFA salt. MSI (ESI): 292.2 [M+H]+ 
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Synthesis of UNC2338 (10) 
 
Fmoc-Lys(Boc)-NMe (210 mg, 0.43 mmol, 1.0 eq.) was dissolved in DCM (4 mL). TFA (2 mL) was added 
and the solution was stirred at room temperature until the reaction was complete. The solution was 
concentrated by rotary evaporation and the residue was taken up in 3.5 mL EtOH. Iodomethane (240 µL, 
3.8 mmol, 10 eq.) and K2CO3 (180 mg, 1.3 mmol, 3.3 eq.) were added and the solution was stirred 
overnight at room temperature. The solution was concentrated by rotary evaporation, taken up in 1600 µL 
MeOH, filtered, and purified by HPLC ((H2O + 0.1% TFA)/MeOH) to yield 140 mg (68%) of UNC2338 as a 
trifluoroacetate salt. MSI (ESI): 424.3 [M]+ 
 
Synthesis of UNC2402 (11) 
 
Fmoc-Lys(me3)-NMe (100 mg, 0.19 mmol, 1.0 eq.) was dissolved in THF (2 mL). The solution was stirred 
at room temperature and octanethiol (330 µL, 1.9 mmol, 10 eq.) and DBU (2.8 µL, 0.019 mmol, 0.1 eq.) 
were added. The solution was stirred overnight at room temperature. Ice cold ether was added to triturate 
the product. Solvent was decanted off and the crude residue was dried under reduced pressure 
overnight. The residue was taken up in DMF (1 mL). The solution was stirred at room temperature and 
benzoic acid (28 mg, 0.23 mmol, 1.2 eq.), TBTU (78 mg, 0.24 mmol, 1.3 eq.) and TEA (58 µL, 0.41 mmol, 
2.2 eq.) were added and the reaction was stirred overnight at room temperature. The solution was diluted 
with brine (50 mL) and extracted 3X with DCM (50 mL). The aqueous layer was collected, concentrated, 
taken up in 1600 µL MeOH, filtered and purified by HPLC ((H2O + 0.1% TFA)/MeOH) to yield  31 mg 
(39%) of UNC2402 as a trifluoroacetate salt. MSI (ESI): 306.25 [M]+ 
 
65 
 
Synthesis of compounds 12-57: 
Synthetic scheme I: UNC2745 (12), UNC2747(13) and UNC2597 (14) 
 
Synthetic scheme II: UNC2596 (15) 
 Synthetic scheme III: compounds 16-21
 
Synthetic scheme IV: UNC3189 (23) 
 
Synthetic Scheme V: compounds 23-40 
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Synthetic Scheme VI: compounds 41-57
 
 
General Procedures 
 
Amide couplings followed by Boc removal 
To a solution of 0.1 M carboxylic acid (1.0 eq) in DMF was added 1.2 equivalents of amine, 1.3 
equivalents of TBTU and 2.2 equivalents of DIPEA. The reaction was stirred at room temperature for 30 
min to overnight. The mixture was diluted with EtOAc (100 mL) and washed 3X with brine (100 mL). The 
organic layer was then dried over Na2SO4, filtered and concentrated by rotary evaporation. The resulting 
residue was dissolved in a mixture of 20% TFA in DCM. The solution was stirred at room temperature for 
30 minutes to overnight. The mixture was concentrated by rotary evaporation and purified by reverse-
phase column chromatography ((Water + 0.1% TFA)/Methanol) to yield the TFA salt of the target 
compound. Typical yields ranged from 60-90%. 
 
Amide couplings followed by FMOC-removal 
To a solution of 0.1 M carboxylic acid (1.0 eq) in DMF was added 1.2 equivalents of amine, 1.3 
equivalents of TBTU and 2.2 equivalents of DIPEA. The reaction was stirred at room temperature for 30 
min to overnight. The mixture was diluted with EtOAc (100 mL) and washed 3X with brine (100 mL). The 
organic layer was then dried over Na2SO4, filtered and concentrated by rotary evaporation. The resulting 
residue was dissolved in a mixture of 20% diethylamine in DMF. The solution was stirred at room 
temperature for 30 minutes to overnight. The mixture was concentrated by rotary evaporation and purified 
by reverse-phase column chromatography ((Water + 0.1% TFA)/Methanol) to yield the TFA salt of the 
target compound. Typical yields ranged from 40-70%. 
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Reductive aminations with aldehydes  
The lysine containing peptide (1.0 eq) was dissolved in methanol at a concentration of 0.1 M. Sodium 
cyanoborohydride (3.0 eq) and aldehyde (8.0 eq.) were added and the solution was stirred at RT until the 
amine starting material was consumed. The mixture was then concentrated and purified by reverse phase 
column chromatography ((H20 + 0.1% TFA)/MeOH) to yield the target compound as a TFA salt. Typical 
yields ranged from 60-90%. 
 
Reductive aminations with ketones 
The lysine containing peptide (1.0 eq) was dissolved in methanol at a concentration of 0.1 M. Sodium 
cyanoborohydride (3.0 eq) and aldehyde (8.0 eq.) were added and the solution was stirred at 50°C for 2 
hours until the amine starting material was consumed. The mixture was then concentrated and purified by 
reverse phase column chromatography ((H20 + 0.1% TFA)/MeOH) to yield the target compound as a TFA 
salt. Typical yields ranged from 40-70%. 
 
Cyclic alkylations  
The lysine containing peptide (1.0 eq) was dissolved in MeCN at a final concentration of 0.1 M. 
Dibromoalkane (1.2 eq) and DIPEA (3.1 eq) were added. The solution was heated at 110°C in a 
microwave reactor for 1 hour. The solution was then concentrated by rotary evaporation and the residue 
was purified by HPLC ((H20 + 0.1% TFA)/MeOH) to yield the target compound as a TFA salt. Yields 
ranged from 25-70%. 
 
Lysine Trimethylation 
The lysine containing peptide (1.0 eq) was dissolved in MeOH at a final concentration of 0.1 M. 
Iodomethane (10.0 eq) and K2CO3 (6.0 eq) were added and the mixture was stirred overnight at room 
temperature. The mixture was concentrated by rotary evaporation and dissolved in a solution of 1M 
NaOH at a concentration of 0.1 M and stirred for 30 minutes at room temperature. The solution was then 
brought to pH 7 with 37% aq HCl and concentrated by rotary evaporation. The residue was purified by 
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HPLC ((H20 + 0.1% TFA)/MeCN) to yield the target compound as a TFA salt. Typical yields ranged from 
50-80%. 
Table 2.7 Compound structures and characterization by LCMS 
Compound 
ID 
Structure LCMS trace (220 nM) 
Observed 
Mass 
UNC2404 (1) 
 
 
249.25 [M]+ 
UNC2403 (2) 
 
 
348.3 [M+H]+ 
UNC2339 (3) 
 
 
480.4 [M]+ 
UNC2401 (4) 
 
 
362.3 [M]+ 
UNC2720 (5) 
 
 
419.3 [M+H]+ 
UNC2588 (6) 
 
 
433.4 [M]+ 
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UNC2934 (7) 
 
 
580.4 [M]+ 
UNC2994 (8) 
 
 
637 [M]+ 
UNC2746 (9) 
 
 
292.2 [M+H]+ 
UNC2338 
(10) 
 
 
424.3 [M]+ 
UNC2402 
(11) 
 
 
306.25 [M]+ 
UNC2745 
(12) 
 
 
405.30 [M+H]+ 
UNC2747 
(13) 
 
 
419.30 [M]+ 
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UNC2597 
(14) 
 
 
490.35 [M]+ 
UNC2596 
(15) 
 
 
490.40 [M+H]+ 
UNC2864 
(16) 
 
 
578.35 [M]+ 
UNC2867 
(17) 
 
 
363.30 
[M+H]2+ 
725.40 [M]+ 
UNC2868 
(18) 
 
 
391.80 
[M+H]2+  
782.45 [M]+ 
UNC3261 
(19) 
 
 
796.45 [M]+ 
UNC3375 
(20) 
 
 
398.80 
[M+H]2+ 
796.40 [M]+ 
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UNC3403 
(21) 
  
398.80 
[M+H]2+ 
796.40 [M]+ 
UNC3189 
(23) 
  
370.80 
[M+2H]2+ 
740.40 [M+H]+ 
762.40 
[M+Na]+ 
UNC3188 
(22) 
 
 
384.80 
[M+2H]2+ 
768.40 [M+H]+ 
UNC3267 
(24) 
 
 
782.35 [M+H]+ 
UNC3546 
(25) 
 
 
844.50 [M+H]+ 
UNC3563 
(26) 
  
402.80 
[M+H+Na]2+ 
782.40 [M+H]+ 
UNC3315 
(27) 
 
 
808.45 [M+H]+ 
UNC3314 
(24) 
 
 
411.85 
[M+2H]2+ 
422.80 
[M+H+Na]2+ 
822.45 [M+H]+ 
72 
 
UNC3265 
(29) 
  
417.85 
[M+2H]2+ 
834.50 [M+H]+ 
UNC3264 
(30) 
 
 
448.85 
[M+H+Na]2+ 
874.50 [M+H]+ 
UNC3266 
(31) 
 
 
425.30 
[M+2H]2+ 
849.45 [M+H]+ 
UNC3649 
(32) 
 
 
876.00 [M+H]+ 
898.00 
[M+Na]+ 
UNC3313 
(33) 
 
 
435.80 
[M+Na]+ 
848.50 [M+H]+ 
UNC3260 
(34) 
 
 
424.90 
[M+2H]2+ 
435.85 
[M+H+Na]2+ 
848.50 [M+H]+ 
UNC3567 
(35) 
 
 
398.80 
[M+2H]2+ 
409.80 
[M+H+Na]2+ 
796.45 [M+H]+ 
UNC3580 
(36) 
 
 
397.75 
[M+2H]2+ 
408.80 
[M+H+Na]2+ 
794.40 [M+H]+ 
UNC3581 
(37) 
 
 
404.75 
[M+2H]2+ 
415.75 
[M+H+Na]2+ 
808.40 [M+H]+ 
UNC3648 
(38) 
  
411.80 
[M+2H]2+ 
422.80 
[M+H+Na]2+ 
822.50 [M+H]+ 
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UNC3564 
(39) 
  
419.80 
[M+2H]2+ 
430.85 
[M+H+Na]2+ 
838.45 [M+H]+ 
UNC3566 
(40) 
  
405.35 
[M+2H]2+ 
416.25 
[M+H+Na]2+ 
809.50 [M+H]+ 
UNC3486 
(41) 
  
791.45 [M+H]+ 
UNC3562 
(42) 
 
 
806.50 [M+H]+ 
UNC3565 
(43) 
  
806.45 [M+H]+ 
UNC3556 
(44) 
  
841.50 [M+H]+ 
UNC3772 
(45) 
 
 
803.50 [M+H]+ 
UNC3771 
(46) 
 
 
407.80 
[M+H+Na]2+ 
792.45 [M+H]+ 
UNC3773 
(47) 
 
 
416.80 
[M+H+Na]2+ 
832.50 [M+H]+ 
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UNC4973 
(48) 
 
 
753.45 [M+H]+ 
UNC4974 
(49) 
 
 
377.30 
[M+2H]2+ 
754.45 [M+H]+ 
UNC3867 
(50) 
 
 
388.10 
[M+H+Na]2+ 
753.10 [M+H]+ 
UNC3769 
(51) 
 
 
767.50 [M+H]+ 
UNC3865 
(52) 
 
 
402.30 
[M+H+Na]2+ 
781.50 [M+H]+ 
UNC3866 
(53) 
 
 
409.35 
[M+H+Na]2+ 
795.50 [M+H]+ 
UNC4975 
(54) 
 
220 nm
 
 
254 nm
 
385.25 
[M+2H]2+ 
769.45 [M+H]+ 
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UNC3768 
(55) 
 
 
797.40 [M+H]+ 
UNC3770 
(56) 
 
 
807.40 [M+H]+ 
UNC4219 
(57) 
 
Rotamer a 
 
Rotamer b 
 
 
809 [M+H]+ 
UNC4195 
(58) 
 
 
511 [M+3H]3+ 
767 [M+2H]2+ 
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1H NMR spectrum of UNC2404 as a trifluoroacetate salt 
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1H NMR spectrum of UNC2403 as a TFA salt 
 
1H NMR spectrum of UNC2339 as a TFA salt 
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1H NMR spectrum of UNC2339 as a trifluoroacetate salt 
 
1H NMR spectrum of UNC2720 as a TFA salt 
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1H NMR spectrum of UNC2588 as a trifluoroacetate salt 
 
1H NMR spectrum of UNC2934 as a trifluoroacetate salt 
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1H NMR spectrum of UNC2934 as a trifluoroacetate salt 
 
1H NMR spectrum of UNC2746 as a TFA salt 
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1H NMR spectrum of UNC2338 as a trifluoroacetate salt 
 
1H NMR spectrum of UNC2402 as a trifluoroacetate salt 
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1H NMR spectrum of UNC2745 as a TFA salt 
 
1H NMR spectrum of UNC2747 as a trifluoroacetate salt 
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1H NMR spectrum of UNC2597 as a trifluoroacetate salt 
 
1H NMR spectrum of UNC2596 as a TFA salt 
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1H NMR spectrum of UNC2864 as a trifluoroacetate salt 
 
1H NMR spectrum of UNC2867 as a trifluoroacetate salt 
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1H NMR spectrum of UNC2868 as a trifluoroacetate salt 
 
1H NMR spectrum of UNC3261 as a trifluoroacetate salt 
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1H NMR spectrum of UNC3375 as a trifluoroacetate salt 
 
1H NMR spectrum of UNC3403 as a trifluoroacetate salt 
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1H NMR spectrum of UNC3189 as a TFA salt 
 
1H NMR spectrum of UNC3188 as a TFA salt 
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1H NMR spectrum of UNC3267 
 
1H NMR spectrum of UNC3546 
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1H NMR spectrum of UNC3563 as a TFA salt 
 
1H NMR spectrum of UNC3315 as a TFA salt 
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1H NMR spectrum of UNC3314 as a TFA salt 
 
1H NMR spectrum of UNC3265 as a TFA salt 
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1H NMR spectrum of UNC3264 as a TFA salt 
 
1H NMR spectrum of UNC3266 as a TFA salt 
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1H NMR spectrum of UNC3649 
 
1H NMR spectrum of UNC3313 as a TFA salt 
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1H NMR spectrum of UNC3260 as a TFA salt 
 
1H NMR spectrum of UNC3567 as a TFA salt 
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1H NMR spectrum of UNC3580 as a TFA salt 
 
1H NMR spectrum of UNC3581 as a TFA salt 
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1H NMR spectrum of UNC3648 as a TFA salt 
 
1H NMR spectrum of UNC3564 as a TFA salt 
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1H NMR spectrum of UNC3566 as a TFA salt 
 
1H NMR spectrum of UNC3486 as a TFA salt 
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1H NMR spectrum of UNC3562 as a TFA salt 
 
1H NMR spectrum of UNC3565 as a TFA salt 
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1H NMR spectrum of UNC3556 as a TFA salt 
 
1H NMR spectrum of UNC3772 as a TFA salt 
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1H NMR spectrum of UNC3771 as a TFA salt 
 
1H NMR spectrum of UNC3773 as a TFA salt 
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1H NMR spectrum of UNC4973 as a TFA salt 
 
1H NMR spectrum of UNC4974 as a TFA salt 
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1H NMR spectrum of UNC3867 as a TFA salt 
 
1H NMR spectrum of UNC3769 as a TFA salt 
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1H NMR spectrum of UNC3865 as a TFA salt 
 
1H NMR spectrum of UNC3866 as a TFA salt 
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1H NMR spectrum of UNC4975 as a TFA salt 
 
1H NMR spectrum of UNC3768 as a TFA salt 
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1H NMR spectrum of UNC3770 as a TFA salt 
 
1H NMR spectrum of UNC4219 as a TFA salt 
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CHAPTER III: BIOCHEMICAL AND BIOPHYSICAL CHARACTERIZATION OF CBX ANTAGONISTS 
INTRODUCTION 
 The development of UNC3866 was an important step toward a biologically useful CBX7 
antagonist. However, while achieving high affinity for the target of interest is a critical, potency is only one 
of several parameters that define a high quality chemical probe. Qualification of a molecule for use as a 
chemical probe requires that the molecule be thoroughly characterized to the extent that any phenotypic 
effects produced by the molecule can be reliably attributed to modulation of its intended target. Efforts to 
characterize molecules for use as a chemical probe should be focused on the five core principles that 
undergird any quality chemical probe discovery effort58:  
(1) Molecular profiling 
(2) Mechanism of action 
(3) Identity of the active species 
(4) Proven utility as a probe 
(5) Availability 
Molecular profiling involves providing “sufficient in vitro potency and selectivity data to associate the in 
vitro profile of a molecule with its cellular or in vivo profile”58. Our studies in Chapter II laid the initial 
foundations for UNC3866 with respect to this principle. These studies demonstrated on-target potency of 
UNC3866 as an H3-competive antagonist of CBX7 (IC50 ~60 nM). We further validated this interaction by 
ITC (Kd ~97 nM) and X-ray crystallography. Our studies in this chapter were focused on complete 
satisfaction of this principle through:  
(1) Characterization of the in vitro selectivity of the UNC3866 versus the CBX7 orthologues, CBX2, -
4, -6 and -8, as well as against a broader panel of molecular targets 
(2) Kinetic characterization of the interaction between CBX7 and UNC3866.  
Principles 2-5 as they relate to UNC3866 will be addressed in Chapter IV.   
 
106 
 
Key to our initial decision to focus on CBX7 was the availability of a high-throughput screening 
assay already developed in our lab66, 69, 74, 75. We had previously been unsuccessful in developing high 
throughput assays for other CBX chromodomains with H3 substrates, precluding rapid, cost-effective 
selectivity profiling of our compounds against these orthologous chromodomains. The development of 
UNC3866 as a potent CBX7 antagonist made overcoming this challenge a necessity that we successfully 
addressed, as discussed in this chapter, in order to cost-effectively evaluate and understand the 
selectivity profile for UNC3866 amongst the Pc CBX chromodomains.  
 Our purpose for characterizing the kinetics of the UNC3866-CBX7 interaction was two-fold. First, 
it is becoming increasingly apparent that the cellular and in vivo efficacy of many compounds is best 
correlated with the kinetics of their interaction with the intended molecular target (specifically with the 
dissociative kinetics of the interaction)107. Therefore, knowledge of this binding parameter is critical for the 
development of high quality chemical probes. Secondly, we sought to use our kinetic characterization of 
the interaction of UNC3866 with CBX7 to enable further interrogation of the binding mechanism proposed 
by our molecular dynamics simulations described in Chapter II that were critical for the development of 
UNC3866. An understanding of the kinetics of the CBX7-UNC3866 interaction is important for further 
validation of this hypothesis in order to continue its application in the design of improved CBX 
antagonists.  
 Herein we describe our efforts to more fully characterize UNC3866 to enable its use as a 
chemical probe for the chromodomain of CBX7. We profiled UNC3866 against a panel of >250 potential 
molecular targets, and found that it is highly selective for two families of chromodomains. We developed 
high throughput assays for these families of chromodomains, providing important insight into the 
selectivity profile of UNC3866 and its related analogs. In addition to our screening efforts, we also solved 
co-crystal structures of UNC3866 with multiple chromodomains as a means to further understand the 
selectivity determinants for these proteins. Finally, we studied the binding kinetics of a subset of our 
CBX7 antagonists by surface plasmon resonance experiments (SPR). These experiments provided 
critical evidence supporting our induced fit binding mechanism that enabled the design of a second-
generation CBX7 antagonist, UNC4976, which displays dramatically increased target residence time in 
SPR experiments compared to UNC3866. 
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RESULTS AND DISCUSSION 
UNC3866 selectivity 
 Knowledge of the activity profile of a molecule is essential in order to associate its cellular effects 
with modulation of a specific molecular target(s) of interest. Thus, the use and classification of a molecule 
as a chemical probe is dependent upon an in-depth understanding of its activity against a broad panel of 
potential molecular targets58. Accordingly, we profiled the selectivity of UNC3866 against a wide range of 
epigenetic and non-epigenetic targets. First, we focused on the selectivity of UNC3866 against our in-
house panel of Kme reader domains. This panel consists of a small set of Kme readers encompassing 
proteins from the MBT, PHD and Tudor families for which we have established AlphaScreen® and/or ITC 
assays (Table 3.1). Encouragingly, UNC3866 is more than 100-fold selective for CBX7 over the nine 
members of this Kme reader panel.  
 
Table 3.1. Characterization of UNC3866 selectivity by AlphaScreen® or ITC against a panel of Kme 
reader domains. 
 
ID 
AlphaScreen® IC50 (nM) ITC Kd (nM) 
CBX7 53BP1 JARID1A PHF1 PHF19 PHF23 UHRF1 MBTD1 L3MBTL1 L3MBTL1 
UNC3866 64 ± 1.0 >10,000 >10,000 >10,000 >10,000 >10,000 >10,000 >10,000 >10,000 >10,000 
*IC50 represents the average of at least 2 replicates ± the standard deviation. 
 
 We next utilized UNC4195, our biotinylated analog of UNC3866, in order to facilitate further 
selectivity studies. In collaboration with Mark Bedford at MD Anderson, we used this derivative to 
evaluate binding to 96 purified chromatin-associated effector proteins, including at least 19 known 
H3K9me3 or H3K27me3 binding proteins and 28 distinct chromodomains, spotted in duplicate onto a 
nitrocellulose coated membrane (Fig. 3.1) Binding interactions were visualized with fluorescently tagged 
streptavidin, revealing that UNC4195 binds to two families of chromodomains. As expected, a positive 
binding interaction was observed with CBX7 and the other PRC1 orthologues, CBX2, -4, -6 and -8. We 
did not detect binding to CBX1, -3 and -5 (also known as HP1β, - and -, respectively) which are highly 
homologous to CBX7 in their chromodomains. The array also revealed binding to three members of the 
CDY family of chromodomains: CDY1, CDYL1b, and CDYL2.  
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Figure 3.1. Characterization of UNC3866 selectivity with UNC4195. UNC4195 selectively interacts with 2 
subfamilies of chromodomains on a microarray containing 96 epigenetic reader proteins across multiple 
domain types (Bedford lab, MD Anderson). 
 
 We expressed and purified all proteins that demonstrated positive binding to UNC4195 on the 
array and subsequently quantified the affinity for UNC3866 by ITC (Fig. 3.2). In agreement with the 
microarray data, we detected binding to each of these chromodomains. The affinity of UNC3866 for 
CBX2, -4, -6 and -8 is also surprisingly well correlated with the percent sequence identity of each 
chromodomain relative to that of CBX7 (Fig. 3.2c). UNC3866 is equipotent for CBX4, which is most 
similar to CBX7, while it is 18-, 6- and 12-fold selective for CBX4/7 over CBX2, -6 and -8, respectively. 
Additionally, UNC3866 is 65-fold selective for CBX4/7 over CDY1 and 9-fold selective for CBX4/7 over 
CDYL1b and CDYL2. While some work has been done to explore the biochemistry of CDY proteins67, 
their biological function is less well characterized than Polycomb CBX proteins which makes assessing 
the potential consequences of antagonizing these proteins in a cellular context challenging, making this is 
a “known unknown” in the use of UNC3866. 
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Figure 3.2. Selectivity studies with UNC3866 and its chromodomain targets. (a) Binding constants of 
UNC3866 between each of its chromodomain targets identified on the microarray (Fig. 3.1). Data are 
reported as the mean ± the standard deviation of at least two replicates. (b) Graphical illustration of the 
UNC3866 binding constants for its chromodomain targets. (c) Comparison of the UNC3866 binding 
constant for each CBX chromodomain bound by UNC3866 versus that chromodomains % sequence 
identity to CBX7. (d) Comparison of the UNC3866 binding constant for each CDY chromodomain bound 
by UNC3866 versus that chromodomain’s % sequence identity to CBX7. (e) Chromodomain phylogenetic 
tree and the relative affinity of UNC3866 for its target chromodomains. The phylogenetic tree was 
generated using: 
http://apps.thesgc.org/resources/phylogenetic_trees/index.php?treeGroup=epig&tree_type=domain_base
d&domain=CHROMO   
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 UNC3866 was also evaluated against a panel of 48 bromodomains, 33 protein 
methyltransferases, and 7 lysine demethylases and found to be inactive in each case (Table 3.1, Fig. 3.3, 
and Table 3.2). UNC3866 was tested against a general pharmacology panel (Cerep) consisting of 49 G 
protein-coupled receptors (GPCRs), 5 ion channels and 3 transporter proteins (Table 3.3), as well as the 
National Institute of Mental Health’s Psychoactive Drug Screening Program (NIMH PDSP) panel which 
includes 22 additional GPCRs. Follow-up functional assays108, 109 for targets displaying >50% inhibition of 
control radioligand binding at 10 µM UNC3866 were also performed with both UNC3866 and UNC4219 
(negative control) (Figures 3.4-3.7). Both UNC3866 and UNC4219 showed nearly identical profiles in 
these follow-up assays with both compounds showing very weak antagonism for the NK2 and V1a 
receptors (Fig. 3.5 and Fig. 3.7a). The similar profiles of UNC3866 and UNC4219 indicate that UNC4219 
will be a valuable negative control in determining the biological consequences specific to chromodomain 
antagonism.  
 
Table 3.2. Activity of UNC3866 against a panel of bromodomains as measured by ∆Tm. UNC3866 is 
shows no activity for the bromodomains in this panel at 25 µM (∆Tm < 1°C). 
 
 
Target UNC3866 Tm shift Target UNC3866 Tm shift Target UNC3866 Tm shift
ASH1L -0.39 BRDT(2) 0.21 PB1(4) 0.56
ATAD2 -0.62 BRPF1A -0.04 PB1(5) -0.15
BAZ1A -1.44 BRPF1B 0.47 PB1(6) 0.28
BAZ1B 0.37 BRPF3 0 PCAF -0.07
BAZ2A -0.23 BRWD3(2) -0.57 PHIP(2) 0.64
BAZ2B 0.17 CECR2 0.58 SMARCA2 0.14
BRD1 0.49 CREBBP 0.35 SMARCA4 0.24
BRD2(1) 0.19 EP300 0.7 SP140 0.07
BRD2(2) 0.04 FALZ 0 TAF1(1) 0.44
BRD3(1) 0.53 GCN5L2 0 TAF1(2) 0.62
BRD3(2) 0.33 ATAD2B 0 TAF1L(1) 0.45
BRD4(1) 0.88 SP140L 0.53 TAF1L(2) 0.72
BRD4(2) 0.2 MLL 0.04 TIF1-bromo 0.27
BRD7 0.08 PB1(1) -0.03 TIF1-phd-bromo 0.49
BRD9 0.23 PB1(2) 0.24 TRIM28 0.47
BRDT(1) -0.19 PB1(3) 0.33 WDR9(2) 0.95
UNC3866-Bromodomain profile
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Figure 3.3. Activity of UNC3866 against a panel of methyltransferase enzymes. Methyltransferase 
inhibition is evaluated by monitoring the transfer of a radioactive methyl group from SAM to lysine or 
arginine. No significant inhibition was observed in the presence of up to 50 µM UNC3866. 
 
 
 
 
Table 3.3. Activity of UNC3866 against a set of demethylase enzymes as determined by AlphaScreen®. 
Treatment of 100 µM UNC3866 resulted in <50% inhibition of all targets binding to their respective 
histone substrates. 
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Table 3.4. Cerep selectivity profile of UNC3866. Highlighted in yellow are targets which resulted in >50% 
inhibition of binding of the control radioligand upon incubation with UNC3866 (10 µM). Follow-up dose-
response assays for targets displaying >50% inhibition and closely related targets are shown in 
Supplementary Figures 5-8. Information pertaining to these assays can be found at www.cerep.fr  
Assay 
% Inhibition of 
Control Specific 
Binding 
Average % of 
Control Specific 
Binding (N=2) 
Reference Compound 
A1 (h)  (antagonist radioligand) 4 96.3 DPCPX 
A2A (h)  (agonist radioligand) -2 102.3 NECA 
A3 (h)  (agonist radioligand) 3 96.9 IB-MECA 
alpha 1 (non-selective)  (antagonist 
radioligand) 
-11 111.4 prazosin 
alpha 2 (non-selective)  (antagonist 
radioligand) 
-7 107.3 yohimbine 
beta 2 (h)  (agonist radioligand) -1 100.8 ICI 118551 
AT1 (h)  (antagonist radioligand) -4 104.1 saralasin 
BZD (central)  (agonist radioligand) -17 117.4 diazepam 
B2 (h)  (agonist radioligand) -7 106.9 NPC 567 
CB1 (h)  (agonist radioligand) -13 113.2 CP 55940 
CCK1 (CCKA) (h)  (agonist 
radioligand) 
33 67.2 CCK-8s 
D1 (h)  (antagonist radioligand) 4 95.7 SCH 23390 
D2S (h)  (antagonist radioligand) 40 60.5 (+)butaclamol 
ETA (h)  (agonist radioligand) -12 112.5 endothelin-1 
GABA  (non-selective)  (agonist 
radioligand) 
1 99.2 GABA 
GAL2 (h)  (agonist radioligand) -21 121.4 galanin 
CXCR2 (IL-8B) (h)  (agonist 
radioligand) 
-12 111.7 IL-8 
CCR1 (h)  (agonist radioligand) 7 93.4 MIP-1alpha 
H1 (h)  (antagonist radioligand) -6 106.3 pyrilamine 
H2 (h)  (antagonist radioligand) 1 98.6 cimetidine 
MC4 (h)  (agonist radioligand) 16 84.0 NDP-alpha -MSH 
MT1 (ML1A) (h)  (agonist 
radioligand) 
8 92.1 melatonin 
M1 (h)  (antagonist radioligand) 1 99.0 pirenzepine 
M2 (h)  (antagonist radioligand) -6 106.1 methoctramine 
M3 (h)  (antagonist radioligand) 7 93.2 4-DAMP 
NK2 (h)  (agonist radioligand) 75 24.6 [Nleu10]-NKA (4-10) 
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Assay 
% Inhibition of 
Control Specific 
Binding 
Average % of 
Control Specific 
Binding (N=2) 
Reference Compound 
NK3 (h)  (antagonist radioligand) 8 92.4 SB 222200 
Y1 (h)  (agonist radioligand) -20 119.9 NPY 
Y2 (h)  (agonist radioligand) 10 90.1 NPY 
NTS1 (NT1) (h)  (agonist 
radioligand) 
-10 109.8 neurotensin 
delta 2 (DOP) (h)  (agonist 
radioligand) 
29 71.4 DPDPE 
kappa  (KOP)  (agonist radioligand) 91 9.5 U 50488 
mu  (MOP) (h)  (agonist 
radioligand) 
51 48.6 DAMGO 
NOP (ORL1) (h)  (agonist 
radioligand) 
23 76.8 nociceptin 
EP4 (h)  (agonist radioligand) 5 95.2 PGE2 
5-HT1A (h)  (agonist radioligand) 19 81.3 8-OH-DPAT 
5-HT1B  (antagonist radioligand) -11 110.9 serotonin 
5-HT2A (h)  (antagonist 
radioligand) 
39 61.2 ketanserin 
5-HT2B (h)  (agonist radioligand) 7 93.0 (±)DOI 
5-HT3 (h)  (antagonist radioligand) -21 120.8 MDL 72222 
5-HT5a (h)  (agonist radioligand) 7 93.1 serotonin 
5-HT6 (h)  (agonist radioligand) -5 104.7 serotonin 
5-HT7 (h)  (agonist radioligand) 8 92.2 serotonin 
sst (non-selective)  (agonist 
radioligand) 
17 83.1 somatostatin-14 
VPAC1 (VIP1) (h)  (agonist 
radioligand) 
-9 109.5 VIP 
V1a (h)  (agonist radioligand) 85 14.6 
[d(CH2)51,Tyr(Me)2]-
AVP 
Ca2+ channel  (L, verapamil site)  
(phenylalkylamine)  (antagonist 
radioligand) 
16 84.2 D 600 
KV channel  (antagonist 
radioligand) 
0 99.8 alpha -dendrotoxin 
SKCa channel  (antagonist 
radioligand) 
-8 107.9 apamin 
Na+ channel (site 2)  (antagonist 
radioligand) 
35 64.5 veratridine 
Cl- channel  (GABA-gated)  
(antagonist radioligand) 
7 93.3 picrotoxinin 
norepinephrine transporter (h)  
(antagonist radioligand) 
-13 113.4 protriptyline 
dopamine transporter (h)  
(antagonist radioligand) 
7 92.7 BTCP 
5-HT transporter (h)  (antagonist 
radioligand) 
5 94.9 imipramine 
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Figure 3.4. NK1 receptor dose-response functional assays. (a) Both UNC3866 and UNC4219 display no 
agonist activity for the NK1 receptor. Assays (calcium mobilization) were performed with HEK293 cells 
stably expressing the NK1 receptor using FLIPRTETRA (Molecular Devices).  Detailed assay protocols 
and data analysis are available from the PDSP assay protocol book: 
https://pdspdb.unc.edu/pdspWeb/?site=functional. 
 
 
 
Figure 3.5. NK2 receptor dose-response functional assays. Both UNC3866 and UNC4219 display weak 
antagonist activity for the NK2 receptor against either Neurokinin A or Substance P. Significant 
antagonism was primarily observed at the highest concentration (30 μM). Dose-responses were 
determined in the absence and presence of a graded concentration of UNC3866. Assays (calcium 
mobilization) were performed with HEK293 cells stably expressing the NK2 receptor using FLIPRTETRA 
(Molecular Devices).  Detailed assay protocols and data analysis are available from the PDSP assay 
protocol book: https://pdspdb.unc.edu/pdspWeb/?site=functional. 
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Figure 3.6. Opioid receptor dose-response functional assays. (a) Neither UNC3866 nor UNC4219 display 
agonist or antagonist activity against the -opioid receptor. DAMGO and Naltrexone are MOR controls. 
(b) Neither UNC3866 nor UNC4219 display agonist or antagonist activity against the -opioid receptor. 
Sal A and GNTI are KOR controls. (c) Neither UNC3866 nor UNC4219 display agonist or antagonist 
activity against the -opioid receptor. DADLE and Naltrindole are DOR controls. Assays were carried out 
with transiently transfected HEK293 T cells using a split luciferase reporter (GloSensor cAMP, Promega).  
Detailed assay protocols and data analysis are available from the PDSP assay protocol book 
https://pdspdb.unc.edu/pdspWeb/?site=functional. To measure antagonist activity, reference agonist was 
used at 50 nM in each assay (DADLE for DOR; Salvinorin A for KOR; DAMGO for MOR). 
a 
b 
c 
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Figure 3.7. Vasopressin receptor dose-response functional assays. (a) Both UNC3866 and UNC4219 
display weak antagonist activity for the V1A receptor. (b) Neither UNC3866 nor UNC4219 displays 
antagonist activity against the V1B or (c) V2 receptors. Dose-responses were determined in the absence 
and presence of a graded concentration of UNC3866. Vasopressin serves as a control in each case. 
Assays (calcium mobilization) were carried out with CHO cells stably expressing V1A, V1B, or V2 receptors 
using FLIPRTETRA (Molecular Devices).  Detailed assay protocols and data analysis are available from 
the PDSP assay protocol book https://pdspdb.unc.edu/pdspWeb/?site=functional. 
 
 
a 
b 
c 
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SAR studies with Pc CBX, HP1 CBX and CDY chromodomains  
 In order to better understand the chromodomain selectivity profile of UNC3866, we developed 
AlphaScreen®69 assays for three representative members of the Pc CBX chromodomains (CBX4, -7 and -
8), with CBX4 and -7 being the most potent targets of UNC3866, and CBX8 representing the remaining 
Pc CBX chromodomains (CBX2, -6, and -8), all of which display somewhat weaker affinity for UNC386631. 
We also developed assays for one member of the CDY family of chromodomains, CDYL2, and a 
representative of the HP1 family of chromodomains, CBX5, in order to better understand the molecular 
determinants for selectivity between these three structurally related families of chromodomains. Each of 
these assays use His-tagged recombinant protein and UNC4195, our biotinylated analog of UNC3866, as 
the bait ligand. It should be noted that our previously reported AlphaScreen® studies with UNC3866 were 
performed utilizing a similar assay with a biotinylated H3K9me3 bait ligand and CBX7. The improved 
potency of UNC4195 for our target chromodomains over the H3K9me3 peptide allowed us to reduce the 
amount of all reagents used in the assay and also reduce the tight binding limit. For CBX5, which does 
not appreciably bind to UNC4195, we again utilized a biotinylated version of the endogenous substrate, 
H3K9me368. We tested many of the compounds described in Chapter II against these proteins as well as 
several new compounds (Tables 3.5-3.8). 
 We selected a subset of our series of peptides designed to interrogate the length requirements 
for binding to CBX7 based on the ALKme3S motif and found that, minimally, the 5 residue UNC2867 (17) 
was the shortest peptide capable of not only CBX7 antagonism, but also antagonism all three of the other 
CBX chromodomains in our panel (Table 3.5, compounds 7, 14, 16-18). UNC2867 displayed modest 
affinity for CBX4 and -7, weak affinity for CBX8 and CBX5, and submicromolar potency for CDYL2. In 
contrast to the Pc CBX chromodomains, the chromodomain of CDYL2 maintains weak affinity for the 
shorter peptides, UNC2934 (7), UNC2597 (14), and UNC2864 (16). UNC2868 (18) displays somewhat 
reduced affinity for each panel member relative to UNC2867 (17), suggesting that there are subtle 
differences in the way these different chromodomains recognize the N-terminus of these molecules. 
UNC2934 (7) binding affinities were consistent with previous observations that binding of all CBX 
chromodomains, not just CBX7 requires the presence of a serine C-terminal to the methyl-lysine38, 68. 
Interestingly, this was not the case for CDYL2. The tolerance of CDYL2 for shorter peptide antagonists 
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relative to CBX chromodomains suggests that targeting this chromodomain through a more traditional 
small molecule approach may be a viable strategy. 
 We also evaluated the effect of our N-methylated backbone analogs of UNC2868 (18) on 
chromodomain binding (peptides 19-21). Methylation of the alanine amide nitrogen UNC3261 (19) 
resulted in loss of binding to all chromodomains tested. Methylation of the phenylalanine amide nitrogen 
UNC3375 (20) selectively bound to CDYL2 while methylation of the glycine amide in compound 
UNC3403 (21) had little effect on binding to any of our panel members when compared to the 
corresponding unmethylated analog, UNC2868 (18). UNC3375 (20) indicates that CDY-selective 
antagonists will be accessible through the use of N-methylation at the phenylalanine position of 
UNC3866. 
 
Table 3.5. Determination of peptide length requirements for chromodomain antagonism of ALKme3S 
peptides 
 
 
IC50 (µM)
a 
Polycomb CDY HP1 
Compound R1 R2 R3 CBX4 CBX7 CBX8 CDYL2 
CBX5 
(HP1α) 
UNC2934 
(7) 
Bz-Phe -H -H >60 >60 >60 37 ± 4.2 >60 
UNC2597 
(14) 
Bz -CONMe -H >60 >60 >60 54 ± 16 >60 
UNC2864 
(16) 
Bz -CO-Ser-OMe -H >60 >60 >60 16 ± 1.9 >60 
UNC2867 
(17) 
Bz-Phe -CO-Ser-OMe -H 6.9 ± 1.3 2.6 ± 0.39 33 ± 7.1 0.57 ± 0.042 49 ± 4.1 
UNC2868 
(18) 
Bz-Gly-Phe -CO-Ser-OMe -H 58 ± 5.3 18 ± 4.5 >60 1.0 ± 0.23 >60 
UNC3261 
(19) 
Bz-Gly-Phe -CO-Ser-OMe -Me >60 >60 >60 >60 >60 
UNC3375 
(20) 
Bz-Gly-N(me)Phe -CO-Ser-OMe -H >60 >60 >60 15 ± 6.4 >60 
UNC3403 
(21) 
Bz-N(me)Gly-Phe -CO-Ser-OMe -H 57 ± 6.0 26 ± 8.3 >60 0.47 ± 0.14 >60 
aIC50 values are reported as the mean ± the standard deviation of at least two biological replicates each 
performed in duplicate. 
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 We screened our library of Kme3 replacements against our chromodomain panel to determine 
the tolerance of the various aromatic cages on these proteins to non-natural lysine analogs.(Table 3.6) 
Consistent with previous studies, the non-methylated lysine analog of UNC2868 (18), UNC3189 (22), 
displayed no antagonism of any of the chromodomains in the panel68. Replacement of the quaternary 
amine with bulky secondary amines (compounds 26-30) was not well tolerated by all CBX 
chromodomains, while the CDYL2 chromodomain is able to bind these ligands with modest affinity. For 
example, the isopropyl-lysine of UNC3563 (26) showed no affinity for CBX chromodomains but single-
digit micromolar affinity for CDYL2. Incorporation of a cyclopentyl- or cyclohexyl-lysine (UNC3315, 27 and 
UNC3314, 28, respectively) did not recover CBX activity. Norbornyl-lysine (UNC3265, 29) showed weak 
CBX7 antagonism, but no antagonism for CBX4 or -8 while being equipotent for CDYL2 when compared 
to cyclopentyl alone (UNC3315, 27). Adamantyl substitution (UNC3264, 30) resulted in no measurable 
CBX activity and CDYL2 activity comparable to the cyclohexyl compound (UNC3314, 28), indicating that 
increasing the size of the fused ring system beyond norbornyl (UNC3265, 29) is not beneficial for binding 
to any of the chromodomain families in our panel. Taken together, this data suggests that CDYL2 is more 
accommodating to various secondary amine Kme3 replacements than the CBX chromodomains. 
 We next focused on our tertiary substitutions at the -nitrogen of the lysine residue. 
Unsurprisingly67, 68, we found that dimethylation (UNC3188, 25) reduced the activity for both CBX7 and 
CDYL2 about 3-fold relative to the analogous Kme3 compound (UNC2868, 18). However, the diethyl-
lysine of UNC3567 (35) resulted in similar affinities for all chromodomains as UNC2868 (18), albeit with 
slighted improved affinity for CBX8. Our pyrrolidinyl derivative, UNC3580 (36), resulted in a reduction in 
potency across the panel, while increasing the ring size to a piperidinyl group (UNC3581, 27) or a 7-
membered azepane (UNC3648, 38) also did not appear to be beneficial. Our bulkier dicyclobutyl-lysine 
analog (UNC3260, 34) also did not display any significant enhancements in potency for any 
chromodomain.  
 We again tested our acetyl, norbornyl-lysine derivative (UNC3649, 32) and found that, in contrast 
to our studies in Chapter II, binding to CBX7 was undetectable in our new assay format. Binding of this 
compound was also undetectable to all other CBX chromodomains. However, this compound did show 
affinity for CDYL2 in our assay, albeit with an approximately 7-fold reduction in potency. Changing from 
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the acetyl, norbornyl to the methyl, norbornyl of UNC3313 (33) produced the most potent analog of 
UNC2868 (18) for all members of our chromodomain panel (except CBX5), further emphasizing the 
importance of a basic amine. However, the more strongly basic tetramethylguanidine derivative 
(UNC3564, 39) and dibasic compounds UNC3261 (31) and UNC3566 (40) showed no activity for any of 
the CBX chromodomains and weakened affinity for CDYL2, suggesting that enhanced cation- 
interactions are not beneficial for binding to our chromodomain panel. Taken together, the SAR data 
resulting from modification of the lysine indicates that the presence of a quaternary amine is not required 
for engagement of our chromodomain panel; however, both the diethyl-lysine containing compound (18) 
and methyl, norbornyl-lysine analog (UNC3313, 33) presented themselves as viable Kme3 replacements 
for Pc CBX and CDY chromodomains. Our data indicates that substantially improving both the selectivity 
and potency of this series of compounds through modification of the lysine amine presents a significant 
challenge for CBX chromodomains, but may be a more viable strategy for CDY chromodomain ligand 
optimization. 
 
Table 3.6. Exploration of secondary and tertiary amine Kme3 replacements. 
 
 
IC50 (µM)a 
Polycomb CDY HP1 
Compound R1 CBX4 CBX7 CBX8 CDYL2 CBX5 
UNC3189 
(22)  
>60 >60 >60 >60 >60 
 UNC3563 
(26) 
 
>60 >60 >60 2.3 ± 0.48 >60 
 UNC3315 
(27) 
 
>60 >60 >60 3.0  ± 0.28 >60 
UNC3314 
(28) 
 
>60 >60 >60 17 ± 4.3 >60 
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IC50 (µM)a 
Polycomb CDY HP1 
Compound R1 CBX4 CBX7 CBX8 CDYL2 CBX5 
UNC3265 
(29) 
 
>60 51 ± 10 >60 5.0 ± 0.48 >60 
 UNC3264 
(30) 
 
>60 >60 >60 14 ± 2.0 >60 
UNC3188 
(25) 
 
>60 51 ± 10 >60 2.8 ± 0.41 >60 
UNC3567 
(35) 
 
46 ± 19 16 ± 3.7 47 ± 19 0.67 ± 0.071 >60 
UNC3580 
(36) 
 
>60 53 ± 5.6 >60 1.1 ± 0.25 >60 
UNC3581 
(37) 
 
>60 41 ± 6.6 >60 0.54 ± 0.039 >60 
UNC3648 
(38) 
 
>60 28 ± 3.6 31 ± 7.8 0.59 ± 0.080 >60 
UNC3260 
(34) 
 
>60 32 ± 8.9 34 ± 27 1.8 ± 0.56 >60 
UNC3313 
(33) 
 
25 ± 8.9 7.3 ± 1.3 31 ± 22 0.30 ± 0.042 >60 
 UNC3649 
(32) 
 
>60 >60 >60 38 ± 13 >60 
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IC50 (µM)a 
Polycomb CDY HP1 
Compound R1 CBX4 CBX7 CBX8 CDYL2 CBX5 
UNC3564 
(39) 
 
>60 >60 >60 2.5 ± 0.48 >60 
 UNC3266 
(31) 
 
>60 >60 >60 24 ± 9.7 >60 
UNC3566 
(40) 
 
>60 >60 >60 8.6 ± 0.62 >60 
aIC50 values are reported as the mean ± the standard deviation of at least two biological replicates each 
performed in duplicate. 
 We next tested our variations to the N-terminus of our molecules in the context of diethyl-lysine 
(Table 3.7). We synthesized additional molecules from those in Chapter II to more fully understand the 
SAR at this position (UNC4940, 59 and UNC4972, 60). UNC4940 (59) which is the diethyl-lysine analog 
of UNC2867 (17), showed similar or improved activities toward each of the chromodomains bound by 
UNC2867 (17). Interestingly, UNC4940 (59) demonstrates significantly more affinity for CBX5 in contrast 
to UNC2867 (17), providing our first evidence that the aromatic cage of CBX5 can also accommodate 
non-natural lysine analogs with improved affinity compared to the natural Kme3.  
 We next explored our series of analogs methylated at the ortho-, meta- and para-positions of the 
aromatic cap (48-50). Methylation at the ortho-position (UNC4973, 48) of the ring dramatically reduced 
potency for all chromodomains except for CDYL2. Affinity for all chromodomains except CBX5 is 
recovered to levels comparable to UNC4940 (59) when the methyl group is shifted to the meta-position 
UNC4974 (49). Installation of para-Me (UNC3867, 50) resulted in further improvements in binding to both 
CBX7 and CBX4, with submicromolar affinities in each case. Interestingly, CBX8 did not display the same 
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preference as CBX4 and -7 for UNC3867 (50) over UNC4974 (49). For CDYL2, the methyl placement 
had little to no effect on binding. 
 We next evaluated our compounds exploring the effect of increasing steric bulk at the para-
position (compounds 51-53). Overall, increasing lipophilicity had opposing effects on the affinity for 
Polycomb vs HP1 chromodomains. Introduction of a para-ethyl or para-isopropyl substituent as in 
UNC3769 (51) and UNC3865 (52), respectively, increased the affinity ~2-5 fold for CBX4, -7, and -8, as 
well as CDYL2, relative to UNC3867 (50), while the affinity for CBX5 was largely unchanged or slightly 
weakened. t-Butyl substitution (UNC3866, 53) further improved potency for CBX4 and -7 while having no 
significant effect on the affinity for CBX8 and causing a loss of detectable CBX5 affinity. Taken together, 
these data indicate that potency and selectivity can be tuned by systematically adjusting both the position 
of alkylation and degree of lipophilicity on the benzoyl cap at the N-terminus.  
 We also evaluated our compounds incorporating electron-withdrawing groups at the para-position 
of the N-terminal phenyl cap (UNC3768, 55, and UNC3770, 56). The methyl ester at the para-position of 
UNC3768 (55) resulted in an approximately 15-fold loss in potency for both CBX4 and -7 relative to 
compound UNC3866 (53), but only an approximately 3-fold loss in potency for CBX8, further suggesting 
that CBX4 and -7 depend more strongly on the presence of bulky alkyl substituents at this position. The 
strongly electron-withdrawing trifluoromethyl substituent of UNC3770 (56) also weakened binding to the 
Pc chromodomains, although to a lesser extent than UNC3768 (55). CDYL2 affinity is largely unaffected 
by replacement of para-alkyl substituents with electron-withdrawing groups, consistent with the generally 
less stringent binding preferences of CDYL2. Inclusion of an electron-donating group as in UNC4975 (54) 
also did not further improve binding to Pc CBX chromodomains, further indicating that alkyl substituents 
at this position are preferred. In contrast, these results suggest that CBX5 prefers less sterically 
demanding functional groups at the N-terminus.  
 We next investigated the importance of the spacing between the N-terminal hydrophobic group 
and the rest of the peptide. As can be seen with UNC4972 (60), addition of a single methylene group 
relative to UNC3866 (53) resulted in an approximately 100-fold loss of potency for CBX4 and -7 and 
almost a 20-fold loss for CBX8, while CDYL2 was largely unable to distinguish between the t-butyl phenyl 
and t-butyl benzyl moieties. Additionally, our larger bicyclic aromatic capping groups with a methylene 
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spacer (UNC3771, 45 and UNC3772, 46) were also less well tolerated by CBX4, -7 and -8. Consistent 
with our prior results, the increased steric demand of these functionalities was detrimental to CBX5 
activity.   
 Our studies in Table 3.6 indicated that the tolerance of Pc CBX chromodomains to unnatural Kme 
analogs is fairly limited, yet we were interested in exploring a small number of lysine modifications, as well 
as the native Kme3 residue, in the context of our more potent peptide scaffold. We generated the Kme3 
analog of UNC3866 (53), UNC4938 (61), and three asymmetric tertiary amine derivatives, UNC4941 (62) 
UNC4971 (63), and UNC4976 (64). The isopropyl group of UNC4941 (62) and UNC4971 (63) was 
hypothesized to make additional contacts with the aromatic cage of the Pc CBX proteins and to more 
completely fill the cage based on the crystal structures of UNC3866 (53) bound to these chromodomains 
(Fig. 3.8a). The methyl, norbornyl derivative was synthesized because of its improved potency in Table 
3.6 over diethyl-lysine. Mirroring prior results, the Kme3 containing compound, UNC4938 (61) was about 
equipotent to UNC3866 (53), while the bulkier lysine mimetics of UNC4941 (62), UNC4971 (63) and 
UNC4976 (64) did not appear to pick up any additional interactions to further improve potency for Pc CBX 
chromodomains. However, UNC4976 (64) did show improved affinity for both CDYL2 and CBX5.   
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Table 3.7. Effect of N-terminal variations and select lysine modifications. 
 
 
IC50 (µM)a 
Polycomb CDY HP1 
Compound R1 R2 CBX4 CBX7 CBX8 CDYL2 CBX5 
UNC4940 
(59) 
  
3.0 ± 
0.82 
1.2 ± 
0.69 
4.8 ± 
1.4 
0.34 ± 
0.021 
6.9 ± 
0.52 
 UNC4973 
(48) 
  
58 ± 5.4 25 ± 2.5 >60 
0.56 ± 
0.054 
>60 
UNC4974 
(49) 
  
2.7 ± 1.0 
0.74 ± 
0.11 
5.1 ± 
1.4 
0.34 ± 
0.12 
>60 
UNC3867 
(50) 
  
0.77 ± 
0.030 
0.22 ± 
0.049 
4.8 ± 
0.39 
0.28 ± 
0.16 
21 ± 
4.3 
UNC3769 
(51) 
  
0.19 ± 
0.074 
0.081 ± 
0.020 
1.5 ± 
0.19 
0.10 ± 
0.025 
14 ± 
2.4 
UNC3865 
(52) 
  
0.16 ± 
0.021 
0.061 ± 
0.016 
1.9 ± 
0.46 
0.10 ± 
0.026 
38 ± 
6.3 
UNC3866 
(53) 
  
0.083 ± 
0.028 
0.037 ± 
0.017 
1.3 ± 
0.48 
0.14 ± 
0.043 
>60 
UNC3768 
(55) 
  
1.2 ± 
0.45 
0.57 ± 
0.087 
4.8 ± 
0.87 
0.11 ± 
0.026 
26 ± 
2.7 
 UNC3770 
(56) 
  
0.48 ± 
0.11 
0.23 ± 
0.041 
3.0 ± 
0.23 
0.13 ± 
0.019 
33 ± 
8.6 
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IC50 (µM)a 
Polycomb CDY HP1 
Compound R1 R2 CBX4 CBX7 CBX8 CDYL2 CBX5 
UNC4975 
(54) 
  
0.75 ± 
0.11 
0.25 ± 
0.026 
3.3 ± 
0.44 
0.26 ± 
0.018 
12 ± 
2.3 
UNC4972 
(60) 
  
9.7 ± 4.4 
4.4 ± 
0.67 
23 ± 
2.3 
0.20 ± 
0.025 
>60 
 UNC3771 
(46) 
  
3.4 ± 
0.66 
1.7 ± 
0.61 
15 ± 
2.3 
0.11 ± 
0.031 
>60 
UNC3772 
(45) 
  
5.2 ± 
0.72 
1.1 ± 
0.23 
24 ± 
4.2 
0.084 ± 
0.028 
>60 
UNC4938 
(61) 
 
 
0.075 ± 
0.021 
0.035 ± 
0.0064 
1.5 ± 
0.52 
0.11 ± 
0.034 
>60 
 UNC4941 
(62) 
  
0.075 ± 
0.014 
0.035 ± 
0.0084 
1.0 ± 
0.21 
0.13 ± 
0.010 
>60 
UNC4971 
(63) 
  
0.062 ± 
0.016 
0.032 ± 
0.0078 
1.3 ± 
0.34 
0.11 ± 
0.022 
>60 
UNC4976 
(64) 
  
0.058 ± 
0.0065 
0.020 ± 
0.0017 
0.89 ± 
0.17 
0.044 ± 
0.0014 
37 ± 
1.9.9 
aIC50 values are reported as the mean ± the standard deviation of at least two biological replicates each 
performed in duplicate. 
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Figure 3.8. UNC3866 bound to CBX7 (PDB 5EPJ). (a) Interaction of the CBX7 aromatic cage with 
diethyl-lysine. (b) Binding pocket of CBX7 occupied by the Ala side chain of UNC3866. (c) Position of 
Phe of UNC3866 when bound to CBX7.  
 
 Previous studies from the Hof group found that the residue at the (-2) position from the modified 
lysine can have profound effects on the selectivity and potency of peptide antagonists for Pc CBX 
chromodomains39. We explored this in the context of our antagonists by testing the effect of increasing 
the size of the alkyl side chain at this position (Table 3.8, UNC4939, 65, and UNC4030, 66). We found 
that replacing the methyl side chain of alanine with an ethyl or isopropyl group reduced affinity for CBX4, -
7, and CDYL2 while slightly increasing the affinity for CBX8. This was not surprising as previously solved 
co-crystal structures with UNC3866 (53) revealed that the pocket occupied by this alanine side chain is 
larger in CBX8 than in CBX4 and -7 owing to substitution of Val13 in CBX4/7 with Ala13 in CBX8 (Fig. 
3.8b)31. The increased potency and modest selectivity of UNC4030 (66) for CBX8 may make it a useful 
starting point for the development of more potent and selective CBX8 compounds.  
 Modifications to the C-terminus of UNC3866 (53) (compounds 67-69) were reasonably well 
tolerated while the methyl ester of UNC3866 (53) appears to be the preferred functionality at this position. 
Replacement with the corresponding acid (UNC4007, 67), dimethyl amide (UNC4087, 68), or removal of 
the C-terminal carbonyl entirely (UNC4051, 69), resulted in a mere 2- to 4-fold reduction in potency for Pc 
CBX chromodomains. Interestingly, UNC4007 (67) resulted in a slightly larger reduction in potency for 
CDYL2 (5-fold), suggesting that additional exploration of the C-terminus of these molecules may be 
useful for further tuning selectivity. 
128 
 
 The co-crystal structure of CBX7 with UNC3866 (53) revealed that the phenylalanine of UNC3866 
(53) is largely solvent exposed (Fig. 3.8c); therefore, we hypothesized that this was an additional position 
we could use for tagging to access additional tool compounds. An amine functional group was installed 
on the phenylalanine side chain, and as expected from the crystallographic information, UNC4946 (70) 
displayed similar affinities to UNC3866 (53) for each of the chromodomains in our panel. Further, 
because the boc group of UNC4961 (71) does not interfere with binding, this position presents a suitable 
location to place larger chemical moieties in future studies. 
 
Table 3.8. Exploration of modifications to the phenylalanine, alanine, and C-terminus of UNC3866. 
 
 
IC50 (µM)
a 
Polycomb CDY HP1 
Compound R1 R2 R3 CBX4 CBX7 CBX8 CDYL2 CBX5 
 UNC4939 (65) -H -Et COOMe 0.64 ± 0.19 0.24 ± 0.017 0.98 ± 0.22 0.50 ± 0.071 >60 
UNC4030 (66) -H -iPr COOMe 7.9 ± 1.0 3.1 ± 0.87 0.70 ± 0.15 0.75 ± 0.026 >60 
UNC4007 (67) -H -Me COOH 0.24 ± 0.027 0.13 ± 0.021 2.0 ± 0.92 0.74 ± 0.12 >60 
UNC4087 (68) -H -Me CON(Me)2 0.14 ± 0.038 0.047 ± 0.012 2.1 ± 0.50 0.36 ± 0.055 >60 
UNC4051 (69) -H -Me -H 0.20 ± 0.031 0.075 ± 0.012 3.5 ± 0.68 0.41 ± 0.061 >60 
UNC4946 (70) -CH2NH2 -Me COOMe 0.17 ± 0.046 0.063 ± 0.028 2.4 ± 0.61 0.075 ± 0.019 53 ± 4.7 
UNC4961 (71) -CH2NHBoc -Me COOMe 0.098 ± 0.011 0.056 ± 0.016 1.7 ± 0.32 0.16 ± 0.012 44 ± 11 
aIC50 values are reported as the mean ± the standard deviation of at least two biological replicates each 
performed in duplicate. 
 
UNC3866 co-crystallization studies 
 In addition to the co-crystal structure of UNC3866 bound to CBX7, our collaborators at the SGC 
solved X-ray crystal structures of UNC3866 bound to CBX2 (PDB code 5EPK), CBX4 (PDB code 5EPL), 
and CBX8 (PDB code 5EQ0) in order to shed further light on the selectivity profile of UNC3866 (Fig. 3.9). 
Alignment of these structures clearly illustrates that UNC3866 binds in a similar fashion to each 
chromodomain (Fig. 3.9a). These structures are consistent with our observations in Table 3.8 where 
larger side chains at the (-2) position from the modified lysine are preferred for CBX8. The UNC3866 
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alanine binding pocket in CBX2 and -8 is much more open in these chromodomains when compared to 
this pocket in CBX4 and -7 (Fig. 3.9b-f). The smaller pocket in CBX4 and -7 more tightly molds to the 
alanine, enhancing the van der Waals’ interactions with UNC3866. This single residue is likely the 
predominant factor that determines the higher affinity of UNC3866 for CBX4 and -7. Structurally, this 
simple substitution appears to have profound consequences on the conformational preferences of these 
chromodomains (Fig. 3.10).  
 Presently, the only Pc CBX chromodomains whose structures have been solved in the apo 
conformation are CBX2 and CBX7. As already described in Chapter II, CBX7 binds to its substrates 
through an induced fit binding mechanism that is responsible for aromatic cage formation and Kme3 
recognition. In the case of CBX2 however, the aromatic cage is largely pre-organized in the absence of a 
peptide substrate (Fig. 3.10b). Alignment of the apo conformations of CBX2/7 reveals that the residue 
where their structures diverge is at the Ala/Val residues (Fig. 3.10c). This divergence likely requires 
CBX7-UNC3866 binding to undergo a much more complicated binding pathway than CBX2. Our data in 
Table 3.7 strongly agree with this notion as binding to CBX4/7 is highly sensitive to changes at this 
position of the molecule, consistent with this position being important for initiating the induced fit binding 
mechanism. In contrast, binding to CBX8, which, like CBX2, contains an Ala at this position, is much less 
effected by variations in N-terminus of our antagonists. Thus, the added affinity for CBX4/7 is likely 
gained through the ability of UNC3866 to initiate the induced fit binding mechanism whereas, in the case 
of CBX2/6/8, the bound conformation is largely preformed, providing less of a potency boost from the t-
butyl group of UNC3866.    
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Figure 3.9. Co-crystal structures of UNC3866 with CBX2 (PDB code 5EPK), CBX4 (PDB code 5EPL), 
CBX7 (PDB code 5EPJ) and CBX8 (PDB code 5EQ0). (a) Overlay of CBX2, -4, -7 and -8 (gray) co-crystal 
structures with UNC3866 (green). (b) UNC3866 alanine binding pocket of CBX2. (c) UNC3866 alanine 
binding pocket of CBX8. (d) UNC3866 alanine binding pocket of CBX4. (e) UNC3866 alanine binding 
pocket of CBX7. (f) Alignment of the sequences of the chromodomain targets of UNC3866. The bold and 
underlined amino acids are the hypothesized residues of each chromodomain that directly interact with 
UNC3866. These residues contain at least 1 atom located within 4 Å of any atom of UNC3866 in the 
respective crystal structure.  Highlighted in yellow in the CBX family is the residue hypothesized to 
predominantly determine the selectivity of UNC3866 for CBX4 and -7 (Val in CBX4 and -7; Ala in CBX2, -
6, and -8). Highlighted in green is the portion of the CBX proteins that interacts with the tert-butyl cap of 
UNC3866 (D-X-R) and the corresponding residues of the CDY chromodomains (N/H-C-E). The sequence 
diversity at this position may contribute to the selectivity of UNC3866 for CBX4 and -7.  
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Figure 3.10. Comparison of CBX2 and CBX7 in the apo and UNC3866-bound conformations. (a) 
Structural alignment of apo CBX7 (salmon, PDB 2K1B) and CBX7 bound to UNC3866 (light blue, 
UNC3866 not shown, PDB 5EPJ). (b) Structural alignment of apo CBX2 (salmon, PDB 2D9U) and CBX2 
bound to UNC3866 (light blue, UNC3866 not shown, PDB 5EPK). (c) Structural alignment of apo CBX2 
(salmon, PDB 2D9U) and apo CBX7 (light blue, PDB 2K1B).  
 
 Aside from understanding the selectivity of UNC3866, we were also interested in using our co-
crystal studies to learn more about the interactions between the Polycomb CBX chromodomains and the 
diethyl-lysine of UNC3866. While the H3K27me3 side-chain has been modeled as adopting a fully 
extended, all anti-conformation68, the lysine side chain of UNC3866 when bound to CBX proteins in our 
crystal structures is modeled as adopting a gauche conformation about the C-C bond in Fig. 3.11a. 
Although the corresponding electron density is comparatively weak for CBX7, we model the side chain in 
the gauche conformation based on the higher resolution CBX8-UNC3866 co-crystal structure (1.2 Å as 
compared to 1.6 Å for the CBX7-UNC3866 structure, Fig. 3.11). While the electron density of the CBX8-
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UNC3866 structure more strongly supports the gauche conformation of this side chain in the bound state 
(Fig. 3.11b), the ambiguity in the position of these atoms may reflect that the side chain in UNC3866 
remains somewhat flexible when bound to CBX7. Further, this apparent flexibility in the bound state may 
explain the ability of CBX7 and the other Polycomb chromodomains to accommodate the diethyl 
functional group, which is more sterically demanding than the endogenous Kme3 recognized by these 
domains.  
 
 
Figure 3.11 Comparison of the UNC3866 diethyl-lysine side chain electron densities from the CBX7 (PDB 
code 5EPJ) or CBX8 (PDB code 5EQ0) co-crystal structures. (a) The modelled gauche conformation of 
the lysine side chain (green) in the 1.6 Å CBX7-UNC3866 is only weakly supported by the electron 
density (blue). (b) Compared to the CBX7-UNC3866, the modelled gauche conformation of the lysine 
side chain (green) in the 1.2 Å CBX8-UNC3866 structure is more strongly supported by the electron 
density (blue). Taken together, the electron densities for these two structures suggest that the gauche 
conformation is the favored, but possibly not the exclusive, conformation of the side chain when 
UNC3866 binds to either of these two chromodomains. Both electron density maps were prepared after 
deletion of the inhibitor atoms from the model and subsequent torsion-based simulated annealing with 
PHENIX. The maps are contoured at the 3.0  level. 
  
Kinetic characterization of CBX7 antagonists by surface plasmon resonance 
 As extensively discussed above, our proposed binding model for our CBX7 antagonists involves 
an induced-fit mode of recognition in which the N-terminus of these ligands makes the first specific 
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contact with CBX7 and that initial hydrophobic interaction nucleates a series of backbone hydrogen 
bonds, allowing CBX7 to close and the aromatic cage to form, generating the stably bound state. While 
we were able to apply this model to develop more potent chromodomain antagonists, largely through 
modification of the N-terminal aromatic capping group, as described in Chapter II, we were motivated to 
further interrogate the validity of the model. We therefore turned to surface-plasmon resonance (SPR) 
studies with CBX7 and a subset of our compounds that differ at the N-terminus in order to determine if the 
binding kinetics could provide any evidence to further support this induced-fit hypothesis.  
 When first comparing the SPR data for UNC3567 (Fig. 3.12), which contains the larger benzoyl 
glycine N-terminus, to the ortho-Me phenyl derivative (UNC4973), both of which have similar IC50’s for 
CBX7, we observed that the kon for UNC3567 was slightly faster but that the koff increased in a 
proportional manner, resulting in comparable affinities. When the methyl group of compound UNC4973 is 
shifted to the meta-position (UNC4974), the higher potency observed for this compound is largely driven 
by a significant increase in kon. Moving the methyl substituent to the para-position (UNC3867) did not 
substantially change the kon relative to compound UNC4974 but did slightly improve koff, resulting in the 3-
fold improvement in CBX7 potency for UNC3867 over UNC4974 observed in AlphaScreen®. Inclusion of 
a para-t-butyl moiety in UNC3866 further improves both kon and koff, resulting in one of our most potent 
CBX7 inhibitors to date.  
 We were intrigued by the fact that the majority of the potency improvements resulting from 
modification of the N-terminus were driven primarily by enhanced association rates instead of decreased 
dissociation rates107. Based on molecular dynamics simulations, we believe that N-terminal portion of 
these molecules forms the first stable interaction with CBX7, which is consistent with modifications at this 
position primarily affecting the association kinetics. More specifically, the improvement in association 
kinetics may result from a reduction in the conformational flexibility at the N-terminus, thereby increasing 
the likelihood of a productive binding collision between CBX7 and the antagonist. SPR results with CBX7 
and UNC4972, which is approximately 100-fold less potent than UNC3866 for CBX7, demonstrate that 
insertion of a flexible methylene linker primarily reduced kon while koff was minimally affected. Finally, 
analysis of the kon and koff rates of these select compounds with respect to their Kd’s (Fig. 3.12c) revealed 
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that the binding is better correlated with kon as opposed to koff, providing even stronger support for this 
hypothesis.  
 
Figure 3.12. (a) Comparison of compound-CBX7 associates rates. (b) Comparison of compound-CBX7 
dissociation rates. Negative log values of the dissociation rates (1/s) are shown. Data are reported as the 
mean ± the standard error of the mean (n ≥ 5). (c) CBX7 binding affinities of compounds with N-terminal 
variations are better correlated with the association rates as compared to the dissociation rates. The log 
transformations of kon (1/M/s), koff (1/s) and Kd (nM) are plotted. 
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Figure 3.13. Example SPR sensorgrams of CBX7 with each respective compound.  
  
 Having demonstrated even stronger support for our binding hypothesis between CBX7 and our 
antagonists, we were encouraged to further apply this binding pathway for the development of improved 
CBX7 antagonists. One potential pitfall for the use of UNC3866 in biological settings that our SPR studies 
revealed is the relatively short target residence time (~100 seconds). A short target residence time 
indicates that, at equilibrium in vitro, there is a rapid, continuous cycle of binding, unbinding and rebinding 
occurring between the target and its antagonist. This can be problematic in the context of a biological 
setting. Once a compound has dissociated from its target in a cellular context, it can diffuse away from 
the target. Diffusion away from the target allows the compound to be acted on by metabolic enzymes, be 
bound by off target proteins or be effluxed out of the cell. Increasing the residence time creates a long 
lived antagonist-target complex that prevents diffusion away from the target, producing more efficient 
target modulation107.  
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Figure 3.14. Induced fit binding equilibrium between CBX7 and peptidic antagonists. 
  
 In order to rationally design antagonists with improved off-rates, we again turned to our induced fit 
binding hypothesis. We approximated our hypothesized binding pathway as a two-step binding 
equilibrium based on a theoretical treatment of the binding kinetics of induced-fit binding pathways set 
forth by Weikl and von Deuster110 (Fig. 3.14). The first step involves association of CBX7 (P) with the N-
terminus of the ligand (L), leading to the initial formation of the antagonist-target complex (PL). This 
equilibrium will be dictated by its own association (k1) and dissociation (k-1) rate constants. The transition 
from PL to the stably bound state (PL*), wherein the N-terminus of CBX7 wraps around the ligand to form 
a functional aromatic cage, is then governed by its own set of association (k2) and dissociation (k-2) rate 
constants.  
 In the theoretical model set forth by Weikl and von Deuster, for their treatment of induced fit 
binding kinetics, the transition into the ground state is assumed to be much faster than the binding and 
unbinding processes, that is, k2 >>> k1. Therefore, the on-rate of an induced fit system is approximately 
k1. Since the stably bound state (PL*) is the ground state conformation, then (k2/k-2) must be >>>1, 
leading them to assume that k-2 is the dominate rate during dissociation. Encouragingly, deductions from 
our SPR experiments lead to the same conclusions. The nature of SPR makes it incapable of 
distinguishing between PL and PL*, thus the SPR measured association rate will best represent k1, the 
rate limiting step by Weikl and von Deuster. Rigidifying and optimizing the N-terminus of our antagonists 
primarily increased the SPR association rate (k1) while having a limited effect on the SPR dissociation 
rate. Because SPR cannot distinguish between PL and PL*, the measured SPR dissociation rate must be 
the combined rate of both (k-1) and (k-2). However, because our modifications to the N-terminus of our 
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antagonists had minimal effects on the SPR measured off-rate (~3-fold vs ~70-fold improvements in the 
association rate); k-2 is likely the rate-limiting step along our proposed binding pathway, in perfect 
agreement with the assumptions of Weikl and von Deuster.  
 Therefore, we hypothesized that modifications to our antagonists that can decrease k-2 will likely 
improve the residence time of these molecules. Our proposed binding pathway hypothesizes that 
dissociation is initiated when Phe11 of the aromatic cage loses contact with the modified-lysine residue 
(Fig. 3.15), allowing the N-terminus of CBX7 to open up (k-2) followed by complete protein-ligand 
dissociation (k-1). Therefore, modifications to the antagonist which prevent opening of Phe11 and the 
CBX7 N-terminus should decrease koff, increasing the residence time of the target complex.    
 
Figure 3.15. X-ray co-crystal structure of UNC3866 bound to CBX7 (PDB code 5EPJ). 
 
 While efforts to improve the off-rates of our CBX7 antagonists is still an on-going area of 
optimization, our initial approach to test this hypothesis was to test the effect of replacing the diethyl-
lysine of UNC3866 with one of our other possible Kme3 replacements. The methyl, norbornyl-lysine 
derivative UNC4976 (Fig. 3.16a) has a CBX7 Kd in ITC of 53 ± 25 nM and is approximately equipotent in 
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AlphaScreen IC50 to UNC3866. However, the complex formed between CBX7 and UNC4976 is 
exceptionally long-lived with little-to-no dissociation observed over the course of SPR experiments. 
Further, this compound possesses a similar association rate with CBX7 as UNC3866 (Fig. 3.16c). This 
results further supports our binding hypothesis and lays the basis for future design seeking to further 
improve the kinetics of the interaction between CBX7 and our antagonists.  
 
Figure 3.16. (a) Structures of UNC3866 and UNC4976. (b) SPR sensorgrams for UNC3866 (left) and 
UNC4976 (right) with CBX7. (c) comparison of UNC3866 and UNC4976 association rates.  
 
CONCLUSIONS 
 We extensively profiled the selectivity of UNC3866 and found it to be a highly selective CBX4/7 
antagonist. Further, we found that our negative control compound, UNC4219 has a similar off-target 
profile as UNC3866, making these two molecules a powerful toolset for interrogating CBX biology. We 
developed AlphaScreen® assays CDYL2 and for multiple CBX chromodomains, enabling us to better 
understanding the selectivity determinants for each of these chromodomains. These studies, coupled with 
our X-ray crystallographic studies will aid in the future development of antagonists with varying 
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chromodomain selectivity profiles. Further, our studies suggest CBX2, -6 and -8 may in fact be tractable 
targets for more traditional small molecule discovery efforts. In the meantime, the selectivity and potency 
of UNC3866 makes it a potentially powerful chemical tool for studying CBX4/7 in cellular systems. Our 
studies characterizing its effects in cellular systems are described in Chapter IV. 
 Our SPR studies with CBX7 provided powerful support for our hypothesized induced fit binding 
mechanism. These studies revealed what is to our knowledge, the first example of a protein-ligand 
system in which the association kinetics can be rationally tuned. The identification of the slow-dissociating 
CBX7 antagonist, UNC4976, further demonstrated the utility of our molecular dynamics based binding 
model and will serve as the basis for future SAR efforts seeking to optimize the dissociative kinetics of our 
antagonists with CBX7, paving the way for a second-generation CBX7chemical probe. 
 
METHODS 
Kme Reader panel AlphaScreen® assays 
 The AlphaScreen® assay (Perkin Elmer) was generally performed as previously described.69 In 
brief, compound plates (1 µL at 10 mM highest concentration; 3-fold, 10-point dilutions in DMSO) were 
diluted in 1X assay buffer (20 mM TRIS pH 8.0, 25 mM NaCl, 2 mM DTT and 0.05% Tween-20) to 1 mM 
using a Multimek robotic pipettor (Nanoscreen) and 1 µL was spotted into the wells of 384-well low-
volume Proxiplates (Perkin Elmer). To these plates 9 µL of protein-peptide mix in 1X assay buffer was 
added by Multidrop (Thermo) to bring the final compound concentration to 100 µM and incubated for 30 
min at room temperature. Next, 2 µL of a 1:1 mixture of streptavidin-conjugate donor and nickel-chelate or 
α-GST acceptor beads (45 µg/mL in 1X assay buffer) were added and the plates were allowed to 
incubate for an additional 30 min in the dark at room temperature. After incubation, the plates were read 
on an EnVision multi-label reader equipped with an HTS AlphaScreen laser (Perkin Elmer). The 
expression and purification of the constructs used in this assay was described previously76. 
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Table 3.9. Kme reader AlphaScreen® proteins and their corresponding peptide substrates. 
 
Protein Peptide Peptide sequence 
53BP1 H4K20Me2  Biotin-AHX-KGGAKRHRK(Me2)VLRDNIQ-OH 
L3MBTL1 H4K20Me1  Biotin-AHA-KGGAKRHRK(Me1)VLRDNIQ-OH 
L3MBTL3 H4K20Me2  Biotin-AHX-KGGAKRHRK(Me2)VLRDNIQ-OH 
MBTD1 H4K20Me1 Biotin-AHA-KGGAKRHRK(Me1)VLRDNIQ-OH 
CBX7 H3K9Me3 ARTKQTARK(Me3)STGGKAPRKQL-K(Biotin)-NH2   
UHRF1 H3K9Me3  ARTKQTARK(Me3)STGGKAPRKQL-K(Biotin)-NH2   
PHF23 H3K4Me3 ARTK(Me3)QTARKSTGGKAPRKQYT-K(Biotin)-NH2   
JARID1A H3K4Me3 ARTK(Me3)QTARKSTGGKAPRKQYT-K(Biotin)-NH2   
PHF1 H3K36me3 KSAPSTGGVK(Me3)KPHRYRPGTV-K(biotin)-NH2 
PHF19 H3K36me3 KSAPSTGGVK(Me3)KPHRYRPGTV-K(biotin)-NH2 
 
Protein microarray layout 
 
Figure 3.17 
 
ITC studies 
 All ITC measurements were recorded at 25 °C with an AutoITC200 microcalorimeter (MicroCal 
Inc., MA).  All protein and compound stock samples were in the target buffer (25 mM Tris-HCl, pH 8, 150 
mM NaCl, and 2 mM β-mercaptoethanol), and then diluted in the same buffer to achieve the desired 
concentrations: 50 µM protein and 0.5 mM compound.  The concentration of the protein stock solution 
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was established using the Edelhoch method, whereas compound stock solutions were prepared based on 
mass. A typical experiment included a single 0.2 µl compound injection into a 200 µl cell filled with 
protein, followed by 25 subsequent 1.5 µl injections of compound.  Injections were performed with a 
spacing of 180 seconds and a reference power of 8 µcal/sec.  Control experiments were performed 
titrating each compound into buffer under identical conditions to determine the heat signals, if any, that 
arise from diluting the compound.  If applicable, the heats of dilution generated were then subtracted from 
the protein-compound binding curves. The initial data point was routinely deleted.  The titration data was 
analyzed using Origin Software (MicroCal Inc., USA) by non-linear least squares, fitting the heats of 
binding as a function of the compound:protein ratio to a one site binding model.   
 
Bromodomain Selectivity Assays  
 Thermal melting experiments were carried out using an Mx3005p Real Time PCR machine 
(Stratagene). Proteins were buffered in 10 mM HEPES pH 7.5, 500 mM NaCl and assayed in a 96-well 
plate at a final concentration of 2 μM in 20 μL volume.  Compounds were added at a final concentration of 
25 μM.  SYPRO Orange (Molecular Probes) was added as a fluorescence probe at a dilution of 
1:1000.  Excitation and emission filters for the SYPRO-Orange dye were set to 465 and 590 nm, 
respectively.  The temperature was raised with a step of 3 °C per minute from 25 °C to 96 °C and 
fluorescence readings were taken at each interval. 
 
Methyltransferase Selectivity Assays 
 The effect of UNC3866 on the methyltransferase activity of G9a, EHMT1, SUV39H1, SUV39H2, 
SETDB1, SETD8, SUV420H1, SUV420H2, SETD7, MLL1 trimeric complex, MLL3 tetrameric complex, 
EZH2 trimeric complex, PRMT1, PRMT3, PRMT5-MEP50 complex, PRMT6, PRMT7, PRMT8, PRDM9, 
SETD2, SMYD2, SMYD3, BCDIN3D and DNMT1 was assessed by monitoring the incorporation of 
tritium-labeled methyl group to lysine or arginine residues of peptide substrates using Scintillation 
Proximity Assay (SPA) as previously described111.  Assays were performed in a 20 µL reaction mixture 
containing 3H-SAM (Cat. # NET155V250UC; Perkin Elmer; www.perkinelmer.com) at substrate 
concentrations close to the Km values for each enzyme.  Three concentrations (1 µM, 10 µM, and 50 µM) 
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of UNC3866 were used in all selectivity assays.  To stop the enzymatic reactions, 7.5 M Guanidine 
hydrochloride was added, followed by 180 µl of buffer (20 mM Tris, pH 8.0). The reactions were mixed 
and then transferred to a 96-well FlashPlate (Cat. # SMP103; Perkin Elmer; www.perkinelmer.com). The 
reaction mixtures in Flash plates were incubated for 1 hour and the CPM were measured using a 
TopCount plate reader (Perkin Elmer, www.perkinelmer.com). The CPM counts in the absence of 
compound for each data set were defined as 100% activity. In the absence of the enzyme, the CPM 
counts in each data set were defined as background (0%).  
 For DOT1L, NSD1, NSD2, NSD3, ASH1L, METTL21A, METTL21D, DNMT3A/3L, and 
DNMT3B/3L, a filter-based assay was used. In this assay, 20 µl of reaction mixtures were incubated at 22 
°C for 1 hour, 100 µl of 10% trichloroacetic acid (TCA) was added, and the samples were mixed and 
transferred to filter-plates (Millipore; cat.# MSFBN6B10; www.millipore.com). Plates were centrifuged at 
2000 rpm (Allegra X-15R - Beckman Coulter, Inc.) for 2 min, followed by two additional 10% TCA washes, 
one ethanol wash (180 µl), and centrifugation. Plates were dried and 100 µl of MicroO (MicroScint-O; Cat. 
# 6013611, Perkin Elmer; www.perkinelmer.com) was added to each well, centrifuged and removed. 
Another 70 µl of MicroO was added and the CPM was measured using a TopCount plate reader. 
Demethylase AlphaScreen® Assays  
 The demethylase AlphaScreen® assay was performed in 384-well plate format using white 
proxiplates (Perkin Elmer) and compound transfers (100 nl) were performed using an ECHO 550 Acoustic 
Dispenser (Labcyte). All subsequent steps were carried out in assay buffer (50 mM HEPES pH 7.5, 0.1% 
(w/v) Bovine Serum Albumin and 0.01 % (v/v) Tween-20). In brief, 5 ml of assay buffer containing 
demethylase enzyme at 2X final assay concentration (see Table 3.12 for assay specifics) was pre-
incubated for 15 minutes with dilutions of compound. The enzyme reaction was initiated by addition of 
substrate (5 ml) consisting of L-Ascorbic Acid (100 mM), 2-oxoglutarate (2X final assay concentration), 
Ferrous Ammonium Sulphate (2X final assay concentration) and Histone H3 substrate peptide (2X final 
assay concentration) and the enzyme reaction was allowed to proceed for the required time. The final 
assay DMSO concentration was 1%. The enzyme reaction was stopped by addition of 5 ml assay buffer 
containing EDTA (30 mM) and NaCl (800 mM). Streptavidin Donor beads (0.08 mg/ml) and Protein-A 
conjugated acceptor beads (0.08 mg/ml) were pre-incubated for 1 hour with anti-methyl mark antibody 
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(4X final assay concentration) and the presence of Histone H3 product methyl mark was detected by 
addition of the pre-incubated AlphaScreen® beads (5 ml). Detection was allowed to proceed for 2 hour at 
room temperature and the assay plates were read in a BMG Pherastar FS plate reader (Excitation 680 
nM / Emission 570 nM).  Data were normalized to the no enzyme control and the IC50 determined from 
the nonlinear regression curve fit using GraphPad Prism 5. 
Table 3.10. Biotinylated peptide substrates.  
Peptide Supplier Code 
H3K4Me3 (JARIDs) Anaspec 64192 
H3K27Me3 (JMJD3) Anaspec 64367 
H3K9Me3 (JMJD2C) Anaspec 64360 
H3K9Me2 (JMJD1A) Anaspec 64359 
 
Table 3.11. Anti-methyl mark antibodies. 
Assay Supplier Code 
Anti-H3K4Me2 (JARIDs) Cell Signalling Technology 9725S 
Anti-H3K9Me2 (JMJD2C) Abcam ab1220 
Anti-H3K9Me1 (JMJD1A) Abcam ab8896 
Anti-H3K27Me2 (JMJD3) Millipore 07-452 
 
Table 3.12. Demethylase Alphascreen® assay specifics. 
Assay 
Enzyme  
(nM) 
Peptide  
(nM) 
2-OG  
(μM) 
Fe2+ (μM) 
Incubation  
(min) 
Antibody 
(Conc.) 
JARID1A 4 100 5 10 25 1:2500 
JARID1B 2 100 5 10 20 1:2500 
JARID1C 2 100 5 10 20 1:2500 
JARID1D 2 100 5 10 15 1:2500 
JMJD2C 1 30 10 1 15 50 mg/ml 
JMJD1A 0.5 60 5 10 5 40 mg/ml 
JMJD3 0.1 60 10 10 15 40 mg/ml 
 
NIMH PDSP Functional Assays  
 The NK1 and NK2 receptors; ∆-, -, and -opioid receptors; and  V1A, V1B and V2 receptor 
functional assays were performed according to the NIMH PDSP Assay Protocol Book Version II found at 
https://pdspdb.unc.edu/pdspWeb/?site=binding 
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Conditions for newly developed AlphaScreen assays 
Table 3.13. Protein-bait ligand concentrations used for AlphaScreen® assays. 
Protein (final assay 
concentration) 
Bait ligand (final assay concentration) 
CBX4 (10 nM) UNC4195 (2) (10 nM) 
CBX7 (15 nM) UNC4195 (2) (15 nM) 
CBX8 (125 nM) UNC4195 (2) (15 nM) 
CDYL2 (8 nM) UNC4195 (2) (8.0 nM) 
CBX5 (31 nM) ARTKQTARK(Me3)STGGKAPRKQL-K(Biotin)-NH2  (65 nM) 
 
Protein expression and purification  
 All expression constructs were transformed into Rosetta BL21(DE3)pLysS competent cells 
(Novagen, EMD Chemicals, San Diego, CA).  Protein expression was induced by growing cells at 37°C 
with shaking until the OD600  reached ~0.6-0.8 at which time the temperature was lowered to 18°C and 
expression was induced by adding 0.5mM IPTG and continuing shaking overnight.  Cells were harvested 
by centrifugation and pellets were stored at -80°C.   
 His-tagged proteins were purified by re-suspending thawed cell pellets in 30ml of lysis buffer 
(50mM sodium phosphate pH 7.2, 50mM NaCl, 30mM imidazole, 1X EDTA free protease inhibitor cocktail 
(Roche Diagnostics, Indianapolis, IN)) per liter of culture.  Cells were lysed on ice by sonication with a 
Branson Digital 450 Sonifier (Branson Ultrasonics, Danbury, CT) at 40% amplitude for 12 cycles with 
each cycle consisting of a 20 second pulse followed by a 40 second rest.  The cell lysate was clarified by 
centrifugation and loaded onto a HisTrap FF column (GE Healthcare, Piscataway, NJ) that had been 
preequilibrated with 10 column volumes of binding buffer (50mM sodium phosphate pH 7.2, 500mM NaCl, 
30mM imidazole) using an AKTA FPLC (GE Healthcare, Piscataway, NJ).  The column was washed with 
15 column volumes of binding buffer and protein was eluted in a linear gradient to 100% elution buffer 
(50mM sodium phosphate pH 7.2, 500mM NaCl, 500mM imidazole) over 20 column volumes.  Peak 
fractions containing the desired protein were pooled and concentrated to 2ml in Amicon Ultra-15 
concentrators 3,000 molecular weight cut-off (Merck Millipore, Carrigtwohill Co. Cork IRL).  Concentrated 
protein was loaded onto a HiLoad 26/60 Superdex 75 prep grade column (GE Healthcare, Piscataway, 
NJ) that had been preequilibrated with 1.2 column volumes of sizing buffer (25mM Tris pH 7.5, 250mM 
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NaCl, 2mM DTT, 5% glycerol) using an ATKA Purifier (GE Healthcare, Piscataway, NJ).  Protein was 
eluted isocratically in sizing buffer over 1.3 column volumes at a flow rate of 2ml/min collecting 3ml 
fractions.  Peak fractions were analyzed for purity by SDS-PAGE and those containing pure protein were 
pooled and concentrated using Amicon Ultra-15 concentrators 3,000 molecular weight cut-off (Merck 
Millipore, Carrigtwohill Co. Cork IRL). 
 GST-tagged proteins were purified by re-suspending thawed cell pellets in 30ml of lysis buffer 
(1xPBS, 5mM DTT, 1X EDTA free protease inhibitor cocktail (Roche Diagnostics, Indianapolis, IN)) per 
liter of culture.  Cells were lysed on ice by sonication as described for His-tagged proteins.  Clarified cell 
lysate was loaded onto a GSTrap FF column (GE Healthcare, Piscataway, NJ) that had been pre-
equilibrated with 10 column volumes of binding buffer (1xPBS, 5mM DTT) using a AKTA FPLC (GE 
Healthcare, Piscataway, NJ).  The column was washed with 10 column volumes of binding buffer and 
protein was eluted in 100% elution buffer (50mM Tris pH 7.5, 150mM NaCl, 10mM reduced glutathione) 
over 10 column volumes.  Peak fractions containing the desired protein were pooled and concentrated to 
2ml in Amicon Ultra-15 concentrators, 10,000 molecular weight cut-off (Merck Millipore, Carrigtwohill Co. 
Cork IRL).  Concentrated protein was loaded onto a HiLoad 26/60 Superdex 200 prep grade column (GE 
Healthcare, Piscataway, NJ) that had been preequilibrated with 1.2 column volumes of sizing buffer 
(25mM Tris pH 7.5, 250mM NaCl, 2mM DTT, 5% glycerol) using an ATKA FPLC (GE Healthcare, 
Piscataway, NJ).  Protein was eluted isocratically in sizing buffer over 1.3 column volumes at a flow rate 
of 2ml/min collecting 3ml fractions.  Peak fractions were analyzed for purity by SDS-PAGE and those 
containing pure protein were pooled and concentrated using Amicon Ultra-15 concentrators 10,000 
molecular weight cut-off (Merck Millipore, Carrigtwohill Co. Cork IRL). 
 
Affinity tag removal 
 The N-terminal affinity tag was removed from CBX2, CBX6, CDY1, CDYL1b and CDYL2 by 
thrombin cleavage according to manufacturer’s recommendations (Novagen, EMD Chemicals, San 
Diego, CA).  Briefly, purified protein was incubated with biotinylated thrombin at a final concentration of 1 
unit thrombin per milligram tagged protein for 16 hours at 4⁰C.  The cleavage reaction was then passed 
over either a HisTrap FF column (His-tagged proteins) or a GSTrap FF column (GST-tagged proteins) to 
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remove any protein that still retained the tag.  The column flow through was collected and incubated with 
streptavidin agarose to remove thrombin from the sample.  Streptavidin agarose was removed from the 
sample by centrifugation and the protein was concentrated using Amico Ultra-15 concentrators, 3,000 
molecular weight cut-off (Merck Millipore, Carrigtwohill Co. Cork IRL).  Protein was exchanged into a 
buffer containing 25mM Tris pH 7.5, 150mM NaCl, 2mM β-mercaptoethanol prior to use in ITC. 
 
Preparation of proteins for crystallization 
 Expression and purification followed a previous description68. The coding DNA fragments of 
single chromodomains of CBX2 (residues 9-62), CBX4 (residues 8-65), CBX7 (residues 8-62) and CBX8 
(residues 8-61) were subcloned into modified pET28-MHL or pET28a-Lic vectors to encode N-terminal 
His-tagged fusion proteins. Recombinant proteins were overexpressed in E. coli BL21 (DE3) Codon plus 
RIL cells (Stratagene) at 15 °C, purified by affinity chromatography on Ni-nitrilotriacetate resin (Qiagen), 
and treated with TEV or thrombin protease to remove the tag. The proteins were further purified by gel 
filtration over a Superdex75 column (GE Healthcare, Piscataway, NJ). For crystallization, purified proteins 
were concentrated to 10 mg/mL in a buffer containing 20 mM Tris, pH 7.5, 150 mM NaCl and 1 mM DTT. 
 
Crystallization 
 Purified protein was mixed with compound at a 1:2 molar ratio and crystallized using the sitting 
drop vapor diffusion method at 18–20°C by mixing 0.5 μL of the protein with 0.5 μL of the reservoir 
solution. Reservoir solutions were 20% PEG 3350, 0.2 M KSCN for CBX2, 30% PEG 3350, 0.2 M NaCl, 
0.1 M sodium cacodylate, pH 5.5 for CBX4, 20% PEG 3350, 0.2 M ammonium formate for CBX7, and 1.4 
M sodium citrate, 0.1 M Hepes, pH 7.5, 5% glycerol for CBX8. Crystals were soaked in a cryoprotectant 
consisting of 85% reservoir solution and 15% glycerol, and flash-frozen in liquid nitrogen.  
 
Data collection/structure determination and refinement 
 Diffraction data for model refinement were collected at a copper rotating anode (CBX2, CBX7) or 
APS beam line 19ID (CBX4, CBX8; wavelength 0.979 Å). Diffraction intensities were integrated with 
XDS112 and merged with AIMLESS113. Molecular replacement was performed with the program 
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PHASER114. Geometry restraints for the modified lysyl residue as well as the 4-t-butylbenzoyl protecting 
group were prepared with eLBOW/Mogul, restraints for selected peptide links with jLigand. Current 
crystallographic models underwent iterative re-building, refinement, validation in COOT, REFMAC, 
MOLPROBITY, respectively. Favored regions of the respective model’s MOLPROBITY Ramachandran 
plot included at least 98% of the residues. Anisotropic displacement parameters were analyzed on the 
PARVATI server. PDB_EXTRACT as well as PHENIX, IOTBX and CCP4 software were used to compile 
data for model deposition in the Protein Data Bank and for publication. 
Specifically: 
CBX2. Coordinates from PDB entry 3H9168 were used for molecular replacement. 
CBX4. The structure of an isomorphous crystal was solved by molecular replacement with CBX2 
coordinates.  ARP/WARP was used in “map improvement” and “automated model building” modes. The 
model refinement was further refined against data from the current crystal. 
CBX7. The structure was first solved in the lower symmetry P41 setting by molecular replacement with 
coordinates from PDB entry 4MN338. After merging of data in space group P41212, molecular 
replacement was performed with  preliminarily refined CBX7 coordinates. 
CBX8. The structure of an isomorphous crystal was solved by molecular replacement with CBX7 
coordinates. ARP/WARP was used in “map improvement” and “automated model building” modes. The 
model was further refined against data from an additional crystal and, subsequently, the current crystal. 
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Table 3.14. Data collection and refinement statistics (molecular replacement). 
 
Protein (PDB 
ID) 
CBX2 (5EPK) CBX4 (5EPL) CBX7 (5EPJ) CBX8 (5EQ0) 
Data 
collection 
    
Space group P6 P6122 P41212 P21 
Cell 
dimensions     
    a, b, c (Å) 78.89,78.89,30.61 65.18,65.18,133.06 40.29,40.29,82.09 30.57,30.01,36.10 
 ()  90.00,90.00,120.00 90.00,90.00,120.00 90.00,90.00,90.00 90.00,100.17,90.00 
Resolution 
(Å) 
34.16-1.80(1.84-
1.80) 
44.35-1.81(1.84-
1.81) 
36.17-1.60(1.63-
1.60) 
35.54-1.18(1.20-
1.18) 
Rsym or Rmerge 0.067(0.886) 0.064(0.664) 0.039(0.187) 0.038(0.343) 
I / I 29.2(3.1) 37.4(5.4) 51.8(13.8) 20.5(3.7) 
Completeness 
(%) 100.0(100.0) 99.9(98.7) 99.9(98.2) 99.5(94.5) 
Redundancy 10.6(10.3) 20.4(19.6) 12.4(12.3) 3.5(3.3) 
     
Refinement     
Resolution 
(Å) 34.00-1.80 44.00-1.81 36.17-1.60 35.54-1.18 
No. 
reflections 
work/free 9752/506 14370/1566 8760/671 20239/1069 
Rwork / Rfree 0.189/0.212 0.183/0.216 0.237/0.260 0.156/0.186 
No. atoms 569 1195 572 630 
    Protein 460 938 454 511 
    Ligand 61 131 57 57 
    Water 40 118 48 50 
    Other 8 8 13 12 
B-factors 31.5 27.1 12.8 11.9 
    Protein 31.4 26.9 12.1 11.2 
    Ligand 32.2 23.4 12.0 10.2 
    Water 31.4 32.6 18.8 20.8 
    Other 32.6 27.1 19.3 17.0 
R.m.s. 
deviations     
    Bond 
lengths (Å) 0.019 0.018 0.015 0.021 
    Bond 
angles () 1.9 1.8 1.6 2.0 
*Numbers in parentheses are for highest-resolution shell. 
 
All images were rendered using the PyMOL Molecular Graphics System, Version 1.7.4 Schrödinger, LLC. 
 
Surface Plasmon Resonance Experiments 
SPR experiments were performed on a ProteOn™ XPR36 Interaction Array System. C-terminally His-
tagged CBX7 was immobilized using a ProteOn™ HTE sensor chip. Compounds were flowed at a rate of 
50-100 μL/minute with a contact time of 150 seconds. Dissociation steps were run for 300 seconds at a 
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flow rate of 100 µL/minute. Double referencing subtraction was done with buffer and protein blank 
channels to account for nonspecific binding to the sensor chip. 
 
Compound synthesis and characterization 
General experimental procedures used for all compounds except UNC4976 are described in depth in the 
METHODS section of CHAPTER II. 
 
Synthesis of UNC4976 (64) 
 
methyl (4-(tert-butyl)benzoyl)-L-phenylalanyl-L-alanyl-L-leucyl-L-lysyl-L-serinate (200 mg, 0.23 mmol, 1.0 
eq.) was dissolved in 2 mL of MeOH. Norcamphor (210 mg. 1.9 mmol, 8.0 eq.) and sodium 
cyanoborohydride (44 mg, 0.70 mmol, 3.0 eq.) were added and the solution was stirred at 50°C until 
complete consumption of methyl (4-(tert-butyl)benzoyl)-L-phenylalanyl-L-alanyl-L-leucyl-L-lysyl-L-serinate 
(~2 hours). The mixture was cooled to room temperature and 50 µL of 37% Aq. Formaldehyde (excess) 
was added and the solution was stirred at room temperature. Upon completion, the solution was 
concentrated by rotary evaporation and loaded onto silica gel. The crude mixture was purified by normal 
phase column chromatography with the UV detector to 220 nm and 254 nm. Mobile phases of A (DCM) 
and B (Methanol) were used with a gradient of 0 to 40% methanol. Product containing fractions were 
combined, concentrated by rotary evaporation and the resulting residue was purified by reverse phase 
column chromatography ((H2O + 0.1% TFA)/MeCN) to yield 100.2 mg (45%) of the title compound as a 
TFA salt. MSI (ESI): 847.50 [M+H]+ 
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Table 3.15. Compound structures and characterization by LCMS 
Compound 
ID 
Structure LCMS trace (220 nM) Observed Mass 
UNC4940 
(59) 
  
739.40 [M+H]+ 
UNC4972 
(60) 
  
809.50 [M+H]+ 
UNC4938 
(61) 
  
391.35 [M+H]+ 
781.45 [M]+ 
UNC4941 
(62) 
 
 
405.35 [M+2H]2+ 
809.50 [M+H]+ 
UNC4971 
(63) 
  
823.50 [M+H]+ 
UNC4976 
(64) 
  
847.5 [M+H]+ 
UNC4939 
(65) 
  
809.50 [M+H]+ 
UNC4030 
(66) 
  
823.15 [M+H]+ 
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UNC4007 
(67) 
  
391.20 [M+2H]2+ 
402.15 [M+H+Na]2+ 
781.10 [M+H]+ 
UNC4087 
(68) 
  
404.65 [M+2H]2+ 
808.20 [M+H]+ 
UNC4051 
(69) 
  
737.20 [M+H]+ 
 
UNC4946 
(70) 
 
220 nm 
  
 
254 nm 
  
412.85 [M+2H]2+ 
UNC4961 
(71) 
  
924.55 [M+H]+ 
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1H NMR spectrum of UNC4940 as a TFA salt 
 
1H NMR spectrum of UNC4972 as a TFA salt 
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1H NMR spectrum of UNC4938 as a trifluoroacetate salt 
 
1H NMR spectrum of UNC4941 as a TFA salt 
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1H NMR spectrum of UNC4971 as a TFA salt 
 
1H NMR spectrum of UNC4976 as a TFA salt 
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1H NMR spectrum of UNC4939 as a TFA salt 
 
1H NMR spectrum of UNC4030 as a TFA salt 
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1H NMR spectrum of UNC4007 as a TFA salt 
 
1H NMR spectrum of UNC4087 as a TFA salt 
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1H NMR spectrum of UNC4051 as a TFA salt 
 
1H NMR spectrum of UNC4946 as a TFA salt 
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1H NMR spectrum of UNC4961 as a TFA salt 
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CHAPTER IV: CELLULAR CHARACTERIZATION OF UNC3866 
INTRODUCTION 
 Our selectivity studies in Chapter III uncovered that UNC3866 is highly selective for two families 
of chromodomains and is overall a selective antagonist for CBX4/7. Further, the limited number of GPCR 
targets engaged by CBX7 can be controlled for in biological settings through the use of UNC4219 in 
parallel studies, as the off-target profiles of UNC3866 and UNC4219 are nearly identical. While our 
studies have demonstrated that UNC3866 has an acceptable molecular profile for use as a chemical 
probe, four of the core principles of a quality chemical probe remained following our studies in Chapter 
III58:  
(1) Molecular profiling 
(2) Mechanism of action 
(3) Identity of the active species 
(4) Proven utility as a probe 
(5) Availability 
Mechanism of action studies involve providing sufficient data demonstrating modulation of the intended 
molecular target in a dose-dependent fashion by the probe candidate. In the case of methyl-lysine reader 
proteins, this particular principle is difficult to satisfy when compared to evaluating antagonists of 
enzymatic proteins. Typical approaches for demonstrating modulation of reader proteins have focused on 
techniques such as Fluorescence Recovery after Photobleaching (FRAP) and the Cellular Thermal Shift 
Assay (CETSA)8, 75, 115. Unfortunately, CBX proteins are not amenable to either of these studies, the 
reasons for which will be discussed in this chapter. This forced us to pursue an alternative approach to 
demonstrate target engagement by UNC3866. Confidence in mechanism of action studies is inseparably 
tied to knowledge of the active species. Characterization of both the permeability and metabolic stability 
of any probe candidate is essential for understanding its mechanism of action and attributing its 
phenotypic effects to modulation of the target of interest. The utility of a probe candidate (Principle 4) can 
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be proven through satisfaction of principles 1-3 coupled with carefully controlled cellular experiments 
demonstrating phenotypic effects through target modulation. 
 To evaluate the utility of UNC3866 as a CBX7 chemical probe, we focused on well characterized 
role of CBX7 in prostate tissue. The ability of CBX7 to regulate normal epithelial and cancerous prostate 
cell proliferation has been well-studied. CBX7 increases cell proliferation in prostate tissue by bypassing 
replicative senescence, although the precise mechanism by which it does so is unclear15, 16, 18, 43. Further, 
CBX7 may be an important contributor in the conversion of prostate cancer cells to androgen-
independence16. 
 Herein we report our efforts to characterize UNC3866 in both cellular and in vivo contexts. We 
primarily focused our studies in the context of PC3 cells, an advanced staged prostate cancer cell model 
previously shown to have its growth regulated by CBX715, 16, 18, 43. We describe our studies characterizing 
the cellular effects of UNC3866 and its validation as a cellular chemical probe for the chromodomains of 
PRC1. 
 
RESULTS AND DISCUSSION 
UNC3866 engages canonical PRC1 
 Our studies described in Chapters II and III utilized recombinant protein constructs consisting only 
of the chromodomain of each of UNC3866’s targets: CBX2/4/6/7/8, CDY1, CDYL1b and CDYL2. To verify 
that UNC3866 is capable of interacting with the full-length, endogenous forms of these proteins, we 
utilized our biotinylated derivative, UNC4195 in a series of pull-down studies from PC3 cell lysates (Fig. 
4.1). We blotted for each of the chromodomain targets of UNC3866 except CDY1, for which we were 
unable to obtain a reliable antibody. We detected pull-down of all chromodomain targets of UNC3866 
except CBX2 and -6 (Fig. 4.1b). Furthermore, pull-down is antagonized when excess soluble UNC3866 is 
added to the lysate. We also blotted for and detected representatives from each of the 4 core families of 
canonical PRC1 (Fig. 4.1b and 4.1c).  
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Figure 4.1. (a) UNC4195 pull-down studies from PC3 cell lysates. (b) Core components of PRC1 and 
their respective family members. (c) Pull-down of representative PRC1 components from PC3 cell lysates 
with UNC4195.  
 
 The recent finding that EED, an H3K27me3 reader once thought to only participate in PRC2, can 
participate in CBX-containing PRC1 complexes intrigued us57; therefore, we investigated the ability of 
UNC4195 to pull-down EED in PC3 cells. Three of the four mammalian isoforms of EED (EED1, -3 and -
4)116 were detected in the PC3 lysate input; however, UNC4195 pulled-down only EED3 and EED4, both 
of which could be competed away through the addition of UNC3866 to the lysate (Fig. 4.1c). Additionally, 
because EED binds H3K27me3 via its WD40 Kme reading domain, we confirmed that UNC3866 does not 
bind directly to EED (Fig. 4.2a and 4.2b), indicating that pull-down is mediated through incorporation of 
EED into PRC1. We next examined the presence of EED in PRC2 using the EZH1 and EZH2 biotinylated 
pull-down reagent, UNC239923. Interestingly, we detected only EED4 in PRC2 (Fig. 4.2c). It has been 
shown that the incorporation of different isoforms of EED into PRC2 can dictate the in vitro histone 
substrate of PRC2117, and hence our discovery that EED incorporates into PRC1 in an isoform-dependent 
fashion provides the basis for future work to examine the effects of these isoforms on PRC1 function. 
Furthermore, the absence of EED1 in either PRC1 or PRC2 raises questions as to the binding partners 
and function of this isoform in PC3 cells.  
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Figure 4.2. UNC3866 does not bind to EED as assessed by ITC (a) Titration of UNC3866 into a 
solution of EED.  (b) Titration of EED into a solution of UNC3866. (c) EED incorporation into PRC2. Only 
EED4 is detected in PRC2 following pull-down in PC3 cell lysates with UNC2399, a biotinylated derivative 
of the EZH1/2 inhibitor, UNC199923. Soluble UNC1999 was added to the lysate and successfully prevents 
chemiprecipitation of EED4. 
 
 Our studies in Table 3.8 indicated that the 4-position of the phenylalanine of UNC3866 is able to 
accommodate larger functionalities. To this end, we generated a biotinylated derivative of UNC4946 as 
an alternative pull-down reagent with the aim of accessing CBX2 and -6 in our pull-down studies. 
Surprisingly, we found that not only was Biotin-4946 unable to pull-down CBX2 and -6, it also lost the 
ability to pull-down CBX7, indicating that pull-down of these endogenous proteins from cell lysates is 
highly sensitive to the positioning of the chemical tag (Fig. 4.3). It is possible that biotinylation of the 
ligand produces a steric clash in the context of specific intact PRC1 complexes that can’t be anticipated 
from CBX domain co-crystal structures. 
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Figure 4.3. (a) structures of UNC4946 and Biotin-4946. (b) Western blots from pulldown Experiments 
with biotin-47. Target protein bands are marked with an *. For CBX2, two isoforms are known to exist, 
resulting in the presence of two CBX2 bands. For each experiment, lane 1 = input, lane 2 = biotin-47 pull-
down and lane 3 = biotin-47 pull-down + 100 μM UNC3866 (1). 
 
UNC3866 mechanism of action studies 
 Having demonstrated that UNC3866 is capable of engaging full-length, endogenous CBX4/7/8 
and CDYL1b/2, we sought to demonstrate dose-dependent modulation of CBX7 in a cellular context. As 
discussed, the non-enzymatic nature of chromodomains makes demonstrating cellular engagement of 
these proteins challenging. However, we reasoned that UNC3866 may be able to modulate the E3 ligase 
activity of PRC1. Therefore, we evaluated the ability of UNC3866 modulate monoubiquitination of 
H2AK119 (H2AK119ub) by PRC1 and found that it was unable to do so (Fig. 4.4a). To understand this 
result, we evaluated whether UNC3866 is capable of displacing CBX7 and/or RING1B from chromatin 
and again found no effect from UNC3866 treatment (Fig. 4.4b). These results were not surprising for 
several reasons. First, the presence of non-canonical PRC1 complexes that do not contain CBX 
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proteins89 makes monoubiquitination of H2AK119 an unreliable readout. Second, it has been shown 
previously that the E3 ligase components (RING1b and PCGF proteins) maintain strong affinity for 
nucleosomes in the absence of CBX proteins13. Finally, previous studies have shown that both 
inactivating mutations and deletions of the chromodomain of CBX proteins have no effect on the 
association of PRC1 with chromatin96. While FRAP has been previously applied to study the effects of 
antagonists on chromatin readers8, 75, previous studies of have shown that mutation and deletion of CBX 
chromodomains has no detectable effect on their FRAP-based cellular mobility81, ruling out this technique 
as a part of mechanism of action studies. Additionally, we failed to detect thermostabilization of CBX7 by 
UNC3866 in cell lysates (Fig. 4.4c), likely because the chromodomain comprises a relatively small portion 
(~25%) of the full-length protein, which precludes evaluation of cellular target engagement via the Cellular 
Thermal Shift Assay (CETSA)115.   
 
 
Figure 4.4. (a) Western blot analysis of global H2AK119ub levels in PC3 cells following DMSO, UNC3866 
or UNC4219 treatment. (b) Western blot analysis following subcellular fractionation of nuclear soluble and 
chromatin bound fractions of whole cells treated with DMSO or UNC3866 for 24 hours. This result was 
the same in both isolated nuclei and isolated chromatin treated with UNC3866 (data not shown). (c) 
UNC3866 does not thermostabilize CBX7 in PC3 cells lysates.  CETSA was performed in PC3 cell 
lysates using DMSO or 30 μM of UNC3866. No change in the TM of CBX7 was observed (N=3). 
 
 Our struggles to demonstrate cellular target engagement through established techniques 
prompted us to pursue an alternative approach. We hypothesized that competition-based 
chemiprecipitation experiments could be utilized to demonstrate cellular target engagement, with the 
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expectation that pretreatment with UNC3866 would block chemiprecipitation (Fig. 4.5a). Whole PC3 cells 
were incubated with varying concentrations of UNC3866 for 24 hours, after which excess media and 
compound were removed and the cells were washed, harvested with trypsin and lysed. Encouragingly, 
CBX7 chemiprecipitation with UNC4195 was completely inhibited in lysates from cells pretreated with 30 
µM UNC3866, indicating that UNC3866 effectively engages CBX7 in cells at this concentration (Fig. 
4.5b).  
 
Figure 4.5. (a) Cartoon schematic of competition pull-down assay. (b) Incubation of intact PC3 cells with 
UNC3866 for 24 hours inhibits pull-down of CBX7 with UNC4195. 
 
 We sought to determine whether any of our C-terminal derivatives of UNC3866 (Table 3.8, Fig. 
4.6a were better able to engage the chromodomain of CBX7. While these molecules do display an 
approximately 2-fold reduction in their potency for CBX7 relative to UNC3866 (Table 3.8 and Fig. 4.5a), 
we hypothesized that the lack of a C-terminal methyl ester on these molecules, which eliminates their 
susceptibility to hydrolysis by esterases, could make them more metabolically stable and possibly more 
membrane permeable, thereby increasing their cellular efficacy. We tested these compounds in our 
competition pull-down assay (Fig. 4.5a) at a concentration of 30 µM and compared their ability to inhibit 
CBX7 pull-down by UNC4195 (Fig. 4.6b). Surprisingly, pull-down was reduced most in cells pretreated 
with UNC3866, indicating that UNC3866 is the most cellularly efficacious of these three compounds. 
166 
 
 
Figure 4.6. (a) Structures of additional CBX7 antagonists tested in our competition pull-down assay. (b) 
UNC3866 is the most potent cellular CBX7 antagonist of the compounds tested.  
 
Identification of the active species 
 Having demonstrated that UNC3866 is capable of antagonizing the chromodomain of CBX7, we 
sought to confirm that UNC3866 was in fact the active species in cells. The high concentration of 
UNC3866 relative to its in vitro Kd suggested that the permeability of UNC3866 is low. This is unsurprising 
as peptidic inhibitors are often plagued by limited membrane permeability118. Therefore, we assessed the 
permeability of UNC3866 using a Caco-2 assay and found it to be low (Fig. 4.7), consistent with our need 
for relatively high compound concentrations for cellular studies. Additionally, as mentioned previously, we 
noted the potential for UNC3866 to serve as a pro-drug if the C-terminal methyl ester is susceptible to 
hydrolysis by intracellular esterases; therefore, we confirmed through a combination of pull-down and ITC 
experiments that the corresponding C-terminal acid, UNC4007, is still capable of engaging PRC1 
chromodomains (Fig. 4.8a and 4.8b). Next, we quantified the intracellular concentration of both UNC3866 
and UNC4007 by LC-MS/MS (Fig. 4.8c). Treatment for 24 hours at 30 µM UNC3866 resulted in an 
intracellular concentration of 1.4 ± 0.3 μM, corresponding to ~5% of the extracellular concentration. The 
UNC3866 intracellular concentration was approximately 7-fold higher than the intracellular concentration 
of UNC4007, indicating that hydrolysis of UNC3866 is limited under these conditions. This data correlates 
well with our pull-down results in Fig. 4.5b, wherein pull-down is reduced only slightly at 10 µM and 
completely at 30 µM. These concentrations would be expected to yield intracellular concentrations of 
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UNC3866 of 500 nM and 1.4 µM, which are approximately 5-and 10-times the Kd of UNC3866 for the 
chromodomains of CBX4 and -7, respectively.   
 
Figure 4.7. UNC3866 exhibits low membrane permeability as measured by the Bi-Directional Caco-2 
Permeability Assay. Assay performed by Absorption Systems LP; Exton, PA. 
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Figure 4.8. UNC4007 interacts with PRC1 chromodomains. (a) Structure of UNC4007 which binds CBX7 
with a Kd of 0.41 ± 0.16 µM. The ITC curve shown is representative of the binding interaction of UNC4007 
to CBX7. The Kd is reported as the average of 3 replicates ± the standard error of the mean. (b) When 
added to PC3 cell lysates, excess soluble UNC4007 inhibits pull-down of CBX4, -7 and -8 while 
UNC4219 does not. (c) Intracellular concentration of UNC3866 and UNC4007 following treatment of PC3 
cells with 30 μM UNC3866 for 24 hrs. Intracellular concentration was calculated using the following 
equation with 2.9 pL used as an estimate for the volume of PC3 cells based on a previous report119. 
𝑝𝑚𝑜𝑙 𝑝𝑒𝑟 𝑡𝑢𝑏𝑒
𝑎𝑣𝑒𝑟𝑎𝑔𝑒 𝑐𝑒𝑙𝑙 𝑐𝑜𝑢𝑛𝑡 𝑜𝑓 𝑡ℎ𝑒 3 𝑠𝑎𝑚𝑝𝑙𝑒𝑠
 =  
𝑝𝑚𝑜𝑙
𝑐𝑒𝑙𝑙
÷ 2.9 𝑝𝐿 = [𝐼𝑛𝑡𝑟𝑎𝑐𝑒𝑙𝑙𝑢𝑙𝑎𝑟] (𝑀) ∗ 1,000,000 = [𝐼𝑛𝑡𝑟𝑎𝑐𝑒𝑙𝑙𝑢𝑙𝑎𝑟](𝜇𝑀) 
 
Utility of UNC3866 as a chemical probe 
 Having demonstrated that UNC3866 is sufficiently membrane permeable to engage the 
chromodomain of CBX7 in a cellular context, we next focused on establishing a biological consequence 
of treating cells with UNC3866. The high levels of CBX proteins in PC3 cells, coupled with the 
demonstrated ability of CBX7 overexpression to confer a growth advantage in these cells16, 43, 
encouraged us to investigate the effects of UNC3866 on PC3 cell proliferation. As a prelude to these 
studies, we confirmed that there were no toxic effects induced upon treatment with UNC3866 up to 100 
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µM as assessed by CellTiter-Glo® in PC3 and HEK293T cells (Fig. 4.9). Similarly, UNC4219 exhibited no 
observable toxicity within the same concentration range. HEK293T cells were used to evaluate UNC3866 
toxicity in a non-cancerous cell line.  
 
 
Figure 4.9. UNC3866 and UNC4219 display no toxicity up to 100µM in PC3 and HEK293T cells as 
assessed by CellTiter-Glo®. 
 
 To assess effects on proliferation, PC3 cells were treated with UNC3866 and the negative 
control, UNC4219, at 30 µM, as this concentration was shown to effectively engage CBX7 in cells (Fig. 
4.5b). Consistent with the known ability of CBX7 to enhance proliferative capacity in PC3 cells14, 43, we 
observed a dramatic decrease in cell proliferation upon UNC3866 treatment, resulting in almost no 
change in cell count after 3 and 6 days, while cells treated with UNC4219 or DMSO exhibited exponential 
cell growth (Fig. 4.10a). Further, we observed that cells resumed proliferating when washed and not 
replenished with UNC3866 after 3 days (Fig. 4.10a, dotted line), indicating that the compound effects are 
at least partially reversible. Dose dependency was next examined for UNC3866 and UNC4219, and a 
significant reduction in PC3 cell count was only observed for UNC3866 treated cells, resulting in an EC50 
of 7.6 ± 2.5 µM (Fig. 4.10b). We also observed that PC3 cells treated with UNC3866 exhibited an 
enlarged and flattened morphology (Fig. 4.8c), suggesting that these cells had become senescent120. We 
checked for the presence of senescence-associated β-galactosidase (SA-β-gal) and observed a dramatic 
increase in the number of cells positive for SA-β-gal following treatment with 30 μM UNC3866 (Fig. 
4.10d). This was an intriguing observation because CBX7 was originally identified in a genetic screen for 
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genes capable of bypassing replicative senescence in Human Prostate Epithelial Cells (HPrEC)15. 
Further, the same study observed that CBX7 knockdown is capable of inducing senescence.    
  
 
Figure 4.10. (a) Treatment of PC3 cells with 30 µM UNC3866 inhibits cell proliferation. UNC4219 
treatment has no effect on PC3 cell proliferation. For washout experiments (dotted line), UNC3866 was 
not replenished at day 3. Error bars represent the SD of that data point (n=3, single biological replicate 
with 3 technical replicates). The data is representative of at least 4 biological replicates with varying 
plating densities. (b) UNC3866 inhibits PC3 cell proliferation in a dose-dependent manner after exposure 
for 6 days (n=8, 2 biological replicates with 3 technical replicates and 1 biological replicate with 2 
technical replicates). The EC50 is reported as the 95% confidence interval.  UNC4219 was used to control 
for off-target effects, which were not evident at concentrations below 100 µM. The EC50 for UNC4219 is 
>76 µM, which is the lower bound of the 95% confidence interval (n=6, 3 biological replicates with 2 
technical replicates each). Error bars represent the SEM of that data point. (c) UNC3866 induces a 
senescent-like morphology in PC3 cells and (d) expression of SA-β-gal. Arrows indicate examples of 
positive SA-β-gal expression. Cell morphology was assessed using phase contrast microscopy (40X). 
SA-β-gal expression was assessed using bright-field microscopy (40X). The images are representative of 
3 biological replicates and the black scale bars are equal to 60 μm. 
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 We attempted an siRNA screen with each of the UNC3866 target chromodomains to determine if 
knockdown of any of these chromodomains could recapitulate the anti-proliferative effect of UNC3866 
(Fig. 4.11). PC3 cells treated with siRNA (up to 100 nM) targeting each protein hinted that knockdown of 
CDY1, CDYL2 and to some extent CBX7 had a slight effect on PC3 cell proliferation. However, 
quantification of the protein levels by In-Cell Western blotting (Fig. 4.11b) of all targets for which we had  
compatible antibodies revealed that we were unable to obtain significant knockdown of any 
chromodomain except CBX2, rendering the results in Fig. 4.11a meaningless. Nonetheless, while we 
could not confirm the on-target effects of UNC3866 through this siRNA screen, the intracellular 
concentration of UNC3866 at its EC50 in PC3 cells is estimated to be 340 nM (Fig. 4.8 and Fig. 4.10), 
which is adequate to fully engage CBX4 and -7 based on the measured ~100 nM Kd’s versus these 
targets (Fig. 3.2a). Although some contribution of other chromodomains bound by UNC3866 to this 
antiproliferative phenotype cannot be ruled out, the concordance of this result with previously published 
CBX7 genetic manipulation is striking15, 17.  
 
 
Figure 4.11. (a) Relative cell counts of PC3 cells 96-hours post siRNA exposure. (b) Relative protein 
levels of siRNA targets. 
  
 While it has been suggested that CBX7 controls cellular proliferation, especially in prostate tissue, 
through regulation of the Ink4a/ARF locus15, its actual role in regulating this locus is controversial15, 19, 87. 
For example, CBX7 has been shown to enhance proliferative capacity without negatively regulating this 
locus19, and negative regulation of this locus does not necessarily enhance proliferative capacity80. 
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Further, there are conflicting reports on the regulation of this locus by CBX7 in PC3 cells15, 16, 18, 43. 
Nonetheless, we analyzed the expression of this locus in response to knockdown of CBX7 by shRNA 
(>60% mRNA reduction) in PC3 cells and did not observe a statistically significant change in expression 
of the Ink4a/ARF locus under these conditions. Further, evaluation of the effects of UNC3866 on 
expression of this locus showed no change at 30 μM, ruling out Ink4a/ARF regulation in the 
antiproliferative effects of UNC3866 (Fig. 4.12). This was not entirely surprising as there is considerable 
evidence indicating that this locus is deeply repressed in PC3 cells through DNA hypermethylation121-124. 
Further, methylation of this locus is unaffected by both DNMT knockdown and inhibition with 5-AzaC, 
suggesting that this gene may be irreversibly repressed in PC3 cells121-123. 
 
Figure 4.12. Analysis of mRNA transcript levels from the Ink4a/ARF locus by RT-qPCR following CBX7 
knockdown in PC3 cells (a) and treatment of PC3 cells with UNC3866 or UNC4219 (b) for 3 (left) or 4 
(right) days. For the CBX7 knockdown experiments, the data are plotted as the mean ± the standard 
deviation of 3 biological replicates, each done in duplicate. Values from compound treated cells are the 
average of 2 technical replicates from a single biological replicate ± the standard error of the mean. 
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 Next, we sought to compare the cellular activity of UNC4938 to UNC3866 since we initially 
hypothesized that replacement of the Kme3 was required for passive membrane permeability. We first 
measured the intracellular concentration of UNC4938. While treatment at a 30 µM extracellular dose of 
UNC3866 for 24 hours results in an intracellular concentration of 1.4 ± 0.3 µM in PC3 cells, under the 
same conditions, we observed an intracellular concentration of 0.61 ± 0.2 µM of UNC4938. It was 
surprising that incorporation of trimethyl-lysine resulted in only an approximately 2-fold decrease in the 
permeability of the compound, and we were intrigued to investigate whether UNC4938 was functionally 
available for chromodomain binding in cells since it is known that highly charged compounds may 
accumulate in endosomes and lysosomes99, 100.  
 Having shown that inhibition of PC3 cell proliferation by UNC3866 is predominantly accomplished 
through antagonism of polycomb CBX chromodomains, we wanted to assess the effect of Kme3 
substitution on the functional activity of our peptidic antagonists. Therefore, we compared the anti-
proliferative effects of UNC3866 and UNC4938 to our negative control analog of, UNC4219 (Fig. 4.13). 
Despite having nearly identical in vitro potencies for CBX chromodomains as UNC3866 (Table 3.7) and 
only a 2-fold reduction in permeability, UNC4938 had no effect on PC3 cell proliferation, analogous to the 
negative control (Fig. 4.13), supporting our hypothesis that Kme3 replacement is required for cellular 
activity. We suspect that the lack of biological activity observed upon treatment with UNC4938 may be the 
result of endosomal and lysosomal trapping of the molecule99, 100. 
 
Figure 4.13. Effect of compounds UNC3866, UNC4938, and UNC4219 on PC3 cell proliferation. Cells 
were treated for 72 hours with the indicated compounds (30 µM) or DMSO, fixed and DAPI stained. Cell 
counts were numerated using high content microscopy and normalized to DMSO control (n ≥ 4). 
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 Finally, we tested the anti-proliferative effects of UNC3866 across a panel of multiple cell lines 
(Fig. 4.14). We tested another human prostate cancer cell line, DU-145 cells, HEK293T cells and MEF 
cells and compared them to the anti-proliferative effects of UNC3866 in PC3 cells. UNC3866 is most 
potent in PC3 cells, but still has a substantial anti-proliferative effect in DU-145 cells. We observed no 
effect on proliferation in HEK293T cells, which was not surprising as these cells have previously shown to 
proliferate in a CBX7-independent fashion. Finally, we tested MEF cells to determine if UNC3866 is able 
to affect growth in non-human cell line known to have its proliferation regulated by CBX7. Consistent with 
the role of CBX7 in MEFs15, we found that UNC3866 reduces proliferation in these cells. Further, this 
strongly suggests that UNC3866 is able to engage mouse CBX7, which was to be expected as mouse 
and human CBX7 are identical in their chromodomain regions. 
 
Figure 4.14. Varying effects of UNC3866 on cellular proliferation. 
 
Pharmacokinetic studies with UNC3866  
 We examined the pharmacokinetic properties of UNC3866 in male Swiss Albino mice in order to 
determine the potential utility of UNC3866 in vivo. We investigated the effects of dosing both 
intravenously (IV) and intraperitoneally (IP). Mice were dosed IV at 3 mg/kg and IP at 10 mg/kg. The 
concentration of both UNC3866 and UNC4007 were quantified at multiple time points. When given 
intravenously, UNC3866 is rapidly eliminated with an observed half-life of 0.09 hours (5.4 minutes) and 
does not significantly accumulate in body tissues (Vss = 0.19 L/kg). Encouragingly, UNC3866 does have 
moderate clearance (26 mL/min/kg). When administered intraperitoneally, UNC3866 showed 25% 
bioavailability and is detectable in the blood of mice for up to 4 hours with maximum levels occurring at 2 
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hours. Additionally, UNC3866 was the dominate species present over UNC4007 at all time points tested, 
further highlighting the stability of the UNC3866 methyl ester. While these PK results are promising for a 
peptidic compound, the use of UNC3866 in vivo may be limited because of the high circulating levels 
required for intracellular target engagement due to its poor cell permeability. The potential utility of 
UNC3866 at higher doses for in vivo experiments is currently under investigation. 
      
Table 4.1. Mean pharmacokinetic parameters of UNC3866 (Prodrug) in blood following a single 
intravenous (Dose: 3 mg/kg) and intraperitoneal (Dose: 10 mg/kg) administration to male Swiss Albino 
mice  
Route 
Compound 
(Dose) 
Tmax 
(hr) 
aC0/Cmax 
(ng/mL) 
AUClast 
(hr*ng/mL) 
AUCinf 
(hr*ng/mL) 
T1/2 
(hr) 
CL 
(mL/min/kg) 
Vss 
(L/kg) 
i.v. 
UNC3866 
(Prodrug) 
- 10911.87 1887.25 1887.95 0.09 26.48 0.19 
UNC4007 
(Parent) 
- NC NC NC NC NC NC 
i. p. 
UNC3866 
(Prodrug) 
2.00 580.01 1553.89 NC - - - 
UNC4007 
(Parent) 
2.00 379.34 463.57 NC - - - 
a - back extrapolated conc. for i.v. group 
NC: Not calculated due to insufficient data 
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Figure 4.15. Mean blood concentration-time profiles of UNC3866 (Prodrug) and UNC4007 (parent) 
following a single intravenous administration to male Swiss Albino mice (Dose: 3 mg/kg) 
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Figure 4.16. Mean blood concentration-time profiles of UNC3866 (Prodrug) and UNC4007 (parent) 
following a single intraperitoneal administration to male Swiss Albino mice (Dose: 10 mg/kg) 
 
The importance of compound residence time on CBX7 antagonism 
 We were intrigued to determine whether the increased residence time of UNC4976 with CBX7 
relative to UNC3866 significantly effects its interaction with CBX7 in a cellular system. First, we quantified 
the intracellular concentration of UNC4976 in PC3 cells following a 30 µM dose for 24 hours. We found 
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that the intracellular concentration of UNC4976 was slightly nearly half of that of UNC3866 (0.78 ± 0.3 µM 
vs 1.4 ± 0.3 µM, respectively).  Interestingly however, pull-down with UNC4195 was more strongly 
antagonized in cells pretreated with UNC4976 relative to UNC3866 (Fig. 4.17), despite the reduced 
permeability and only slightly improved binding affinity (UNC4976-CBX7 Kd = 53 nM vs UNC3866-CBX7 
Kd = 97 nM) Nearly complete pull-down inhibition was observed at the 10 µM dose of UNC4976, relative 
to UNC3866, which requires a 30 µM dose in order to completely block pull-down. Further studies are 
underway to continue to optimize UNC4976 and comparing its cellular efficacy relative to UNC3866, but 
this result strongly suggests that the development of more cellularly efficacious CBX7 antagonists 
depends more strongly on off-rate optimization than optimization of the binding constant per se.  
 
Figure 4.17. Comparison of the ability of UNC4976 to antagonize CBX7 in cells compared to UNC3866. 
 
CONCLUSIONS 
 UNC3866 is a highly selective, cellularly active antagonist of PRC1 chromodomains. Our studies 
have demonstrated that UNC3866 is capable of engaging CBX4/7/8-containing canonical PRC1 
complexes. It is currently unclear whether CBX2/6-containing PRC1 complexes are simply inaccessible to 
pull-down, or are inaccessible to UNC3866 in general. Further, the precise mechanism by which 
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UNC3866 antagonism of PRC1 chromodomains modulates their signaling without displacing them from 
chromatin is currently unclear. Further studies are needed to elucidate whether UNC3866 works by 
inhibiting the interaction of PRC1 chromodomains with non-histone proteins or whether it exerts its effects 
through changes in the genomic distribution of PRC1. 
 The ability of UNC3866 to inhibit proliferation with little apparent toxicity, especially in PC3 cells, 
is encouraging for the development of CBX antagonists as oncological therapeutic agents. While 
UNC3866 has modest PK properties, its utility is likely to be limited to cellular systems. Therefore, 
evaluation of the efficacy and safety of CBX antagonists as therapeutic agents in vivo will require the 
continued development of CBX antagonists with improved permeability and PK properties. Nonetheless, 
UNC3866 represents an important first step toward these molecules and is a reasonable starting point for 
further optimization.  
 While our studies have provided strong support that the phenotypic effects of UNC3866 are 
exerted through its ability to modulate CBX7, future studies will focus on providing stronger evidence for 
direct modulation of CBX7 by UNC3866 and its derivatives. Preliminary studies which will be disclosed in 
future publications have provided much more powerful evidence demonstrating the ability of UNC3866 to 
antagonize CBX7-mediated repression in cell-based assays. Further, the results of these studies 
corroborate our findings in Fig. 4.5, wherein the methyl ester of UNC3866 is the preferred functionality at 
the C-terminus of this peptidic antagonist. Finally, these same studies suggest that UNC4976, while only 
approximately 2-fold more potent for CBX7 than UNC3866 in vitro, is > 15-fold more potent at 
antagonizing CBX7-mediated repression in cells. This result, coupled with our pull-down studies in Fig. 
4.17, strongly indicates that the efficacy of CBX7 antagonists in biological systems is intimately tied to 
their dissociative kinetics and that our antagonists will benefit from continued improvements in their target 
residence time.   
 
METHODS 
Cell culture and lysis 
PC3 cells were obtained from ATCC® (CRL-1435™) through the UNC Lineberger Tissue Culture Facility. 
Cells were cultured using GIBCO® DMEM/F12 (Ham), [+] L-Glutamine, and [+] 15 mM HEPES media. 
180 
 
Cells were trypsinized using 0.25% trypsin. Lysis was performed using CytobusterTM protein extraction 
reagent supplemented with protease inhibitors and Benzonase® (used at 25 U/mL). For analysis of 
H2AK119ub, 50 µM of the deubiquitinase inhibitor, PR-619, was added to the lysis buffer. Samples were 
incubated at 37°C for 10 minutes, followed by incubation at RT on a rotator for 20 minutes. The samples 
were spun down and the supernatant collected and transferred to a clean Eppendorf tube. Protein 
concentrations were quantified using the Bradford protein assay. 
 
Pull-down studies 
Cells were cultured on a T175 tissue culture flask until reaching ~80-90% confluency. Following 
trypsinization, the pellet was washed twice with PBS and lysed with 500 µL of lysis buffer. When 
applicable, vehicle control or 100 µM UNC3866 was added to an aliquot of 1000 µg of total protein and 
diluted to 500 µL with 20 mM Tris (pH 8)/150 mM NaCl/0.1% Tween-20 (TBST).   Pull-down reagents 
were bound to Streptavidin M-270 Dynabeads® by rotating 30 µL of beads with a 20-fold excess of pull-
down reagent for 30 minutes at room temperature in. Unbound pull-down reagent was then removed and 
the beads were washed 3X with 200 µL of TBST. The lysate was then transferred to an Eppendorf tube 
containing 30 µL of Streptavidin M-270 Dynabeads® that had been pre-bound to UNC4195 or 2399. The 
mixture was rotated overnight at 4°C. The following morning, the depleted lysate was removed and the 
beads were washed 3X with 300-500 µL of TBST. The beads were re-suspended with 30 µL of 1X 
Laemmli sample buffer and heated at 95°C for 3 minutes. Fifteen microliters of the sample was then 
loaded into a gel and analyzed via western blotting using the appropriate primary antibody (Table 4.2) 
and detected using a LI-COR Odyssey® instrument and the appropriate fluorescent secondary antibodies 
(diluted 1:10 ,000 in PBST).  One percent of input was used for western blotting of all proteins except 
CBX8 and HPH2. For both of these proteins, 3% of sample input was used. 
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Table 4.2. Primary antibodies used for western blot detection. 
Antibody Dilution Vendor (catalog number) 
Rabbit αCBX2 1:5000 in PBST Abcam (ab184968) 
Rabbit αCBX4 1:5000 in PBST Abcam (ab174300) 
Rabbit αCBX6 1:5000 in PBST Abcam (ab195235) 
Rabbit αCBX7 1:5000 in PBST Abcam (ab21873) 
Rabbit αCBX8 1:5000 in PBST Abcam (ab182627) 
Rabbit αRING1B 1:5000 in PBST Abcam (ab101273) 
Rabbit αHPH2 1:2000 in PBST Abcam (ab168441) 
Rabbit αH2AK119ub 1:5000 in PBST Cell Signaling (8240) 
Mouse αBMI-1 1:5000 in PBST Active Motif (39993) 
Mouse αEED 1:5000 in PBST EMD Millipore (17-663) 
 
Cell Proliferation Assay 
PC3 cells were seeded at 200 cells/well into 24-well plates (Costar #3524).  Cells were allowed to adhere 
overnight. The media (DMEM supplemented with 10 % FBS) was then exchanged with fresh media 
containing DMSO, UNC3866 or UNC4219. On day three, the media were exchanged with fresh media 
containing DMSO, UNC3866 or UNC4219. For dose-response studies, the EC50 was derived from a six-
point titration ranging from 100 µM to 0.4 µM of UNC3866 or UNC4219.  At day 0, 3 or 6, cells were fixed 
with ice-cold methanol for 30 sec. and rehydrated with PBS.  Nuclei of the cells were stained with DAPI 
(0.05 µg/ml) and numerated using High Content Microscopy (Array Scan™ High Content Analysis, 
Thermo Fisher #NX10002L).  For dose-response studies, the cell count of UNC3866- or UNC4219-
treated cells was normalized to the average cell count of DMSO-treated cells. The EC50 was calculated 
using the “log[inhibitor] vs. the normalized response -- Variable slope” equation in GraphPad Prism 5.    
 
Subcellular fractionation experiments 
PC3 Cells were cultured on a 10-cm dish. For whole cell treatments, compounds were added when cells 
reached ~70% confluency. For treatment of isolated cellular compartments, cells were harvested after 
reaching approximately 80-90~ confluency. Experiments were performed with Subcellular Protein 
Fractionation Kit for Celtured Cells from ThermoFisher (catalog number 78840). The manufacturer’s 
recommended protocol was followed except when treating isolated nuclei and chromatin with compound. 
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In these cases, a 30-minute compound incubation step was added in which the appropriate cellular 
compartment was rotated at room temperature for 30-minutes with DMSO, UNC3866 or UNC4219. 
 
Compound permeability studies 
PC3 cells were cultured until reaching ~80% confluency in a T75 cell culture flask. The media was 
exchanged with 10 mL fresh media (0.3% DMSO) containing 30 µM compound. Cells were incubated with 
compound for 24 hours. After 24 hours, cells were washed with PBS, trypsinized, and wash again with 
PBS. The resulting cell pellets (3) were flash frozen with liquid nitrogen and submitted to Drumetix 
Laboratories (Greensboro, NC) for analysis by LC-MS/MS.  
 
CellTiter-Glo Luminescent Cell Viability Assay 
The effect of UNC3866 and UNC4219 on cell viability was determined using a CellTiter-GloTM ATP 
detection system (Promega #7573).  Ten point, 1:3 dilution curves of compounds starting at 100 µM final 
concentration were diluted to 5X final concentration in PBS (vehicle control) and then 5 µL were added to 
384-well white, clear bottom tissue culture plates (Corning #3707) with a Multimek automated liquid 
handling device (Nanoscreen, Charleston, SC).  Twenty microliters of low passage, subconfluent 
HEK293T/PC3 cells grown in Dulbecco’s Modified Eagle’s Medium without phenol red (GIBCO® #31053) 
and supplemented with 10% Fetal Bovine Serum (GIBCO® #26140) were immediately added at a density 
of 5,000 cells per well using a Multidrop 384 (Titertek).  Cell plates were incubated for 48 hours at 37oC 
and 5% C02, and then lysed with 25 microliters of CellTiter-GloTM reagent.   Luminescence was read on an 
Envision platereader (Perkin Elmer) after 15 minutes at room temperature in dim light.   
 
Cellular Thermal Shift Assay (CETSA) 
 A PC3 cell pellet consisting of 107 cells was re-suspended in 1200 µL of PBS complete with 
protease inhibitors. The suspension was subjected to 3 consecutive freeze-thaw cycles performed with 
liquid N2 in order to lyse the cells. Following the final freeze-thaw cycle, the suspension was centrifuged at 
20,000 g for 20 minutes at 4°C. The supernatant was collected and the resulting pellet was discarded. 
The lysate was then divided into two tubes (600 µL) each. The volume of each tube was brought up to 
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650 µL with PBS + protease inhibitors. DMSO or 30 µM UNC3866 was added to each tube. The tubes 
were incubated at RT for 30 minutes. The lysates were aliquoted into 12 thin-walled PCR tubes (50 
µL/tube). The tubes were incubated for 3 minutes at temperatures ranging from 37°C to 73°C in 3° 
increments in a Mastercycle® nexus gradient qPCR machine. Tubes were then incubated at room 
temperature for 3 minutes followed by centrifugation at 20,000 g for 20 minutes at 4°C. The supernatant 
was collected. Ten microliters of 6X Laemmli buffer was added to each tube. The tubes were then heated 
to 95°C for 3 minutes. Twenty microliters was then loaded into an SDS page gel and analyzed by western 
blotting. 
 
CBX7 knockdown and quantitative PCR 
 PC3 cells were seeded at a density of 105 cells/well in a 6-well plate and allowed to adhere 
overnight.  The media was then exchanged for 2 mL of media containing polybrene (8 µg/mL) and pre-
packaged shRNA (200,000 Transducing Units/well) targeting CBX7 (Mission CBX7, SHCLNV (Sigma) 
TRCN0000019144RNA) or Non-targeting control (Mission pLKO.1-puro Non-Target shRNA, SHC016V 
(Sigma)). After 20 hours, the transduction mixture was exchanged with fresh media (GIBCO® DMEM/F12 
(Ham), [+] L-Glutamine, and [+] 15 mM HEPES) and allowed to incubate for an additional 24 hours. The 
media was then replaced with media containing 2 µg/mL of puromycin and allowed to incubate until 
selection was complete as evidence by the death of all control cells that were not transduced. RNA was 
extracted using the RNeasy Plus Mini Kit (Qiagen) and RNA was quantified on the NanoDrop    2000 
spectrophotometer (Thermo Fisher Scientific). The reverse transcription reaction was performed with 500 
ng RNA and the Superscript III First Strand Synthesis Supermix (Invitrogen #1172-050) according to 
manufacturer instructions. The resulting cDNA was diluted 1:10, and 2 μL was used for each PCR 
reaction. Quantitative PCR was performed using Roche FastStart Universal SYBR Green Master Mix 
(Rox) in a 384-well plate format on the ABI 2900HT instrument. Oligo sequences are available upon 
request.   
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Phase contrast microscopy images 
 PC3 cells were seeded at 200 cells/well into 24-well plates (Costar #3524).  Cells were allowed to 
adhere overnight. The media (DMEM supplemented with 10 % FBS) was then exchanged with fresh 
media containing DMSO or 30 µM UNC3866. On day three, the media were exchanged with fresh media 
containing DMSO or 30 µM UNC3866. At day 6, cells were fixed with ice-cold methanol for 30 sec. and 
rehydrated with PBS.  Samples were imaged using Volocity software and an Olympus IX81 microscope 
equipped with an Orca ER digital camera.  
 
Senescence-associated β-Gal staining 
 PC3 cells were seeded in a 96-well plate at a density of 100-200 cells/well and allowed to adhere 
overnight. The media was then replaced with fresh media containing 30 µM UNC3866 or DMSO. After 3 
days, the media was removed and the cells were fixed and stained using the Senescence β-
Galactosidase Kit (#9860) from Cell Signaling Technology® according to the manufacturer’s 
recommendations. Wells were imaged using bright-field microscopy with an Olympus IX81 microscope 
equipped with an Orca ER digital camera.  
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CHAPTER V: FUTURE DIRECTIONS 
SUMMARY OF KEY FINDINGS 
 Our efforts to develop antagonists for the chromodomain of CBX7 proved to be both challenging 
and informative. The primary accomplishment of these studies was the development of a chemical toolkit 
consisting of UNC3866, a potent antagonist (Kd of ~100 nM) of the chromodomains of CBX4/7 with 
modest affinity for the chromodomains of CBX2/6/8, CDY1, CDYL1b and CDYL2; a negative control 
analog, UNC4219; and UNC4195, a biotinylated analog of UNC3866. We have made these compounds 
freely available to the research community to be used as a toolset that can be used to study CBX and 
CDY chromodomains both biochemically and in cell-based systems (Fig. 5.1).  
 
Figure 5.1. Structures of UNC3866, UNC4219 and UNC4195. 
  
 UNC3866 was developed through systematic SAR studies focused on testing our induced fit 
binding pathway of recognition of H3 by CBX7 based on previous structural studies and our own 
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molecular dynamics simulations. Our proposed binding pathway hypothesizes that the N-terminus of our 
peptidic antagonists forms the first specific interaction with CBX7. Further, these interactions are critical 
for facilitating rearrangement of the chromodomain around the inhibitor and entrance of the 
chromodomain-antagonist complex into the stably bound state in which the aromatic cage forms last by 
collapsing around the modified lysine. In agreement with this hypothesis, we found optimization of the N-
terminus of our antagonists led to dramatic improvements in their binding affinity primarily through 
increases in their association rates (as determined by SPR) with CBX7. In further agreement with this 
hypothesis, we found that appropriate modification of the lysine residue can dramatically slow the 
dissociation rate of the inhibitor-chromodomain complex (Fig. 5.2). 
 
Figure 5.2. Relationship between various modifications to our antagonists and their Kd, kon, and koff for 
CBX7. 
 
 We were able to leverage the high affinity of UNC4195 to each of the UNC3866 target 
chromodomains and utilize this molecule to develop high throughput assays for CBX4/7/8 and CDYL2. 
The development of these assays enabled us to begin to understand the selectivity determinants between 
these different chromodomains. Further, we developed an AlphaScreen® assay for the closely related 
chromodomain of CBX5 which allowed us to gain valuable insight into the selectivity of UNC3866 for Pc 
chromodomains over HP1 chromodomains. The results of these studies are summarized in Fig. 5.3.  
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Figure 5.3. Summary of selectivity parameters determined from UNC3866 SAR studies 
 
 Finally, we demonstrated that UNC3866 is capable antagonizing CBX7 in cells and inhibits PC3 
cell proliferation with an EC50 of approximately 7.5 µM. Proliferation is inhibited through induction of 
cellular senescence, a mechanism that is consistent with antagonism of CBX7. Further, cellular activity is 
dependent upon replacement of the endogenous Kme3 with a non-natural lysine derivative (Fig. 5.4). The 
utility of UNC3866 in vivo is likely to be limited, but it represents an important starting point for the 
development of in vivo chemical probes targeting PRC1 chromodomains.  
 
Figure 5.4. Kme3 replacement is required for inhibition of proliferation by peptidic CBX7 antagonists. 
 
FUTURE DIRECTIONS 
Potency and PK optimization of peptidic antagonists 
 Efforts to discover antagonists of PRC1 chromodomains, and Kme readers in general, are still in 
their infancy. Our studies have provided evidence that high-affinity molecules targeting PRC1 
chromodomains are not only possible, but may one day serve as therapeutically useful molecules. While 
methods, such as liposomal packaging125, that are known to improve the pharmacokinetic properties of 
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peptidic molecules should be pursued with respect to UNC3866 and especially UNC4976 and its 
derivatives, continued medicinal efforts should also be pursued with the aim of discovering molecules with 
higher potency and more drug like properties. For example, continued peptide-based SAR studies could 
be done with the goal of further improving potency and decreasing the number of natural amino acids 
present in the antagonist. Figure 5.5 depicts some modifications that could be made to potentially 
improve potency. The poor permeability of our antagonists could be overcome by continued 
improvements in potency provided the permeability is unaffected.  
 The gauche conformation of the diethyl-lysine side chain when bound to CBX7 is another area of 
potential optimization. While shortening the side chain to diethyl-ornithine appears to be too short based 
on the co-crystal structure of UNC3866 bound to CBX7, cyclization may prove effective as this would 
produce the appropriate spacing (Fig. 5.6). Additionally, currently ongoing crystallization studies with 
UNC4976 and CBX7 may provide valuable insight into the interaction between the methyl, norbornyl-
lysine and CBX7, which is currently the preferred Kme3 replacement for future studies. Finally, pro-drug 
approaches, such as conversion of the C-terminal serine methyl ester to a lactone derivative, or increases 
in the hydrophobicity of the ester could be employed to improve the permeability of these compounds. 
Retroinversion peptides126 also present a viable alternative for improvement of the pharmacokinetic 
properties of our compounds (Fig. 5.7) as well as exploration of various amide isoteres127. 
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Figure 5.5. van der Waals’ interactions between UNC3866 and CBX7. Interactions are depicted as black 
dashed lines. Possible amino acid replacements to improve these interactions are shown. 
 
 
Figure 5.6. Strategies for side chain optimization of UNC3866 based on the UNC3866-CBX7 co-crystal 
structure. Distances from the β-carbon to the nitrogen are shown in Å. 
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Figure 5.7. Strategies for improving the in vivo efficacy of UNC4976 
 
Pc CBX selectivity 
  Our structural and SAR studies in Chapter III indicated that larger alkyl substituents tune the 
selectivity of our antagonists for CBX8 (and likely CBX2 and -6) while reducing the affinity for CBX4/7. 
Additionally, the degree of alkylation on the aromatic cap of UNC3866 affects binding to a much lesser 
extent for CBX8 than for CBX4/7. Thus, molecules such as those shown in Fig. 5.8a may represent a 
simple and straightforward approach for CBX antagonists with a preference for CBX2/6/8 over CBX4/7. 
Interestingly, CBX2 is unique in that it contains a cysteine residue in close proximity to the t-butyl group of 
UNC3866 (~7.5 Å, Fig. 5.8b and c). Thus, CBX2 selective compounds may be attainable through the 
development of covalent reversible antagonists128 that target this unique residue. 
191 
 
 
Figure 5.8. (a) Structures of potential CBX2/6/8 selective antagonists. (b) Sequence alignment of 
chromodomain targets of UNC3866. (c) Representation of the CBX2 cysteine residue in close proximity 
to the t-butyl group of UNC3866. (d) Hypothetical covalent reversible CBX2 antagonist. 
 
Toward small molecule CBX antagonists 
 While continued exploration of peptides for use in vivo chemical probes for CBX chromodomains 
presents a promising option, traditional small molecules scaffolds are still the most attractive chemotypes 
for in vivo chemical probes. As mentioned in Chapter III, the chromodomain of CBX2 (likely CBX6 and -8 
as well), does not require an induced fit binding pathway like that of CBX7 (Fig. 5.9). Hence, a small 
molecule screening campaign for these chromodomains would be expected to be much more fruitful than 
a campaign targeting CBX4/7. Additionally, the development of UNC4195 and its application as an 
AlphaScreen® bait ligand makes a high throughput screen for these proteins a cost-feasible option. 
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Figure 5.9. Overlay of the CBX2 chromodomain in the apo (salmon) and UNC3866-bound conformation 
(light blue, UNC3866 not shown). 
 
 Our studies have highlighted the challenges of developing CBX7 small molecule antagonists. 
While these studies indicate that the probability of identifying a reasonable small molecule scaffold for 
SAR studies is low, our cellular studies indicate that such a molecule could be a powerful chemical tool 
with important therapeutic potential. In order to facilitate the identification of a small molecule scaffold 
targeting the CBX7 chromodomain, a fragment-based approach could be applied utilizing the N-terminus 
of UNC3866 in conjunction with a library of small molecule fragments (Fig. 5.10). Our binding hypothesis, 
for which we have provided extensive experimental evidence, indicates that the N-terminus of UNC3866 
is responsible for initiating the induced fit binding pathway. Therefore, screening libraries of various 
fragments in the presence of this fragment of UNC3866 could lead to the identification of fragments that 
display synergistic antagonism of CBX7 with the N-terminus of UNC3866. The N-terminal fragment of 
UNC3866 should help to initiate the induced fit binding mechanism and create a binding pocket for the 
fragments to interact with (Fig. 5.10a). Screening could be done through traditional NMR studies, 
AlphaScreen® or SPR. Libraries could also be designed with reactive functionalities in order to enable a 
dynamic combinatorial chemistry (DCC) approach129 (Fig. 5.10b). Alternatively, similar to a DCC 
approach, a library of acrylamide-containing compounds could also be incubated with a thiol-derivative of 
the N-terminus of UNC3866 in which the solution was analyzed for covalent products formed in the 
presence of CBX7130 (Fig. 5.10c). While the risk of failure is significant for all three of these approaches, 
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they present perhaps the most rational and likely approach to the discovery of traditional small molecule 
antagonists of CBX7.   As is always the case, there are numerous other approaches which may lead to 
an in vivo chemical probe of PRC1 chromodomains and only time will tell which, if any, will be effective. 
 
 
Figure 5.10 Fragment-based approaches for the development a CBX7 small molecule antagonist.  
 
Biological studies 
 The development of UNC3866 provides a novel mechanism by which to interrogate the canonical 
Polycomb signaling pathway. If the canonical Polycomb signaling pathway holds true, the UNC3866 and 
EZH2 inhibitors would be expected to act synergistically, especially in inhibiting proliferation of cancerous 
cell lines that have been shown to depend on either PRC1 or PRC2 for their growth and proliferation. Our 
own preliminary studies have already begun to argue against this model. In the context of PC3, our own 
preliminary studies found no antiproliferative effect upon EZH2 inhibition, in agreement with a previous 
study24. The dependence of PC3 cells on CBX7 for their growth, their susceptibility to UNC3866 and 
resistance to EZH2 inhibition strongly suggests that CBX7 functions independently of PRC2 and 
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H3K27me3. Further, our own preliminary studies indicate that CBX7 mediated repression is not inhibited 
by EZH2 antagonism and no synergy is observed between our CBX antagonists and inhibitors of EZH2. 
However, as discussed in the introduction, the relevance of Polycomb signaling appears to be cell-type 
dependent. Thus, our molecules may help to identify in which cell types and on what signaling pathways, 
if any, canonical Polycomb signaling plays a critical role. Intriguingly, the role of EED in PRC1 suggests 
that antagonists of PRC2 that target EED could be synergistic with our PRC1 antagonists while EZH2 
antagonists preliminarily do not appear to be. 
 We noted in our pull-down studies that UNC3866 in Chapter IV is capable of engaging what 
appears to be three different isoforms of CBX7 present in PC3 cells (Fig. 5.11). Consistent with this, two 
variant, protein-coding transcripts have been annotated in the Ensembl database. Future studies 
confirming the identity of these bands may ultimately help shed light on which isoform(s) incorporate into 
PRC1 and which one(s) are responsible for enhancing PC3 cell proliferation. It is conceivable that the 
effect of UNC3866 is a result of modulation of a CBX7 isoform not incorporated into PRC1, which could 
explain our lack of evidence for the canonical polycomb signaling model. 
 
Figure 5.11. Putative CBX7 isoforms engaged by UNC3866. 
 
CONCLUSIONS 
 The studies described in this dissertation have answered many questions concerning strategies 
to target CBX chromodomains. Additionally, these studies have begun to answer important biological 
questions concerning CBX antagonism. However, seemingly endless questions remain, some of which 
have been highlighted in this chapter. Undoubtedly, many of these “known unknowns” will be answered in 
time. However, as is nearly always the case in scientific endeavors, continued research into CBX 
antagonism is likely to reveal numerous “unknown unknowns” and produce more questions than it 
answers.  
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